imgn_Current_Folio

0001558370-17-003635.txt : 20170505 0001558370-17-003635.hdr.sgml : 20170505 20170505140009 ACCESSION NUMBER: 0001558370-17-003635 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170505 DATE AS OF CHANGE: 20170505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOGEN INC CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 17817612 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 imgn-20170331x10q.htm 10-Q imgn_Current_Folio_10Q

Table of Contents

987654321`qwer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-17999

ImmunoGen, Inc.

Massachusetts		04-2726691
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices, including zip code)

(781) 895-0600

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12-b2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☒

Non-accelerated filer ☐ (Do not check if a smaller reporting company)		Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Shares of common stock, par value $.01 per share: 89,348,389 shares outstanding as of May 1, 2017.

Table of Contents

IMMUNOGEN, INC.

FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2017

TABLE OF CONTENTS

Item		Page Number

	Part I
1.

1a.	Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016	2

1b.	Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2017 and 2016	3

1c.	Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016	4

1d.	Notes to Consolidated Financial Statements	5

2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23

3.	Quantitative and Qualitative Disclosures about Market Risk	33

4.	Controls and Procedures	33

	Part II

1A.	Risk Factors	33

6.	Exhibits	34

	Signatures	35

Table of Contents

ITEM 1. Financial Statements

IMMUNOGEN, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

In thousands, except per share amounts


	March 31,		December 31,
	2017		2016
ASSETS
Cash and cash equivalents	$	126,568	$	159,964
Accounts receivable		3,893		2,026
Unbilled revenue		2,051		6,778
Inventory		3,225		2,192
Prepaid and other current assets		6,394		5,386
Total current assets		142,131		176,346
Property and equipment, net of accumulated depreciation		17,997		19,498
Other assets		3,193		3,020
Total assets	$	163,321	$	198,864
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Accounts payable	$	5,100	$	7,895
Accrued compensation		4,927		6,946
Other accrued liabilities		12,078		11,150
Current portion of deferred lease incentive		784		784
Current portion of liability related to the sale of future royalties, net of deferred financing costs of $832 and $850, respectively		15,664		14,470
Current portion of deferred revenue		1,814		14,531
Total current liabilities		40,367		55,776
Deferred lease incentive, net of current portion		5,718		5,914
Deferred revenue, net of current portion		18,992		19,086
Convertible 4.5% senior notes, net of deferred financing costs of $2,869 and $3,035, respectively		97,131		96,965
Liability related to the sale of future royalties, net of current portion and deferred financing costs of $2,943 and $3,144, respectively		164,460		169,858
Other long-term liabilities		4,183		4,115
Total liabilities		330,851		351,714
Commitments and contingencies (Note H)
Shareholders’ deficit:
Preferred stock, $.01 par value; authorized 5,000 shares; no shares issued and outstanding		—		—
Common stock, $0.01 par value; authorized 150,000 shares; issued and outstanding 89,348 and 87,301 shares as of March 31, 2017 and December 31, 2016, respectively		893		873
Additional paid-in capital		781,492		778,847
Accumulated deficit		(949,915)		(932,570)
Total shareholders’ deficit		(167,530)		(152,850)
Total liabilities and shareholders’ deficit	$	163,321	$	198,864

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

IMMUNOGEN, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

In thousands, except per share amounts


	Three Months Ended
	March 31,
	2017		2016

Revenues:
License and milestone fees	$	18,730	$	10,077
Non-cash royalty revenue related to the sale of future royalties		7,613		7,380
Research and development support		1,478		1,059
Clinical materials revenue		678		1,198
Total revenues		28,499		19,714
Operating Expenses:
Research and development		32,888		36,094
General and administrative		8,119		11,235
Restructuring charge		386		—
Total operating expenses		41,393		47,329
Loss from operations		(12,894)		(27,615)
Investment income, net		115		108
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes		(3,575)		(4,972)
Interest expense on convertible senior notes		(1,125)		—
Other income, net		134		551
Net loss	$	(17,345)	$	(31,928)
Basic and diluted net loss per common share	$	(0.20)	$	(0.37)
Basic and diluted weighted average common shares outstanding		87,160		87,035
Total comprehensive loss	$	(17,345)	$	(31,928)

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

IMMUNOGEN, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

In thousands, except per share amounts


	Three Months Ended
	March 31,
	2017		2016

Cash flows from operating activities:
Net loss	$	(17,345)	$	(31,928)
Adjustments to reconcile net loss to net cash used for operating activities:
Non-cash royalty revenue related to sale of future royalties		(7,613)		(7,380)
Non-cash interest expense on liability related to sale of future royalties and convertible senior notes		3,575		4,972
Depreciation and amortization		1,506		1,435
Loss (gain) on sale/disposal of fixed assets and impairment charges		180		(3)
Stock and deferred share unit compensation		2,665		7,283
Deferred rent		25		42
Change in operating assets and liabilities:
Accounts receivable		(1,867)		699
Unbilled revenue		4,727		(142)
Inventory		(1,033)		629
Prepaid and other current assets		(1,008)		(717)
Other assets		(173)		17
Accounts payable		(2,543)		(2,378)
Accrued compensation		(2,019)		1,134
Other accrued liabilities		775		1,490
Deferred revenue, net of non-cash upfront license payment		(12,811)		(1,232)
Net cash used for operating activities		(32,959)		(26,079)
Cash flows from investing activities:
Purchases of property and equipment		(437)		(3,479)
Net cash used for investing activities		(437)		(3,479)
Cash flows from financing activities:
Proceeds from stock options exercised		—		188
Net cash provided by financing activities		—		188
Net change in cash and cash equivalents		(33,396)		(29,370)
Cash and cash equivalents, beginning of period		159,964		212,283
Cash and cash equivalents, end of period	$	126,568	$	182,913

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

IMMUNOGEN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

A.Nature of Business and Plan of Operations

ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development of antibody-drug conjugates, or ADCs, for the treatment of cancer.

In August 2014, the FASB issued ASU 2014‑15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. (ASU 2015-14). Under the new standard, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved before the date that the financial statements are issued. This standard was adopted by the Company at December 31, 2016.

The Company has incurred operating losses and negative cash flows from operations since inception, incurred a net loss of approximately $17.3 million during the three months ended March 31, 2017, and has an accumulated deficit of approximately $949.9 million as of March 31, 2017. The Company has primarily funded these losses through payments received from its collaborations and equity and convertible debt financings. To date, the Company has no product revenue and management expects operating losses to continue for the foreseeable future. At March 31, 2017, the Company had $126.6 million of cash and cash equivalents on hand. The Company anticipates that its current capital resources and expected future collaborator payments will enable it to meet its operational expenses and capital expenditures (operating plan) into the second quarter of calendar year 2018. Without such collaborator payments, the Company’s existing capital resources at March 31, 2017 would not be sufficient to support the current operating plan through May 5, 2018, which is twelve months after the date that the March 2017 financial statements were issued. Management expects to seek additional funds from collaboration partners through a combination of upfront license payments, milestone payments, royalty payments, research funding, and clinical material reimbursement or from equity or debt financings. Because those plans have not been finalized, receipt of additional funding is not considered probable under the new standard. If the Company does not obtain sufficient funds when needed, the Company expects it would scale back its operating plan by deferring or limiting some or all of its research, development or clinical projects, or initiate further reductions to its workforce. Because such contingency plans have not been finalized (because the specifics would depend on the situation at the time), such actions also are not considered probable for purposes of the new standard. Because, under the new standard, neither receipt of future collaboration payments, nor management’s contingency plans to mitigate the risk and extend cash resources through May 5, 2018, are considered probable, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern.

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, collaboration arrangements, third‑party reimbursements and compliance with governmental regulations.

Table of Contents

B.Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements at March 31, 2017 and December 31, 2016 and for the three months ended March 31, 2017 and 2016 include the accounts of ImmunoGen, Inc., or the Company, and its wholly owned subsidiaries, ImmunoGen Securities Corp., ImmunoGen Europe Limited and Hurricane, LLC. The consolidated financial statements include all of the adjustments, consisting only of normal recurring adjustments, which management considers necessary for a fair presentation of the Company’s financial position in accordance with accounting principles generally accepted in the U.S. for interim financial information. The December 31, 2016 condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. The preparation of interim financial statements requires the use of management’s estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenditures during the reported periods. The results of the interim periods are not necessarily indicative of the results for the entire year. Accordingly, the interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Transition Report on Form 10-K for the six months ended December 31, 2016.

Subsequent Events

The Company has evaluated all events or transactions that occurred after March 31, 2017 up through the date the Company issued these financial statements. The Company did not have any material recognizable or unrecognizable subsequent events during this period.

Revenue Recognition

The Company enters into licensing and development agreements with collaborative partners for the development of ADC therapeutics. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company’s antibody‑drug conjugate, or ADC, technology, (ii) rights to future technological improvements, (iii) research activities to be performed on behalf of the collaborative partner, (iv) delivery of cytotoxic agents and (v) the manufacture of preclinical or clinical materials for the collaborative partner. Payments to the Company under these agreements may include upfront fees, option fees, exercise fees, payments for research activities, payments for the manufacture of preclinical or clinical materials, payments based upon the achievement of certain milestones and royalties on product sales. The Company follows the provisions of the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605‑25, “Revenue Recognition—Multiple‑Element Arrangements,” and ASC Topic 605‑28, “Revenue Recognition—Milestone Method,” in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has stand‑alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

At March 31, 2017, the Company had the following two material types of agreements with the parties identified below:

Development and commercialization licenses, which provide the party with the right to use the Company’s ADC technology and/or certain other intellectual property to develop compounds to a specified antigen target:

Amgen (two exclusive single-target licenses(1))

Bayer (one exclusive single-target license)

Table of Contents

Biotest (one exclusive single-target license)

CytomX (one exclusive single-target license)

Fusion Pharmaceuticals (one exclusive single-target license)

Lilly (three exclusive single-target licenses)

Novartis (five exclusive single-target licenses and one license to two related targets: one target on an exclusive basis and the second target on a non-exclusive basis)

Roche, through its Genentech unit (five exclusive single-target licenses)

Sanofi (one exclusive single-target license and one exclusive license to multiple individual targets)

Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (one exclusive single-target license)

⁽¹⁾

Amgen has sublicensed one of its exclusive single-target licenses to Oxford BioTherapeutics Ltd.

Research license/option agreement for a defined period of time to secure development and commercialization licenses to use the Company’s ADC technology to develop anticancer compounds to specified targets on established terms (referred to herein as right-to-test agreements):

CytomX

Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.

There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.

Development and Commercialization Licenses

The deliverables under a development and commercialization license agreement generally include the license to the Company’s ADC technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research activities to be performed on behalf of the collaborative partner and the manufacture of preclinical or clinical materials for the collaborative partner.

Generally, development and commercialization licenses contain non‑refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator’s request, provide research services at negotiated prices which are generally consistent with what other third parties would charge, (ii) at the collaborator’s request, manufacture and provide to it preclinical and clinical materials or deliver cytotoxic agents at negotiated prices which are generally consistent with what other third parties would charge, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments, generally until the later of the last applicable patent expiration or 10 to 12 years after product launch. In the case of Kadcyla®, however, the minimum royalty term is 10 years and the maximum royalty term is 12 years on a country‑by‑country basis, regardless of patent protection. Royalty rates may vary over the royalty term depending on the Company’s intellectual property rights and/or the presence of comparable competing products. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. The Company does not directly control when or whether any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments. As a result, the Company cannot predict when or if it will recognize revenues in connection with any of the foregoing.

Table of Contents

availability of ADC technology research expertise in the general marketplace. If the Company concludes that the license has stand‑alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity‑specific factors such as the terms of the Company’s previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s ADC technology, the Company’s pricing practices and pricing objectives, the likelihood that technological improvements will be made, and, if made, will be used by the Company’s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services.

Upfront payments on development and commercialization licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand‑alone value from the undelivered elements, which generally include rights to future technological improvements, research services, delivery of cytotoxic agents and the manufacture of preclinical and clinical materials.

The Company recognizes revenue related to research services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.

The Company may also provide cytotoxic agents to its collaborators or produce preclinical and clinical materials at negotiated prices which are generally consistent with what other third parties would charge. The Company recognizes revenue on cytotoxic agents and on preclinical and clinical materials when the materials have passed all quality testing required for collaborator acceptance and title and risk of loss have transferred to the collaborator. Arrangement consideration allocated to the manufacture of preclinical and clinical materials in a multiple‑deliverable arrangement is below the Company’s full cost, and the Company’s full cost is not expected to ever be below its contract selling prices for its existing collaborations. During the three months ended March 31, 2017 and 2016, the difference between the Company’s full cost to manufacture preclinical and clinical materials on behalf of its collaborators as compared to total amounts received from collaborators for the manufacture of preclinical and clinical materials was $727,000 and $3.0 million, respectively. The majority of the Company’s costs to produce these preclinical and clinical materials are fixed and then allocated to each batch based on the number of batches produced during the period. Therefore, the Company’s costs to produce these materials are significantly affected by the number of batches produced during the period. The volume of preclinical and clinical materials the Company produces is directly related to the scale and scope of preclinical activities and the number of clinical trials the Company and its collaborators are preparing for or currently have underway, the speed of enrollment in those trials, the dosage schedule of each clinical trial and the time period such trials last. Accordingly, the volume of preclinical and clinical materials produced, and therefore the Company’s per‑batch costs to manufacture these preclinical and clinical materials, may vary significantly from period to period.

The Company may also produce research material for potential collaborators under material transfer agreements. Additionally, the Company performs research activities, including developing antibody specific conjugation processes, on behalf of its collaborators and potential collaborators during the early evaluation and preclinical testing stages of drug development. The Company records amounts received for research materials produced or services performed as a component of research and development support revenue. The Company also develops conjugation processes for materials for later stage testing and commercialization for certain collaborators. The Company is compensated at negotiated rates and may receive milestone payments for developing these processes which are recorded as a component of research and development support revenue.

The Company’s development and commercialization license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration, or FDA, or other countries’ regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.

Table of Contents

At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Non‑refundable development and regulatory milestones that are expected to be achieved as a result of the Company’s efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we do not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.

Under the Company’s development and commercialization license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. Generally, under these agreements the Company is to receive royalty reports and payments from its licensees approximately one quarter in arrears, that is, generally in the second or third month of the quarter after the licensee has sold the royalty bearing product or products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. As such, the Company generally recognizes royalty revenues in the quarter reported to the Company by its licensees, or one quarter following the quarter in which sales by the Company’s licensees occurred.

Right‑to‑Test Agreements

The Company’s right‑to‑test agreements provide collaborators the right to (a) test the Company’s ADC technology for a defined period of time through a research, or right‑to‑test, license, (b) take options, for a defined period of time, to specified targets and (c) upon exercise of those options, secure or “take” licenses to develop and commercialize products for the specified targets on established terms. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as “upfront” fees or payments), (ii) upon taking an option with respect to a specific target (referred to as option fees or payments earned, if any, when the option is “taken”), (iii) upon the exercise of a previously taken option to acquire a development and commercialization license(s) (referred to as exercise fees or payments earned, if any, when the development and commercialization license is “taken”), or (iv) some combination of all of these fees.

The accounting for right to test agreements is dependent on the nature of the options granted to the collaborative partner. Options are considered substantive if, at the inception of a right to test agreement, the Company is at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments or economic penalties imposed on the collaborator as a result of exercising the options. None of the Company’s right to test agreements entered into subsequent to the adoption of Accounting Standards Update, or ASU, No. 2009 13, “Revenue Arrangements with Multiple Deliverables” on July 1, 2010 has been determined to contain substantive options. For right to test agreements where the options to secure development and commercialization licenses to the Company’s ADC technology are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple element revenue recognition criteria to determine the appropriate revenue recognition. Subsequent to the adoption of ASU No. 2009-13, the Company determined that its research licenses lack stand-alone value and are considered for aggregation with the other elements of the arrangement and accounted for as one unit of accounting.

Table of Contents

The Company does not control when or if any collaborator will exercise its options for development and commercialization licenses. As a result, the Company cannot predict when or if it will recognize revenues in connection with any of the foregoing.

Financial Instruments and Concentration of Credit Risk

Cash and cash equivalents are primarily maintained with three financial institutions in the U.S. Deposits with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. The Company’s cash equivalents consist of money market funds with underlying investments primarily being U.S. Government issued securities and high quality, short term commercial paper. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. The Company held no marketable securities as of March 31, 2017 and December 31, 2016. The Company’s investment policy, approved by the Board of Directors, limits the amount it may invest in any one type of investment, thereby reducing credit risk concentrations.

Cash and Cash Equivalents

All highly liquid financial instruments with maturities of three months or less when purchased are considered cash equivalents. As of March 31, 2017 and December 31, 2016, the Company held $126.6 million and $160.0 million, respectively, in cash and money market funds consisting principally of U.S. Government-issued securities and high quality, short-term commercial paper which were classified as cash and cash equivalents.

Non-cash Investing Activities

The Company had approximately $104,000 and $356,000 of accrued capital expenditures as of March 31, 2017 and December 31, 2016, respectively, which have been treated as a non-cash investing activity and, accordingly, are not reflected in the consolidated statement of cash flows.

Fair Value of Financial Instruments

Fair value is defined under ASC Topic 820, “Fair Value Measurements and Disclosures,” as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy to measure fair value which is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Table of Contents

As of March 31, 2017, the Company held certain assets that are required to be measured at fair value on a recurring basis. The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2017 (in thousands):

Fair Value Measurements at March 31, 2017 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

108,296

—

As of December 31, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis. The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2016 (in thousands):

Fair Value Measurements at December 31, 2016 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

144,176

—

The fair value of the Company’s cash equivalents is based on quoted prices from active markets.

The carrying amounts reflected in the consolidated balance sheets for accounts receivable, unbilled revenue, prepaid and other current assets, accounts payable, accrued compensation, and other accrued liabilities approximate fair value due to their short‑term nature. The gross carrying amount and estimated fair value of the convertible 4.5% senior notes was $100.0 million and $111.0 million, respectively, as of March 31, 2017 compared to $100.0 million and $79.0 million, respectively, as of December 31, 2016. The increase in estimated fair value as of March 31, 2017 compared to December 31, 2016 is due primarily to an increase in the Company’s stock price. The fair value of the Convertible Notes is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in a market which is a Level 2 input for fair value purposes.

Unbilled Revenue

The majority of the Company’s unbilled revenue at March 31, 2017 represents research funding earned prior to that date based on actual resources utilized under the Company’s agreements with various collaborators. In addition to that type of unbilled revenue, also included in unbilled revenue at December 31, 2016 was a $5 million partner milestone achieved in December 2016 which was subsequently invoiced in January 2017 and received in March 2017.

Inventory

Inventory costs relate to clinical trial materials being manufactured for sale to the Company’s collaborators. Inventory is stated at the lower of cost or net realizable value as determined on a first-in, first-out (FIFO) basis.

Inventory at March 31, 2017 and December 31, 2016 is summarized below (in thousands):


	March 31,		December 31,
	2017		2016
Raw materials	$	125	$	357
Work in process		3,100		1,835
Total	$	3,225	$	2,192

Table of Contents

than a twelve month supply of raw materials that is not supported by firm, fixed orders and/or projections from its collaborators to be excess and establishes a reserve to reduce to zero the value of any such excess raw material inventory with a corresponding charge to research and development expense. In accordance with this policy, the Company recorded $403,000 of expense related to excess inventory in the three months ended March 31, 2017 as a result of inventory purchased in the current period in order to manufacture drug product to supply the Company’s mirvetuximab soravtansine studies. There were no expenses recorded for excess inventory during the three-month period ended March 31, 2016.

Work in process inventory consists of conjugate manufactured for sale to the Company’s collaborators to be used in preclinical and clinical studies. All conjugate is made to order at the request of the collaborators and subject to the terms and conditions of respective supply agreements. Based on historical reprocessing or reimbursement required for conjugate that did not meet specification and status of current conjugate on hand or conjugate shipped to collaborators but not yet released per the terms of the respective supply agreements, no reserve for work in process inventory was determined to be required at March 31, 2017. As discussed above, the Company’s costs to manufacture conjugate on behalf of its partners are greater than the supply prices charged to partners, and therefore costs are capitalized into inventory at the supply prices which represents net realizable value.

Computation of Net Loss per Common Share

Basic and diluted net loss per share is calculated based upon the weighted average number of common shares outstanding during the period. During periods of income, participating securities are allocated a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities (the “two-class method”). Shares of the Company’s restricted stock participate in any dividends declared by the Company and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to participating securities since they have no contractual obligation to share in the losses of the Company. Diluted (loss) income per share is computed after giving consideration to the dilutive effect of stock options and restricted stock that are outstanding during the period, except where such non-participating securities would be anti-dilutive.

The Company’s common stock equivalents, as calculated in accordance with the treasury‑stock method for the options and the if-converted method for the convertible notes, are shown in the following table (in thousands):


	Three Months Ended
	March 31,
	2017	2016
Options outstanding to purchase common stock and unvested restricted stock	13,690	11,679
Common stock equivalents under treasury stock method for options	110	361
Shares issuable upon conversion of convertible notes	23,878	—
Common stock equivalents under if-converted method for convertible notes	23,878	—

The Company’s common stock equivalents have not been included in the net loss per share calculation because their effect is anti‑dilutive due to the Company’s net loss position.

Stock-Based Compensation

As of December 31, 2016, the Company is authorized to grant future awards under one employee share‑based compensation plan, which is the ImmunoGen, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan, or the 2016 Plan. At the annual meeting of shareholders on December 9, 2016, the 2016 Plan was approved and provides for the issuance of Stock Grants, the grant of Options and the grant of Stock‑Based Awards for up to 5,500,000 shares of the Company’s common stock, as well as up to 14,250,000 shares of common stock which represent awards granted under the previous stock option plan, the ImmunoGen, Inc. 2006 Employee, Director and Consultant Equity Incentive Plan, or the 2006 Plan, that forfeit, expire, or cancel without delivery of shares of common stock or which resulted in the forfeiture of shares of common stock back to the Company subsequent to December 9, 2016. Option awards are granted

Table of Contents

with an exercise price equal to the market price of the Company’s stock at the date of grant. Options vest at various periods of up to four years and may be exercised within ten years of the date of grant.

The stock-based awards are accounted for under ASC Topic 718, “Compensation—Stock Compensation.” Pursuant to Topic 718, the estimated grant date fair value of awards is charged to the statement of operations and comprehensive loss over the requisite service period, which is the vesting period. Such amounts have been reduced by an estimate of forfeitures of all unvested awards. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model with the assumptions noted in the following table. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. Expected volatility is based exclusively on historical volatility data of the Company’s stock. The expected term of stock options granted is based exclusively on historical data and represents the period of time that stock options granted are expected to be outstanding. The expected term is calculated for and applied to one group of stock options as the Company does not expect substantially different exercise or post-vesting termination behavior among its option recipients. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options.



	Three Months Ended March 31,
	2017		2016
Dividend	None		None
Volatility	66.89	%	63.90	%
Risk-free interest rate	2.03	%	1.61	%
Expected life (years)	6.0		6.3

Using the Black-Scholes option-pricing model, the weighted average grant date fair values of options granted during the three months ended March 31, 2017 and 2016 were $1.52 and $5.55 per share, respectively.

A summary of option activity under the 2006 and 2016 Plans as of March 31, 2017, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):


		Weighted-
	Number	Average
	of Stock	Exercise
	Options	Price
Outstanding at December 31, 2016	13,679	$	10.70
Granted	1,187	$	2.48
Exercised	—
Forfeited/Canceled	(1,176)	$	11.27
Outstanding at March 31, 2017	13,690	$	9.94

In August 2016 and February 2017, the Company granted 117,800 shares and 529,830 shares of restricted common stock with grant date fair values of $3.15 and $2.47, respectively, to certain officers of the Company. These restrictions will lapse in three equal installments upon the achievement of specified performance goals within the next five years. The Company determined it is not currently probable that these performance goals will be achieved, and therefore, no expense has been recorded to date.

Table of Contents

A summary of restricted stock activity under the 2006 and 2016 Plans (inclusive of the performance awards noted above) as of March 31, 2017 and changes during the three month period ended March 31, 2017 is presented below (in thousands):


		Weighted-
	Number of	Average
	Restricted	Exercise
	Stock Shares	Price
Unvested at December 31, 2016	199	$	4.41
Awarded	2,014	$	2.47
Vested	(6)	$	6.53
Forfeited	(20)	$	3.15
Unvested at March 31, 2017	2,187	$	2.63

Stock compensation expense related to stock options and restricted stock awards granted under the 2016 and 2006 Plans was $2.6 million and $7.2 million during the three months ended March 31, 2017 and 2016, respectively. During the three months ended March 31, 2016, the Company recorded $2.8 million of stock compensation cost related to the modification of certain outstanding common stock options with the former Chief Executive Officer’s succession plan. The decrease in expense is also attributable to lower fair values associated with awards vesting in the current period, level of forfeitures experienced since the prior year due to the restructuring disclosed in Note G and greater forfeitures recorded in the current period substantially resulting from the departure of certain senior-level employees. As of March 31, 2017, the estimated fair value of unvested employee awards was $20.2 million, net of estimated forfeitures. The weighted-average remaining vesting period for these awards is approximately two years. Also included in stock compensation expense for the three months ended March 31, 2017 and 2016 are $38,000 and $108,000, respectively, of expense recorded for directors’ deferred share units, the details of which are discussed in Note F.

Segment Information

During the three months ended March 31, 2017, the Company continued to operate in one operating segment which is the business of discovery of monoclonal antibody-based anticancer therapeutics.

The percentages of revenues recognized from significant customers of the Company in the three months ended March 31, 2017 and 2016 are included in the following table:


	Three Months Ended
	March 31,
Collaborative Partner:	2017		2016
Bayer	—	%	51	%
CytomX	48	%	3	%
Roche	27	%	37	%
Sanofi	21	%	—	%

There were no other customers of the Company with significant revenues in the three months ended March 31, 2017 and 2016.

Recent Accounting Pronouncements

Table of Contents

clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company anticipates using the modified retrospective approach to implement this standard. The Company has begun to analyze its existing revenue agreements to evaluate the impact of adoption. The Company has less than ten contracts that have remaining performance obligations that will need to be evaluated under the provisions of the new standard as of January 1, 2018. In performing this assessment, the Company noted that we will be required to recognize royalty income in the same period as the related sales occur on Kadcyla rather than one quarter in arrears, which is the point in which the amount is fixed and determinable. This will require the Company to make an estimate of the royalties as the information is not provided to the Company until 90 days after the end of the quarter. Additionally, some partner milestones, depending on the probability of occurring, may be recognized sooner and at different values than they currently would be under the current accounting standards. The Company is in the process of estimating the impact of adopting the new standard on its consolidated financial statements, however, the Company expects to record a material adjustment upon adoption, which will be recorded as a cumulative effect of initially applying the standard to opening accumulated deficit as of January 1, 2018. The Company will continue to provide disclosures under the legacy accounting for the year ended December 31, 2018.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330). To simplify the principles for subsequent measurement of inventory, this new standard requires inventory measured using any method other than LIFO or the retail method shall be measured at the lower of cost and net realizable value, rather than lower of cost or market. This guidance is effective for annual reporting beginning after December 15, 2016, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.

In January 2016, the FASB issued ASU 2016-1, Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825). The amendments in this Update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. The amendments allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment. The amendments also require enhanced disclosures about those investments. The amendments improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. This guidance is effective for annual reporting beginning after December 15, 2017, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, the standard is effective for the Company on January 1, 2018. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842) that primarily requires lessees to recognize most leases on their balance sheets but record expenses on their income statements in a manner similar to current accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and calls for retrospective application, with early adoption permitted. Accordingly, the standard is effective for the Company on January 1, 2019. The Company is currently evaluating the impact of this guidance on our financial statements and the timing of adoption.

Table of Contents

requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. As a result of the adoption of this guidance, the net operating losses deferred tax assets for federal and state purposes increased by $9.2 million and $1.2 million, respectively, and will be offset by corresponding increases in the valuation allowance. The adoption of the guidance has no impact on the Company’s consolidated financial statements. The Company elected not to adopt the provision that would allow actual forfeitures to be recognized in lieu of maintaining a forfeitures reserve. As such, the Company will continue to estimate forfeitures.

C. Agreements

Significant Collaborative Agreements

Roche

In 2000, the Company granted Genentech, now a unit of Roche, an exclusive license to use the Company’s maytansinoid ADC technology with antibodies, such as trastuzumab, or other proteins that target HER2. Under the terms of this agreement, Roche has exclusive worldwide rights to develop and commercialize maytansinoid ADC compounds targeting HER2. In 2013, the HER2‑targeting ADC compound, Kadcyla, was approved for marketing in the U.S., Japan and the European Union, or EU. Roche has also received marketing approval in various other countries around the world. Roche is responsible for the manufacturing, product development and marketing of any products resulting from the agreement. The Company received a $2 million non‑refundable upfront payment from Roche upon execution of the agreement. The Company is also entitled to receive up to a total of $44 million in milestone payments, plus royalties on the commercial sales of Kadcyla or any other resulting products. Total milestones are categorized as follows: development milestones—$13.5 million; and regulatory milestones—$30.5 million. Through March 31, 2017, the Company has received and recognized $13.5 million and $20.5 million in development and regulatory milestone payments, respectively, related to Kadcyla. The next potential milestone the Company will be entitled to receive will be a $5 million regulatory milestone for marketing approval of Kadcyla for a first extended indication as defined in the agreement. Based on an evaluation of the effort contributed towards the achievement of this future milestone, the Company determined this milestone is not substantive.

The Company receives royalty reports and payments related to sales of Kadcyla from Roche one quarter in arrears. In accordance with the Company’s revenue recognition policy, $7.6 million of non-cash royalties on net sales of Kadcyla for the three‑month period ended December 31, 2016 were recorded and included in non-cash royalty revenue for the three-month period ended March 31, 2017 and $7.4 million of non-cash royalties on net sales of Kadcyla for the three‑month period ended December 31, 2015 is included in non-cash royalty revenue for the three-month period ended March 31, 2016. Kadcyla sales occurring after January 1, 2015 are covered by a royalty purchase agreement whereby the associated cash is remitted to Immunity Royalty Holdings, L.P, or IRH, as discussed further in Note E.

Sanofi

In 2003, the Company entered into a broad collaboration agreement with Sanofi (formerly Aventis) to discover, develop and commercialize antibody‑based products. The collaboration agreement provides Sanofi with worldwide development and commercialization rights to new antibody‑based products directed to targets that are included in the collaboration, including the exclusive right to use the Company’s maytansinoid ADC technology in the creation of products developed to these targets. The product candidates (targets) as of March 31, 2017 in the collaboration include isatuximab (CD38), SAR566658 (CA6), SAR408701 (CEACAM5) and one earlier‑stage program that has yet to be disclosed.

The Company is entitled to receive milestone payments potentially totaling $21.5 million, per target, plus royalties on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$7.5 million; and regulatory milestones—$14 million. Through March 31, 2017, the Company has

Table of Contents

recognized an aggregate of $26.5 million in milestone payments for compounds covered under this agreement now or in the past. In January 2017, Sanofi enrolled its first patient in a Phase III clinical trial for isatuximab, and in March 2017, enrolled its first patient in a Phase IIb clinical trial (as defined in the agreement) for SAR566658, each of which triggered a $3 million milestone payment to the Company, which are included in license and milestone fee revenue for the three months ended March 31, 2017. The next potential milestone the Company will be entitled to receive for SAR566658 will be a development milestone for initiation of a Phase III clinical trial, which will result in a $3 million payment being due. The next potential milestone the Company will be entitled to receive with respect to isatuximab will be a regulatory milestone for submission of a new drug application to the U.S. Food and Drug Administration, which will result in a $3 million payment being due. The next potential milestone the Company will be entitled to receive for SAR408701 will be a development milestone for initiation of a Phase IIb clinical trial (as defined in the agreement), which will result in each case in a $3 million payment being due. The next potential milestone the Company will be entitled to receive for the unidentified target will be a development milestone for commencement of a Phase I clinical trial, which will result in a $1 million payment being due. At the time of execution of this agreement, there was significant uncertainty as to whether these milestones would be achieved. In consideration of this, as well as the Company’s past involvement in the research and manufacturing of these product candidates, these milestones were deemed substantive.

Bayer

In 2008, the Company granted Bayer an exclusive development and commercialization license to the Company’s maytansinoid ADC technology for use with antibodies or other proteins that target mesothelin. Bayer HealthCare is responsible for the research, development, manufacturing, and marketing of any products resulting from the license. The Company received a $4 million upfront payment upon execution of the agreement which was recognized as revenue ratably over the Company’s estimated period of substantial involvement which concluded in September 2012. For each compound developed and marketed by Bayer under this collaboration the Company is entitled to receive a total of $170.5 million in milestone payments, plus tiered royalties between 4 - 7% on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$16 million; regulatory milestones—$44.5 million; and sales milestones—$110 million. Through March 31, 2017, the Company has received and recognized an aggregate of $13 million in milestone payments under this agreement. In January 2016, Bayer initiated a Phase II clinical study designed to support registration of its ADC product candidate, anetumab ravtansine, triggering a $10 million development milestone payment to the Company which is included in license and milestone fee revenue for the three months ended March 31, 2016. The next potential milestone the Company will be entitled to receive will be either a development milestone for commencement of a pivotal clinical trial for a second indication for anetumab ravtansine which will result in a $2 million payment being due or a regulatory milestone for filing of regulatory approval for its first indication for anetumab ravtansine which will result in a $6 million payment being due. At the time of execution of this agreement, there was significant uncertainty as to whether these milestones would be achieved. In consideration of this, as well as the Company’s past involvement in the research and supply of cytotoxic agent for this product candidate, these milestones was deemed substantive.

CytomX

In January 2014, we entered into a reciprocal right‑to‑test agreement with CytomX. The agreement provides CytomX with the right to test our payload agents and linkers with CytomX antibodies that utilize their proprietary antibody-masking technology, termed ProbodiesTM for a specified number of targets and to subsequently take an exclusive, worldwide license to use our technology to develop and commercialize Probody-drug conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. We received no upfront cash payment in connection with the execution of the right‑to‑test agreement. Instead, we received reciprocal rights to test our payload agents and linkers with ImmunoGen antibodies masked using CytomX technology to create Probody-drug conjugates directed to a specified number of targets and to subsequently take exclusive, worldwide licenses to develop and commercialize such conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. The terms of the right‑to‑test agreement require us and CytomX to each take its respective development and commercialization licenses by the end of the term of the research license. In addition, both we and CytomX are required to perform specific research activities under the right‑to‑test agreement on behalf of the other party for no monetary consideration.

Table of Contents

In February 2016, CytomX took its development and commercialization license for a specified target. An amendment of the agreement executed simultaneously with that license granted CytomX the right, for a specified period of time, to substitute the specified target with another as yet unspecified target. Accordingly, the revenue associated with this license was deferred until the expiration of that substitution right in January 2017, whereupon we recognized $12.7 million of the $13 million of arrangement consideration allocated to the development and commercialization license, which is included in license and milestone fee revenue for the three months ended March 31, 2017. With respect to the development and commercialization license taken by CytomX, the Company is entitled to receive up to a total of $160 million in milestone payments plus royalties on the commercial sales of any resulting product. The total milestones are categorized as follows: development milestones—$10 million; regulatory milestones—$50 million; and sales milestones—$100 million. In addition, CytomX may be liable to pay annual maintenance fees if the licensed product candidate covered under the development and commercialization license has not progressed to a specified stage of development within a specified time frame. Assuming no annual maintenance fee is payable, the next payment the Company could receive would be a $1 million development milestone payment with commencement of a Phase I clinical trial. At the time of execution of the right-to-test agreement, there was significant uncertainty as to whether the milestone related to the Phase I clinical trial would be achieved. In consideration of this, as well as the Company's expected involvement in the research and manufacturing of any product candidate, this milestone was deemed substantive. CytomX is responsible for the manufacturing, product development and marketing of any product resulting from the development and commercialization license taken by CytomX under this collaboration.

For additional information related to these agreements, as well as the Company’s other significant collaborative agreements, please read Note C, Agreements, to the consolidated financial statements included within the Company’s 2016 Transition Report on Form 10-K

D. Convertible 4.5% Senior Notes

In June 2016, the Company issued Convertible 4.5% Senior Notes with an aggregate principal amount of $100 million. The Company received net proceeds of approximately $96.6 million from the sale of the Convertible Notes, after deducting fees and expenses of approximately $3.4 million.

The Convertible Notes are governed by the terms of an indenture between the Company, as issuer, and Wilmington Trust, National Association, as the trustee. The Convertible Notes are senior unsecured obligations and bear interest at a rate of 4.5% per year, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2017. The Company recorded approximately $1.1 million of interest expense in the three months ended March 31, 2017. The Convertible Notes will mature on July 1, 2021, unless earlier repurchased or converted. Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the stated maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted notes a number of shares equally to the conversion rate, which will initially be 238.7775 shares of common stock, equivalent to an initial conversion price of approximately $4.19. The conversion rate will be subject to adjustment in some circumstances, but will not be adjusted for any accrued and unpaid interest. In addition, if a “make-whole fundamental change” (as defined in the offering memorandum) occurs prior to the stated maturity date, the Company will increase the conversion rate for a holder who elects to convert its notes in connection with such make-whole fundamental change in certain circumstances. If the Company undergoes a fundamental change, subject to certain conditions, holders may require the Company to repurchase for cash all or part of their notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date. In addition, upon an event of default, the holders may require the Company to repurchase for cash all of their notes at a purchase price equal to 100% of the principal amount, plus accrued and unpaid interest. Upon bankruptcy, this becomes an automatic repurchase obligation. Also, if the Company fails to comply with certain reporting requirements as described in the indenture it will constitute an event of default, however the Company may elect to pay additional interest at an annual rate equal to 0.5% of the principal amount for the 90 days following such event as a remedy for the default. Subsequent to the 90 days, if still in default, the principal amount of the notes and accrued interest may become immediately due and payable. If a “restricted event” occurs as described in the indenture that causes the notes not to become freely tradable by holders other than our affiliates after the first anniversary of the original issuance date of the notes, the Company would also become obligated to pay additional interest at an annual rate equal to 0.5% of the principal amount. The combined additional interest rate under these two circumstances, however, cannot exceed 0.5%.

Table of Contents

The Company analyzed the terms of the Convertible Notes and determined that under current accounting guidance the notes would be entirely accounted for as debt and none of the terms of the notes require separate accounting. As part of the issuance of the Convertible Notes, the Company incurred $3.4 million of transaction costs, which are netted against the Convertible Notes in the accompanying consolidated balance sheet as and are being amortized to interest expense ratably over the term of the Convertible Notes.

E. Liability Related to Sale of Future Royalties

In April 2015, Immunity Royalty Holdings, L.P. (IRH) purchased the right to receive 100% of the royalty payments on commercial sales of Kadcyla subsequent to December 31, 2014, arising under the Company’s development and commercialization license with Genentech (a unit of Roche), until IRH has received aggregate royalties equal to $235 million or $260 million, depending on when the aggregate royalties received by IRH reach a specified milestone. Once the applicable threshold is met, if ever, the Company will thereafter receive 85% and IRH will receive 15% of the Kadcyla royalties for the remaining royalty term. At consummation of the transaction in April 2015, the Company received cash proceeds of $200 million. As part of this sale, the Company incurred $5.9 million of transaction costs, which are presented net of the liability in the accompanying consolidated balance sheet and will be amortized to interest expense over the estimated life of the royalty purchase agreement. Although the Company sold its rights to receive royalties from the sales of Kadcyla, as a result of its ongoing involvement in the cash flows related to these royalties, the Company will continue to account for these royalties as revenue and recorded the $200 million in proceeds from this transaction as a liability related to sale of future royalties (Royalty Obligation) that will be amortized using the interest method over the estimated life of the royalty purchase agreement.

The following table shows the activity within the liability account during the three-month period ended March 31, 2017 (in thousands):


	Period from
	December 31, 2016 to
	March 31, 2017
Liability related to sale of future royalties, net — beginning balance	$	184,328
Non-cash Kadcyla royalty revenue		(7,613)
Non-cash interest expense recognized		3,409
Liability related to sale of future royalties, net — ending balance	$	180,124

As royalties are remitted to IRH, the balance of the Royalty Obligation will be effectively repaid over the life of the agreement. In order to determine the amortization of the Royalty Obligation, the Company is required to estimate the total amount of future royalty payments to be received and remitted to IRH as noted above over the life of the agreement. The sum of these amounts less the $200 million proceeds the Company received will be recorded as interest expense over the life of the Royalty Obligation. Since inception, the Company’s estimate of this total interest expense resulted in an effective annual interest rate of approximately 7.7%. The Company periodically assesses the estimated royalty payments to IRH and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the Royalty Obligation. There are a number of factors that could materially affect the amount and timing of royalty payments from Genentech, most of which are not within the Company’s control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, patent protection, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to IRH are made in U.S. dollars (USD) while significant portions of the underlying sales of Kadcyla are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from Kadcyla, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Obligation. Conversely, if sales of Kadcyla are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Obligation.

Table of Contents

In addition, the royalty purchase agreement grants IRH the right to receive certain reports and other information relating to the royalties and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature.

F. Capital Stock

2001 Non-Employee Director Stock Plan

During the three months ended March 31, 2017, the Company recorded approximately $12,000 in expense related to stock units outstanding under the Company’s 2001 Non-Employee Director Stock Plan, or the 2001 Plan, compared to ($32,000) in expense reduction recorded during the three months ended March 31, 2016. The value of the stock units are classified as a liability and adjusted to market value at each reporting period as the redemption amount of stock units for this plan will be paid in cash. No stock units have been issued under the 2001 Plan subsequent to June 30, 2004.

Compensation Policy for Non-Employee Directors

On December 9, 2016 the Board amended the Compensation Policy for Non-Employee Directors to create a transition period due to the change in the year-end. Effectively, one-half of the annual compensation awards described below were awarded to the directors on December 9, 2016 and a full-year’s compensation will be awarded at the date of the next annual meeting.

Pursuant to the Compensation Policy for Non-Employee Directors, the redemption amount of deferred share units issued will be paid in shares of common stock of the Company on the date a director ceases to be a member of the Board. Annual retainers vest quarterly over approximately one year from the date of grant, contingent upon the individual remaining a director of ImmunoGen as of each vesting date. The number of deferred share units awarded is fixed per the plan on the date of the award. All unvested deferred stock awards will automatically vest immediately prior to the occurrence of a change of control.

During the three months ended March 31, 2017, the Company recorded approximately $38,000 in compensation expense, respectively, related to deferred share units issued and outstanding under the Company’s Compensation Policy for Non-Employee Directors, compared to $108,000 in compensation expense recorded during the three months ended March 31, 2016. Pursuant to the Compensation Policy for Non-Employee Directors, in January 2017, the Company issued a retiring director 53,248 shares of common stock of the Company to settle outstanding deferred share units.

In addition to the deferred share units, the Non-Employee Directors are also entitled to receive a fixed number of stock options determined using the Black-Scholes option pricing model measured on the date of grant, which would be the date of the annual meeting of shareholders. These options vest quarterly over approximately one year from the date of grant. Any new directors will receive a pro-rated award, depending on their date of election to the Board. The directors received a total of 80,000 stock options in November of 2015 and a total of 40,000 options in December 2016, and the related compensation expense for the three months ended March 31, 2017 and 2016 is included in the amounts discussed in the “Stock-Based Compensation” section of footnote B above.

G. Restructuring Charge

On September 26, 2016, the Board of Directors approved a plan to reengineer the business, resulting in a reduction of the workforce by approximately 17%, or 65 positions, which included the separation of 60 current employees. Communication of the plan to the impacted employees was substantially completed on September 29, 2016. All of the workforce reduction was completed as of December 31, 2016. As a result of the workforce reduction, in the six months ended December 31, 2016, the Company recorded a restructuring charge totaling $4.4 million related to termination benefits and other related charges, of which $2.8 million was recorded as a one-time termination benefit, and $593,000 recorded as a benefit under an ongoing benefit plan. The related cash payments initiated in October 2016 and will be substantially paid out by June 30, 2017. Additionally, approximately 762,000 stock options forfeited in connection with the workforce reduction, and as a result, the Company recorded an approximate $837,000 credit to stock

Table of Contents

compensation expense in September 2016, which was included in research and development expense and general and administrative expense in that period.

In addition to the termination benefits and other related charges, the Company is seeking to sub-lease 10,281 square feet of unoccupied office space in Waltham that was leased in February 2016. As of September 30, 2016, based on an estimate of the potential time it would take to find a tenant of approximately nine months, the anticipated sub-lease terms, and consideration of the tenant allowance that was given to the Company to build out the space, the Company determined it did not need to record a loss on the sub-lease. The Company also evaluated the balance of the leasehold improvements for potential impairment as of September 30, 2016. In performing the recoverability test, the Company concluded that a substantial portion of the leasehold improvements were not recoverable. The Company recorded an impairment charge of $970,000 related to these assets after comparing the fair value (using probability weighted scenarios with discounted cash flows) to the leasehold improvements’ carrying value, leaving a $193,000 remaining cost basis. As of March 31, 2017, based on further evaluation of the prospects for sub-leasing the space, the Company determined that additional time would be required to find a tenant. Accordingly, the calculation for the potential sub-lease loss was updated and it was determined that the remaining balance of the leasehold improvements were impaired. Also, due to the additional time that is expected to secure a tenant, a lease loss was recorded based on the change in estimate of the sub-lease assumption. The total of these charges was $386,000.

A summary of activity against the restructuring charge related to the employee terminations during the three-month period ended March 31, 2017 is as follows (in thousands):



	Period from
	December 31, 2016 to
	March 31, 2017
Balance December 31, 2016	$	1,751
Payments for the period		(1,287)
Balance March 31, 2017	$	464

In September 2016, the Compensation Committee of the Board of Directors approved cash and stock option retention incentive awards for certain remaining eligible employees who continue employment with the Company in order to execute the Company’s strategic priorities. The cash awards will be payable to these employees in either October 2017 or March 2018 based on continued employment and services performed during these periods. Stock option awards covering 847,000 shares were granted and will vest annually in equal installments over three years from the date of grant, and the related compensation expense for the three months ended March 31, 2017 is included in the amounts discussed in the “Stock-Based Compensation” section of footnote B above.

H. Commitments and Contingencies

Leases

The Company currently has a lease agreement with CRP/King 830 Winter L.L.C. for the rental of approximately 110,000 square feet of laboratory and office space at 830 Winter Street, Waltham, MA through March 2026. The Company uses this space for its corporate headquarters and other operations. The Company may extend the lease for two additional terms of five years. Pursuant to lease amendments executed in December 2013, April 2014, and December 2015, the Company received construction allowances of approximately $746,000, $1.1 million, and $186,000, respectively, to build out office and lab space to the Company’s specifications. The Company is required to pay certain operating expenses for the leased premises subject to escalation charges for certain expense increases over a base amount.

In February 2016, the Company entered into a lease agreement with PDM 930 Unit, LLC for the rental of 10,281 square feet of additional office space at 930 Winter Street, Waltham, MA through August 31, 2021. The Company received approximately $617,000 as a construction allowance to build out the office space to the Company’s specifications. The Company is required to pay certain operating expenses for the leased premises based on its pro-rata

Table of Contents

share of such expenses for the entire rentable space of the building. The Company is actively seeking to sub-lease this space.

The Company also leases manufacturing and office space at 333 Providence Highway, Norwood, MA under an agreement through 2018 with an option to extend the lease for an additional term of five years. The Company is required to pay certain operating expenses for the leased premises subject to escalation charges for certain expense increases over a base amount.

Effective April 2013, the Company entered into a lease agreement with River Ridge Limited Partnership for the rental of 7,507 square feet of additional office space at 100 River Ridge Drive, Norwood, MA. The initial term of the lease is for five years and two months commencing in July 2013 with an option for the Company to extend the lease for an additional term of five years. The Company is required to pay certain operating expenses for the leased premises subject to escalation charges for certain expense increases over a base amount. The Company entered into a sublease in December 2014 for this space, effective from January 2015 through July 2018. That sublease is in process of being terminated due to payment delinquency. Due to the short span of time remaining on the lease and the estimated amount of time it would take to find another sub-tenant, the remainder of this lease was accrued as a charge in the quarter in the amount of $169,000.

The minimum rental commitments for the Company’s facilities, including real estate taxes and other expenses, for the next five fiscal years and thereafter under the non-cancelable operating lease agreements discussed above are as follows (in thousands):


2017 (nine months remaining)	$	5,959
2018		7,736
2019		7,235
2020		7,283
2021		7,107
Thereafter		30,794
Total minimum lease payments	$	66,114

There are no obligations under capital leases as of March 31, 2017, as all of the capital leases were single payment obligations which have all been made.

Collaborations

The Company is contractually obligated to make potential future success-based development, regulatory or sales milestone payments in conjunction with certain collaborative agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. As of March 31, 2017, the maximum amount that may be payable in the future under the Company’s current collaborative agreements is $161.8 million, $1.2 million of which is reimbursable by a third party under a separate agreement.

The Company is party to a license agreement covering the manufacture of the antibodies used in certain of product candidates which, under certain circumstances, requires periodic payments once the product reaches a specified stage of clinical development, and royalties on commercial sales of the product. The Company believes that the license agreement, by its terms, does not obligate it to make any further payments thereunder and accordingly, has not accrued a potential payment of £300,000 for one of its product candidates that has reached this stage.

Manufacturing Commitments

As of March 31, 2017, the Company has noncancelable obligations under several agreements related to in-process and future manufacturing of antibody and cytotoxic agents required for clinical supply of the Company’s product candidates totaling $8.6 million, of which $6.8 million will be paid in 2017 and $1.8 million will be paid in 2018.

Table of Contents

In February 2017, the Company executed a letter agreement with one of its antibody manufacturers to reserve capacity through calendar 2021. The total commitment over the five-year term of the agreement is €46.2 million, however only €6.3 million euros is noncancelable as of March 31, 2017.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

OVERVIEW

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using our proprietary antibody-drug conjugate, or ADC, technology. An ADC with our technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of our potent anti-cancer agents as a “payload” to kill the tumor cell once the ADC has bound to its target. ADCs are an expanding approach to the treatment of cancer, with two approved products and the number of agents in development more than doubling during the last five years.

We have established a leadership position in ADCs. Our proprietary portfolio is led by mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, or FRα. Following meetings with the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA, in the third quarter of 2016 to review our protocol, we initiated a Phase 3 registration trial, FORWARD I, with mirvetuximab soravtansine for use as single-agent therapy to treat patients with platinum-resistant ovarian cancer whose tumors express high or medium levels of FRα and who have received up to three prior treatment regimens. Additionally, we are accruing patients in a companion study, FORWARD II, to evaluate mirvetuximab soravtansine in combination regimens to expand the number of patients with ovarian cancer eligible for treatment with the ADC. FORWARD II consists of cohorts assessing mirvetuximab soravtansine in combination with, in separate doublets, Avastin® (bevacizumab), pegylated liposomal doxorubicin, or PLD, and carboplatin. We have also entered into a collaboration with Merck under which Merck is providing Keytruda® (pembrolizumab) for evaluation in combination with mirvetuximab soravtansine as part of the FORWARD II study. We expect to begin reporting clinical findings from FORWARD II in the second quarter of 2017.

We have built a productive platform that continues to generate innovative and proprietary ADCs, including IMGN779, our CD33-targeting product candidate for acute myeloid leukemia, or AML. IMGN779 integrates one of our new DNA-alkylating IGN payload agents and is progressing through dose escalation in a Phase 1 trial in AML. We also are advancing IMGN632, a preclinical CD123-targeting ADC that uses an even more potent IGN payload agent with a new engineered linker and novel antibody, which we are developing for hematological malignancies including AML. We expect to file an Investigational New Drug, or IND, application for IMGN632 in the third quarter of 2017.

In addition to fueling our organic growth, we also selectively license limited rights to use of our ADC technology to other companies. These licenses can provide us with cash through upfront and milestone payments, research and manufacturing support payments, and royalties on commercial sales, if any, as well as access to complementary technology and capabilities. The most advanced partner program is Roche’s marketed product, Kadcyla (ado-trastuzumab emtansine), the first ADC to demonstrate superiority over standard of care in a randomized pivotal trial, EMILIA, and gain FDA approval. Following Kadcyla are nine clinical-stage ADCs with our technology through our partnerships with Amgen, Bayer, Biotest, Lilly, Novartis, and Sanofi. We also have partnerships with Takeda and CytomX, which are in the preclinical stage. We expect that substantially all of our revenue for the foreseeable future will result from payments under our collaborative arrangements. In addition to the discussion below for agreements with activity in the periods presented, details for all of our significant agreements can be found in our 2016 Transition Report on Form 10-K.

Roche—In May 2000, we granted Genentech, now a unit of Roche, an exclusive license to use our maytansinoid ADC technology with antibodies, such as trastuzumab, or other proteins that target HER2. Pursuant to this agreement, Roche developed and received marketing approval for its HER2-targeting ADC compound, Kadcyla, in the U.S., Europe, Japan and numerous other countries. We receive royalty reports and payments related to sales of Kadcyla from Roche one quarter in arrears. In accordance with our revenue recognition policy, $7.6 million of non-cash royalties on net sales of Kadcyla for the three-month period ended December 31, 2016 were recorded and included in non-cash royalty revenue for the three months ended March 31, 2017 and $7.4 million of non-cash royalties on net sales of

Table of Contents

Kadcyla for the three-month period ended December 31, 2015 were included in non-cash royalty revenue for the three months ended March 31, 2016. Kadcyla sales occurring after January 1, 2015 are covered by a royalty purchase agreement whereby the associated cash is remitted to Immunity Royalty Holdings, L.P, or IRH, as discussed further in Note E to the consolidated financial statements.

Sanofi— In July 2003, we entered into a broad collaboration agreement with Sanofi (formerly Aventis) to discover, develop and commercialize antibody‑based products. The collaboration agreement provided Sanofi with worldwide development and commercialization rights to new antibody‑based products directed to targets that were included in the collaboration, including the exclusive right to use our maytansinoid ADC technology in the creation of products developed to these targets. No further targets may be added to this agreement and the product candidates (targets) as of March 31, 2017 in the collaboration include isatuximab (CD38), SAR566658 (CA6), SAR408701 (CEACAM5) and one undisclosed target without an associated clinical-stage product candidate.

We are entitled to receive milestone payments potentially totaling $21.5 million, per target, plus royalties on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$7.5 million; and regulatory milestones—$14 million. Through March 31, 2017, we have recognized an aggregate of $26.5 million in milestone payments for compounds covered under this agreement now or in the past, including a $3 million development milestone related to initiation of a Phase III clinical trial for isatuximab and a $3 million development milestone related to initiation of a Phase IIb clinical trial (as defined in the agreement) for SAR566658 which are included in license and milestone fee revenue for the three months ended March 31, 2017.

Bayer—In October 2008, we granted Bayer an exclusive development and commercialization license to our ADC technology for use with antibodies or other proteins that target mesothelin. We received a $4 million upfront payment upon execution of the agreement, and—for each compound developed and marketed by Bayer under this collaboration—we are entitled to receive a total of $170.5 million in milestone payments, plus royalties on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$16 million; regulatory milestones—$44.5 million; and sales milestones—$110 million. Through March 31, 2017, we have recognized an aggregate of $13 million in milestone payments under this agreement, including a $10 million development milestone related to initiation of a Phase II clinical study designed to support registration of its ADC product candidate, anetumab ravtansine, which is included in license and milestone fee revenue for the three months ended March 31, 2016.

CytomX— In January 2014, we entered into a reciprocal right‑to‑test agreement with CytomX. The agreement provides CytomX with the right to test our payload agents and linkers with CytomX antibodies that utilize their proprietary antibody-masking technology, termed ProbodiesTM for a specified number of targets and to subsequently take an exclusive, worldwide license to use our technology to develop and commercialize Probody-drug conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. We received no upfront cash payment in connection with the execution of the right‑to‑test agreement. Instead, we received reciprocal rights to test our payload agents and linkers with ImmunoGen antibodies masked using CytomX technology to create Probody-drug conjugates directed to a specified number of targets and to subsequently take exclusive, worldwide licenses to develop and commercialize such conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. The terms of the right‑to‑test agreement require us and CytomX to each take its respective development and commercialization licenses by the end of the term of the research license. In addition, both we and CytomX are required to perform specific research activities under the right‑to‑test agreement on behalf of the other party for no monetary consideration.

Table of Contents

as follows: development milestones—$10 million; regulatory milestones—$50 million; and sales milestones—$100 million.

To date, we have not generated revenues from commercial sales of internal products and we expect to incur significant operating losses for the foreseeable future. As of March 31, 2017, we had approximately $126.6 million in cash and cash equivalents compared to $160.0 million in cash and cash equivalents as of December 31, 2016.

We anticipate that future cash expenditures will be partially offset by collaboration-derived proceeds, including milestone payments and upfront fees. Accordingly, period-to-period operational results may fluctuate dramatically based upon the timing of receipt of the proceeds. We believe that our established collaborative agreements, while subject to specified milestone achievements, will provide funding to assist us in meeting obligations under our collaborative agreements while also assisting in providing funding for the development of internal product candidates and technologies. However, we can give no assurances that such collaborative agreement funding will, in fact, be realized in the time frames we expect, or at all. Should we or our partners not meet some or all of the terms and conditions of our various collaboration agreements, we may be required to secure alternative financing arrangements, find additional partners and/or defer or limit some or all of our research, development and/or clinical projects. However, we cannot provide assurance that any such opportunities presented by additional partners or alternative financing arrangements will be entirely available to us, if at all.

Critical Accounting Policies

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to our collaborative agreements, clinical trial accruals, inventory and stock-based compensation. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates.

There were no significant changes to our critical accounting policies from those disclosed in our Transition Report on Form 10-K for the six months ended December 31, 2016.

RESULTS OF OPERATIONS

Comparison of Three Months ended March 31, 2017 and 2016

Revenues

Our total revenues for the three months ended March 31, 2017 and 2016 were $28.5 million and $19.7 million, respectively. The $8.8 million increase in revenues in the three months ended March 31, 2017 from the same period in the prior year is attributable to increases in license and milestone fees, non-cash royalty revenue and research and development support revenue, partially offset by a decrease in clinical materials revenue, all of which are discussed below.

License and milestone fees

The amount of license and milestone fees we earn is directly related to the number of our collaborators, the collaborators’ advancement of the product candidates, and the overall success in the clinical trials of the product candidates. As such, the amount of license and milestone fees may vary significantly from quarter to quarter and year to

Table of Contents

year. Total revenue from license and milestone fees recognized from each of our collaborative partners in the three-month periods ended March 31, 2017 and 2016 is included in the following table (in thousands):


	Three Months Ended March 31,
License and Milestone Fees	2017		2016
Collaborative Partner:
Amgen	$	4	$	4
Bayer		—		10,000
CytomX		12,654		—
Lilly		6		6
Novartis		45		45
Sanofi		6,000		1
Takeda		21		21
Total	$	18,730	$	10,077

Revenues from license and milestone fees for the three months ended March 31, 2017 increased $8.6 million to $18.7 million from $10.1 million in the same period ended March 31, 2016. Included in license and milestone fees for the three months ended March 31, 2017 is $12.7 million of non-cash license revenue earned upon the expiration of the right to replace the target specified under the development and commercialization license with CytomX and $6 million of development milestones achieved under a collaboration and license agreement with Sanofi. Included in license and milestone fees for the three months ended March 31, 2016 is a $10 million development milestone achieved under a license agreement with Bayer.

Deferred revenue of $20.8 million as of March 31, 2017 primarily represents consideration received from our collaborators pursuant to our license agreements, which we have yet to earn pursuant to our revenue recognition policy.

Royalty revenue

Kadcyla is an ADC marketed product resulting from one of our development and commercialization licenses with Roche, through its Genentech unit. We receive royalty reports and payments related to sales of Kadcyla from Roche one quarter in arrears. In accordance with our revenue recognition policy, $7.6 million of non-cash royalties on net sales of Kadcyla for the three-month period ended December 31, 2016 were recorded and included in revenue for the three months ended March 31, 2017 and $7.4 million of royalties on net sales of Kadcyla for the three-month period ended December 31, 2015 is included in revenue for the three months ended March 31, 2016. In April 2015, we consummated a royalty purchase transaction relating to the royalty payments on commercial sales of Kadcyla — see Liquidity and Capital Resources below for further details.

Research and development support revenue

The amount of research and development support revenue we earn is directly related to the number of our collaborators and potential collaborators, the stage of development of our collaborators’ product candidates and the resources our collaborators allocate to the development effort. As such, the amount of development fees may vary widely from quarter to quarter and year to year. Research and development support revenue was $1.5 million for the three months ended March 31, 2017 compared with $1.1 million for the three months ended March 31, 2016. Total revenue recognized from research and development support from each of our collaborative partners in the three-month periods ended March 31, 2017 and 2016 is included in the following table (in thousands):

Table of Contents


	Three Months Ended March 31,
Research and Development Support	2017		2016
Collaborative Partner:
Biotest	$	25	$	77
CytomX		398		565
Lilly		42		127
Novartis		52		31
Takeda		952		185
Other		9		74
Total	$	1,478	$	1,059

Clinical materials revenue

The amount of clinical materials revenue we earn, and the related cost of clinical materials charged to research and development expense, is directly related to the number of clinical trials our collaborators who use us to manufacture clinical materials are preparing or have underway, the speed of enrollment in those trials, the dosage schedule of each clinical trial and the time period, if any, during which patients in the trial receive clinical benefit from the clinical materials, and the demand our collaborators have for clinical‑grade material for process development and analytical purposes. As such, the amount of clinical materials revenue and the related cost of clinical materials charged to research and development expense may vary significantly from quarter to quarter and year to year. Clinical materials revenue decreased by $520,000 during the three months ended March 31, 2017 to $678,000 compared to $1.2 million during the three months ended March 31, 2016. During the periods presented, we shipped clinical materials in support of certain collaborators’ clinical trials. We are compensated at negotiated prices which are generally consistent with what other third‑parties would charge.

Research and Development Expenses

Our research and development expenses relate to (i) research to evaluate new targets and to develop and evaluate new antibodies, linkers and cytotoxic agents, (ii) preclinical testing of our own and, in certain instances, our collaborators’ product candidates, and the cost of our own clinical trials, (iii) development related to clinical and commercial manufacturing processes, and (iv) manufacturing operations which also includes raw materials.

Research and development expense for the three months ended March 31, 2017 decreased $3.2 million to $32.9 million from $36.1 million for the three months ended March 31, 2016. We do not track our research and development costs by project. Since we use our research and development resources across multiple research and development projects, we manage our research and development expenses within each of the categories listed in the following table and described in more detail below (in thousands):


	Three Months Ended March 31,
Research and Development Expense	2017		2016
Research	$	5,634	$	6,285
Preclinical and Clinical Testing		16,850		16,390
Process and Product Development		2,943		3,437
Manufacturing Operations		7,461		9,982
Total Research and Development Expense	$	32,888	$	36,094

Research

Research includes expenses primarily associated with activities to identify and evaluate new targets and to develop and evaluate new antibodies, linkers and cytotoxic agents for our products and in support of our collaborators. Such expenses primarily include personnel, contract services, research licensing fees, facilities and lab supplies.

Table of Contents

Research expenses for the three months ended March 31, 2017 decreased $651,000 compared to the three months ended March 31, 2016. This decrease is principally due to a decrease in salaries and related expenses driven primarily by a decrease in personnel and lower stock compensation expense, as well as a decrease in lab supplies.

Preclinical and Clinical Testing

Preclinical and clinical testing includes expenses related to preclinical testing of our own and, in certain instances, our collaborators’ product candidates, regulatory activities, and the cost of our own clinical trials. Such expenses include personnel, patient enrollment at our clinical testing sites, consultant fees, contract services, and facility expenses. Preclinical and clinical testing expenses for the three months ended March 31, 2017 increased $460,000 to $16.9 million compared to $16.4 million for the three months ended March 31, 2016. This increase is primarily the result of an increase in clinical trial costs, particularly related to the Phase 3 and companion mirvetuximab soravtansine studies, partially offset by a decrease in salaries and related expenses driven substantially by lower stock compensation expense, as well as a decrease in contract services and consulting fees due to timing of certain activities.

Process and Product Development

Process and product development expenses include costs for development of clinical and commercial manufacturing processes for our own and collaborator compounds. Such expenses include the costs of personnel, contract services and facility expenses. For the three months ended March 31, 2017, total development expenses decreased $494,000 compared to the three months ended March 31, 2016. This decrease is principally due to a decrease in contract services driven by decreased development activities related to our IGN cytotoxic agents in the current period, and to a lesser extent, a decrease in lab supplies.

Manufacturing Operations

Manufacturing operations expense includes costs to manufacture preclinical and clinical materials for our own and our collaborator’s product candidates, and quality control and quality assurance activities and costs to support the operation and maintenance of our conjugate manufacturing facility. Such expenses include personnel, raw materials for our and our collaborators’ preclinical studies and clinical trials, development costs with contract manufacturing organizations, manufacturing supplies, and facilities expense. For the three months ended March 31, 2017, manufacturing operations expense decreased $2.5 million to $7.5 million compared to $10.0 million in the same period last year. This decrease is principally the result of: (i) a decrease in salaries and related expenses driven by a decrease in personnel and lower stock compensation expense; (ii) a decrease in cost of clinical materials revenue charged to research and development expense due to timing of orders of such clinical materials from our partners; (iii) an increase in costs capitalized into inventory due to a greater number of manufactured batches of conjugated materials on behalf of our collaborators in the period; (iv) a decrease in mirvetuximab soravtansine third-party conjugation costs driven by timing; and (v) a decrease in contract services due primarily to DMx development activities conducted in the prior year period. Partially offsetting these decreases, antibody costs increased driven primarily by timing of antibody supply requirements to support the mirvetuximab soravtansine studies.

General and Administrative Expenses

General and administrative expenses for the three months ended March 31, 2017 decreased $3.1 million compared to the same period last year. This decrease is primarily due to a $2.8 million non-cash stock compensation charge in the prior quarter resulting from the CEO transition, as well as decreased personnel expenses and patent fees in the current period.

Restructuring Charge

As of March 31, 2017, based on further evaluation of the prospects for sub-leasing our unoccupied office space in Waltham due to the restructuring activities highlighted in Note G, “Restructuring Charge” of the consolidated financial statements, we determined that additional time would be required to find a tenant. Accordingly, the calculation for the potential sub-lease loss was updated and it was determined that the remaining balance of the leasehold

Table of Contents

improvements was impaired. Also, due to the additional time it is expected to take to secure a tenant, a lease loss was recorded based on the change in estimate of the sub-lease assumption. The total of these charges was $386,000.

In September 2016, the Compensation Committee of the Board of Directors approved cash and stock option retention incentive awards for certain remaining eligible employees who continue employment with the Company in order to execute the Company’s strategic priorities. The cash awards will be payable to these employees in either October 2017 or March 2018 based on continued employment and services performed during these periods. Stock option awards covering 847,000 shares were granted and will vest annually in equal installments over three years from the date of grant and the related compensation expense for the three months ended March 31, 2017 is included in the amounts discussed in Note B, “Stock-Based Compensation” of the consolidated financial statements.

Investment Income, net

Investment income for the three months ended March 31, 2017 and 2016 was $115,000 and $108,000, respectively.

Non-Cash Interest Expense on Liability Related to Sale of Future Royalty

In April 2015, Immunity Royalty Holdings, L.P. (IRH) purchased our right to receive 100% of the royalty payments on commercial sales of Kadcyla subsequent to March 31, 2014, arising under our development and commercialization license with Genentech, until IRH has received aggregate royalties equal to $235 million or $260 million, depending on when the aggregate royalties received by IRH reach a specified milestone. As described in Note E to our Consolidated Financial Statements, this royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period as Kadcyla royalties are remitted directly to the purchaser. During the three months ended March 31, 2017, we recorded $3.4 million of non-cash interest expense which includes amortization of deferred financing costs. We impute interest on the transaction and record interest expense at the effective interest rate, which we currently estimate to be 6.8%. There are a number of factors that could materially affect the estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of Kadcyla, and we will assess this estimate on a periodic basis. As a result, future interest rates could differ significantly and any such change in interest rate will be adjusted prospectively.

Interest Expense on Convertible Senior Notes

In June 2016, the Company issued Convertible 4.5% Senior Notes with an aggregate principal amount of $100 million. The Convertible Notes are senior unsecured obligations and bear interest at a rate of 4.5% per year, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2017. The Company recorded approximately $1.1 million of interest expense in the three months ended March 31, 2017.

Other Income, net

Other income, net for the three months ended March 31, 2017 and 2016 was $134,000 and $551,000, respectively. We incurred $136,000 and $548,000 in foreign currency exchange gains related to obligations with non-U.S. dollar-based suppliers and Euro cash balances maintained to fulfill them during the three months ended March 31, 2017 and 2016, respectively.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES


	As of
	March 31,		December 31,
	2017		2016
Cash and cash equivalents	$	126,568	$	159,964
Working capital		101,764		120,570
Shareholders’ deficit		(167,530)		(152,850)



	Three Months Ended March 31,
	2017		2016
		(In thousand)
Cash used for operating activities	$	(32,959)	$	(26,079)
Cash used for investing activities		(437)		(3,479)
Cash provided by financing activities		—		188

Cash Flows

We require cash to fund our operating expenses, including the advancement of our own clinical programs, and to make capital expenditures. Historically, we have funded our cash requirements primarily through equity financings in public markets, payments from our collaborators, including license fees, milestones, research funding, and royalties, and more recently, convertible debt. We have also sold our rights to receive royalties on Kadcyla for up-front consideration. As of March 31, 2017, we had approximately $126.6 million in cash and cash equivalents. Net cash used for operations was $33.0 million and $26.1 million for the three months ended March 31, 2017 and 2016, respectively. The principal use of cash for operating activities for both periods presented was to fund our net loss.

Net cash used for investing activities was $437,000 and $3.5 million for the three months ended March 31, 2017 and 2016, respectively, and represents cash outflows for capital expenditures, primarily for the purchase of new equipment and leasehold improvements.

Net cash provided by financing activities was $188,000 for the three months ended March 31, 2016, which represents proceeds from the exercise of approximately 37,000 stock options. There were no stock option exercises in the three months ended March 31, 2017 due to a decline in the Company’s stock price.

As discussed above, in April 2015, Immunity Royalty Holdings, L.P. purchased our right to receive 100% of the royalty payments on commercial sales of Kadcyla. At consummation of the transaction in April 2015, we received gross cash proceeds of $200 million. We recorded these cash proceeds as a deferred royalty obligation liability which is being amortized over the expected royalty recovery period. As part of this transaction, the Company incurred approximately $5.9 million in transaction costs.

We anticipate that our current capital resources and expected future collaborator payments will enable us to meet our operational expenses and capital expenditures into the second quarter of 2018. However, we cannot provide assurance that such collaborative agreement funding will, in fact, be received. Should we or our partners not meet some or all of the terms and conditions of our various collaboration agreements or if we are not successful in securing future collaboration agreements, we may be required to secure alternative financing arrangements, and/or defer or limit some or all of our research, development and/or clinical projects. See Note A of the financial statements for further discussion.

Contractual Obligations

There have been no material changes to our contractual obligations during the current period from those disclosed in our Transition Report on Form 10-K for the six months ended December 31, 2016.

Table of Contents

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014‑9, Revenue from Contracts with Customers (Topic 606), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. We anticipate using the modified retrospective approach to implement this standard. We have begun to analyze our existing revenue agreements to evaluate the impact of adoption. We have less than ten contracts that have remaining performance obligations that will need to be evaluated under the provisions of the new standard as of January 1, 2018. In performing this assessment, we noted that we will be required to recognize royalty income in the same period as the related sales occur on Kadcyla rather than one quarter in arrears, which is the point in which the amount is fixed and determinable. This will require us to make an estimate of the royalties as the information is not provided to us until 90 days after the end of the quarter. Additionally, some partner milestones, depending on the probability of occurring, may be recognized sooner and at different values than they currently would be under the current accounting standards. We are in the process of estimating the impact of adopting the new standard on our consolidated financial statements, however, we expect to record a material adjustment upon adoption, which will be recorded as a cumulative effect of initially applying the standard to opening accumulated deficit as of January 1, 2018. We will continue to provide disclosures under the legacy accounting for the year ended December 31, 2018.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330). To simplify the principles for subsequent measurement of inventory, this new standard requires inventory measured using any method other than LIFO or the retail method shall be measured at the lower of cost and net realizable value, rather than lower of cost or market. This guidance is effective for annual reporting beginning after December 15, 2016, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, we adopted the standard on January 1, 2017. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In January 2016, the FASB issued ASU 2016-1, Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825). The amendments in this Update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. The amendments allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment. The amendments also require enhanced disclosures about those investments. The amendments improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. This guidance is effective for annual reporting beginning after December 15, 2017, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, the standard is effective for us on January 1, 2018. The adoption of this guidance is not expected to have a material impact on our consolidated financial statements.

Table of Contents

In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842) that primarily requires lessees to recognize most leases on their balance sheets but record expenses on their income statements in a manner similar to current accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and calls for retrospective application, with early adoption permitted. Accordingly, the standard is effective for us on January 1, 2019. We are currently evaluating the impact of this guidance on our financial statements and the timing of adoption.

In March 2016, the FASB issued ASU 2016-9, Improvements to Employee Share-Based Payment Accounting (Topic 718) that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. Accordingly, we adopted the standard on January 1, 2017. As a result of the adoption of this guidance, the net operating losses deferred tax assets for federal and state purposes increased by $9.2 million and $1.2 million, respectively, and will be offset by corresponding increases in the valuation allowance. The adoption of the guidance has no impact on our consolidated financial statements. We elected not to adopt the provision that would allow actual forfeitures to be recognized in lieu of maintaining a forfeitures reserve. As such, we will continue to estimate forfeitures.

Forward-Looking Statements

This quarterly report includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to analyses and other information which are based on forecasts of future results and estimates of amounts that are not yet determinable. These statements also relate to our future prospects, developments and business strategies.

These forward-looking statements can be identified by their use of terms and phrases, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will” and other similar terms and phrases, including references to assumptions. They may also use words such as “will,” “would,” “should,” “could” or “may”. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those contemplated by our forward-looking statements. These known and unknown risks, uncertainties and other factors are described in detail in the “Risk Factors” section and in other sections of our Transition Report on Form 10-K for the six months ended December 31, 2016. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Avastin®, Kadcyla® and Keytruda® are registered trademarks of their respective owners

Probody™ is a trademark of CytomX Therapeutics, Inc.

OFF-BALANCE SHEET ARRANGEMENTS

None.

Table of Contents

ITEM 3. Quantitative and Qualitative Disclosure about Market Risk

Our market risks, and the ways we manage them, are summarized in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Transition Report on Form 10-K for the six months ended December 31, 2016. Since then there have been no material changes to our market risks or to our management of such risks.

ITEM 4. Controls and Procedures

(a)Disclosure Controls and Procedures

The Company’s management, with the participation of its principal executive officer and principal financial officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company’s principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were adequate and effective.

(b)Changes in Internal Controls

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. Risk Factors

You should carefully review and consider the information regarding certain factors that could materially affect our business, financial condition or future results set forth under Item 1A. (Risk Factors) in our Transition Report on Form 10-K for the six months ended December 31, 2016. There have been no material changes from the factors disclosed in our 2016 Transition Report on Form 10-K, although we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the Securities and Exchange Commission (the “Commission”).

Table of Contents

ITEM 6. Exhibits

Exhibit No.		Description

10.1		Sales Agreement dated as of March 3, 2017 between the Registrant and Cowen and Company, LLC (incorporated herein by reference to Exhibit 1.2 of the Registrant’s registration statement on Form S-3, filed with the Commission on March 3, 2017 (File No. 333-216438)).
10.2		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and Craig Barrows
10.3		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and Anna Berkenblit
10.4		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and Mark Enyedy
10.5		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and Richard Gregory
10.6		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and David Johnston
10.7		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and Thomas Ryll
10.8		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and Peter Williams
10.9		Change in Control Severance Agreement dated as of March 31, 2017 between the Registrant and Theresa Wingrove
31.1		Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002
32†		Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

†Furnished, not filed.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ImmunoGen, Inc.

Date: May 5, 2017	By:	/s/Mark J. Enyedy
		Mark J. Enyedy
		President, Chief Executive Officer (Principal Executive Officer)

Date: May 5, 2017	By:	/s/ David B. Johnston
		David B. Johnston
		Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer)

EX-10.2 2 imgn-20170331ex10242595c.htm EX-10.2 imgn_Ex10_2

Exhibit 10.2

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Craig Barrows (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS, the Executive desires to enter into this Agreement to provide the Executive with certain financial protection in the event that his employment terminates under certain conditions following a change in control of the Company; and

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(a) Cause. For purposes of this Agreement, “Cause” shall mean that the Executive has (i) willfully committed an act or omission that materially harms the Company; (ii) been grossly negligent in the performance of the Executive’s duties to the Company; (iii) willfully failed or refused to follow the lawful and proper directives of the Board; (iv) been convicted of, or pleaded guilty or nolo contendere, to a felony; (v) committed an act involving moral turpitude that is or is reasonably expected to be injurious to the Company or its reputation; (vi) committed an act relating to the Executive’s employment or the Company involving, in the good faith judgment of the Board, material fraud or theft; (vii) breached any material provision of this Agreement or any nondisclosure or non-competition agreement between the Executive and the Company, as all of the foregoing may be amended prospectively from time to time; or (viii) breached a material provision of any code of conduct or ethics policy in effect at the Company, as all of the foregoing may be amended prospectively from time to time.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

(i)Ownership. Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates (as defined in the Company’s 2016 Employee, Director and Consultant Equity Incentive Plan) or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions which the Board does not approve; or

Executive Severance Agreement rev2017 (18)

(ii)Merger/Sale of Assets. (A) A merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; or

(iii)Change in Board Composition. A change in the composition of the Board, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” shall mean directors who either (A) are directors of the Company as of December 10, 2016, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company).

(c)Disability. For purposes of this Agreement, “Disability” shall mean that the Executive (i) is unable to engage in any substantial gainful activity because of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of at least twelve (12) months, or (ii) is receiving income replacement benefits for a period of at least three (3) months under a Company-sponsored disability plan because of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of at least twelve (12) months. Whether the Executive has a Disability will be determined by a majority of the Board based on evidence provided by one or more physicians selected by the Board and approved by the Executive, which approval shall not be unreasonably withheld. In any case, if a disability is determined to trigger the payment of any “deferred compensation” as defined in Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), disability shall be determined in accordance with Section 409A of the Code.

(d)Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence of one or more of the following without the Executive’s consent: (i) a change in the principal location at which the Executive performs his duties for the Company to a new location that is at least a forty (40) mile longer commute for the Executive from the prior work location; (ii) a material change in the Executive's authority, functions, duties or responsibilities as an executive of the Company, which would cause his position with the Company to become of less responsibility, importance or scope than his highest position with the Company at any time from the date of this Agreement to immediately prior to the Change in Control, provided, however, that such material change is not in connection with the termination of the Executive's employment by the Company for Cause or death or Disability and further provided that it shall not be considered a material change if the Company becomes a subsidiary of another entity and the Executive continues to hold a position in the subsidiary that is at least as high (in both title and scope of responsibilities) as the highest position he held with the Company at any time from

Executive Severance Agreement rev2017 (18)

the date of this Agreement to immediately prior to the Change in Control; (iii) a material reduction in the Executive’s annual base salary; or (iv) a material reduction in the Executive’s target annual bonus as compared to the target annual bonus set for the previous fiscal year.

For purposes of any determination regarding the existence of Good Reason, any claim by the Executive that Good Reason exists shall be presumed to be correct unless the Company establishes by clear and convincing evidence that Good Reason does not exist.

2. Term of Agreement. The term of this Agreement (the "Term") shall commence on the Effective Date and shall continue in effect for two (2) years; provided, however, that commencing on the second anniversary of the Effective Date and continuing each anniversary thereafter, the Term shall automatically be extended for one (1) additional year unless, not later than nine (9) months before the conclusion of the Term, the Company or the Executive shall have given notice not to extend the Term; and further provided, however, that if a Change in Control shall have occurred during the Term, the Term shall expire on the last day of the twelfth (12th) month following the month in which such Change in Control occurred. Notice of termination or termination of this Agreement shall not constitute Cause or Good Reason (both terms as defined above).

3. Termination; Notice; Severance Compensation.

(a) In the event that within a period of two (2) months before or twelve (12) months following the consummation of a Change in Control (such period, the “Change in Control Period”) the Company elects to terminate the Executive’s employment other than for Cause (but not including termination due to the Executive’s Disability), then the Company shall give the Executive no less than sixty (60) days advance notice of such termination (the “Company’s Notice Period”); provided that the Company may elect to require the Executive to cease performing work for the Company so long as the Company continues the Executive’s full salary and benefits during the Company’s Notice Period.

(b) In the event that during the Change in Control Period, the Executive elects to terminate his employment for Good Reason, then the Executive shall give the Company no less than thirty (30) days and no more than sixty (60) days advance notice of such termination (the “Executive’s Notice Period”) by indicating the specific termination provision in this Agreement relied upon and setting forth in reasonable detail any facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated (the “Executive’s Termination Notice”); provided that the Company may elect to require the Executive to cease performing work for the Company so long as the Company continues the Executive’s full salary and benefits during the Executive’s Notice Period. In order to effect a termination for Good Reason pursuant to this Agreement, the Executive must give the Executive’s Termination Notice not later than ninety (90) days following the occurrence of the Good Reason. The Company shall have the opportunity to cure the Good Reason condition within thirty (30) days following receipt of the Executive’s Termination Notice, provided that if the Company has not notified the Executive in writing of its intention to cure the Good Reason Condition within ten (10) days following receipt of the Executive’s Termination Notice, the Company shall be deemed to have irrevocably elected not to cure the Good Reason condition. If the Company elects not to cure the Good Reason condition, or has failed to cure the Good

Executive Severance Agreement rev2017 (18)

Reason condition within the applicable thirty (30)-day period, the Executive must separate from service no later than nine (9) months following initial occurrence of the Good Reason condition. If, within ten (10) days following the earlier of (i) the Company’s election not to cure the Good Reason condition, or (ii) expiration of the thirty (30)-day cure period, either (A) the Company notifies the Executive in writing that it disputes whether the Executive has given the Executive’s Termination Notice in good faith and established Good Reason to quit, or (B) the Executive notifies the Company in writing that the Company has failed to cure the Good Reason condition, then the Executive’s termination date (the “Termination Date”) shall be extended until the sooner of (x) the resolution of the dispute by mutual agreement of the parties, or (y) final order, decree or judgment of an arbitrator (which the parties agree is not appealable), during which time (1) the Executive shall not be required to perform work for the Company, and (2) the Company shall continue to pay the Executive’s full salary in effect immediately prior to the Executive giving the Executive’s Termination Notice (or, if higher, immediately prior to the change in control), and continue the Executive as a participant in all compensation, benefit and insurance plans in which the Executive was participating when the Executive’s Termination Notice was given; provided that the amounts paid under this Section are in addition to all other amounts due under this Agreement and shall not be offset against or reduce any other amounts due under this Agreement.

(c) In the event that during the Change in Control Period the Executive’s employment with the Company is terminated by the Company other than for Cause (but not including termination due to the Executive’s death or Disability), or by the Executive for Good Reason, then, contingent upon the Executive’s execution of a release of claims against the Company in substantially the form attached hereto as Exhibit A (the “Release”) the Executive shall be entitled to, in addition to any amounts due to the Executive for services rendered prior to the termination date:

(i) a lump sum payment from the Company in an amount equal to one and one-half (1.5) times the sum of the Executive's Annual Salary and the Executive’s target annual bonus for the fiscal year in which the termination occurs (without giving effect to any event or circumstance constituting Good Reason) at one hundred percent (100%) of such target annual bonus, which shall be paid on the sixtieth (60th) day following the Executive’s Termination Date, provided that the Release is executed and effective by then or the Executive shall forfeit the payment of such amount;

(ii) all outstanding options, restricted stock and other similar rights held by the Executive, which shall become one hundred percent (100%) vested on the sixtieth (60th) day following the Executive’s Termination Date, provided that the Release is executed and effective by then or the Executive shall forfeit the vesting;

(iii) provided Executive elects continuation of medical insurance coverage for the Executive and/or the Executive’s family subject to and in accordance with the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), the Company will subsidize the Executive’s COBRA premium at the same percentage as it subsidized health insurance premiums for the Executive immediately prior to the Executive’s Termination Date (or, if more favorable to the Executive,

Executive Severance Agreement rev2017 (18)

immediately prior to the consummation of the Change in Control) (the “COBRA Premium Subsidy”) for a period of up to eighteen (18) months from the Executive’s Termination Date; provided that the Company shall have no obligation to provide the COBRA Premium Subsidy after the date the Executive becomes eligible for medical coverage with another employer or becomes entitled to Medicare, notice of which the Executive shall provide to the Company within five (5) business days of the eligibility event. If the Company determines that the COBRA Premium Subsidy is taxable income to the Executive, the income will be reported on Form W-2 as imputed income; and

(iv) the Company shall pay the cost of providing the Executive with outplacement services up to a maximum of $40,000, provided that (A) the Executive begins to use such services within six (6) months following the Executive’s Termination Date, and (B) such services are provided by an outplacement services provider approved by the Company (which approval shall not be unreasonably withheld, conditioned or delayed). Such payment shall be made by the Company directly to the service provider promptly following the presentation to the Company of documentation of the enrollment by the Executive with the provider of outplacement services and the service provider’s invoice for such services. In no event will the Executive be entitled to receive the cash value of the outplacement services in lieu of the outplacement services.

For purposes of this Agreement, “Annual Salary” shall mean the Executive’s annual base salary then in effect or, if higher, in effect at the time of the Change in Control, excluding reimbursements and amounts attributable to stock options and other non-cash compensation; and the “Severance Compensation” shall mean the compensation set forth in (i), (ii), (iii), and (iv) above.

(d) If any of the benefits set forth in this Agreement are deferred compensation as defined in Section 409A of the Code, any termination of employment triggering payment of such benefits must constitute a “separation from service” under Section 409A of the Code before, subject to subsection (e) below, a distribution of such benefits can commence. For purposes of clarification, this Section shall not cause any forfeiture of benefits on the part of the Executive, but shall only act as a delay until such time as a “separation from service” occurs. In addition, the Company Notice Period and the Executive Notice Period shall be interpreted and administered in accordance with Section 409A of the Code and the “separation from service” rules thereunder. In particular, if a waiver of the Company Notice Period or the Executive Notice Period triggers a “separation from service,” such waiver shall constitute a termination and any amounts due to the Executive over the remaining portion of the applicable notice period shall be deemed additional severance under Section 3(c)(ii) of this Agreement and paid accordingly. In addition, any applicable notice or release periods and dates of payment shall be adjusted accordingly.

(e) Notwithstanding any other provision with respect to the timing of payments, if, at the time of the Executive’s termination, the Executive is deemed to be a “specified employee” (within the meaning of Code Section 409A, and any successor statute, regulation and guidance thereto) of the Company, then solely to the extent necessary to comply with the requirements of Code Section 409A, any payments to which the Executive may become entitled under this

Executive Severance Agreement rev2017 (18)

Agreement which are subject to Code Section 409A (and not otherwise exempt from its application) will be withheld until the first (1st) business day of the seventh (7th) month following the termination of the Executive’s employment, at which time the Executive shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to the Executive under the terms of this Agreement.

(f) Notwithstanding any other provision of this Agreement to the contrary, to the extent any payment contemplated hereunder is subject to the Executive’s execution of the Release, the Release must be executed no later than ninety (90) days following the Termination Date. If this 90-day period starts in one tax year and ends in the next, then the payments may not commence until the later of the end of the Release revocation period or the first day of that next tax year.

(g) If any payment or benefit the Executive would receive under this Agreement, when combined with any other payment or benefit the Executive receives pursuant to a Change in Control (“Payment”) would (i) constitute a “parachute payment” within the meaning of Code Section 280G, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either (x) the full amount of such Payment or (y) such less amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, and local employments taxes, income taxes, and the Excise Tax results in the Executive’s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. The Company shall, in a manner compliant with Code Section 409A, determine in good faith which payment(s) or benefit(s) to reduce based on what provides the best economic result for the Executive. The Company shall provide the Executive with sufficient information to support its determination and to allow the Executive to file and pay any required taxes.

4. No Duplication of Compensation. The Severance Compensation shall replace, and be provided in lieu of, any severance or similar compensation, excepting payment during the resolution of a dispute regarding Good Reason as provided in Section 3(b), that may be provided to the Executive under any other agreement or arrangement in relation to termination of employment; provided, however, that this prohibition against duplication shall not be construed to otherwise limit the Executive’s rights to payments or benefits provided under any pension plan (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended), deferred compensation, stock, stock option or similar plan sponsored by the Company. This Agreement supersedes any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof which may have been made by either party, including, without limitation, the Change in Control Severance Agreement dated as of November 30, 2012 between the Company and the Executive.

5. No Mitigation. If the Executive's employment with the Company terminates following a Change in Control, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable to the Executive by the Company pursuant to Section 3 or Section 14. Except as set forth in Section 4, the amount of any payment or benefit provided for in this Agreement shall not be reduced by any compensation earned by the Executive as the result of employment by another employer (with the exception of the COBRA Premium Subsidy,

Executive Severance Agreement rev2017 (18)

which shall terminate when the Executive becomes eligible for medical insurance through another employer or the Executive becomes entitled to Medicare), by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company, or otherwise.

6. Confidentiality, Non-Competition, and Assignment of Inventions. The Company’s obligations under this Agreement are contingent upon the Executive’s execution of the Company’s Proprietary Information, Inventions, and Competition Agreement (the “Proprietary Information Agreement”). The parties agree that the obligations set forth in the Proprietary Information Agreement shall survive termination of this Agreement and termination of the Executive’s employment, regardless of the reason for such termination.

7. Enforceability. If any provision of this Agreement shall be deemed invalid or unenforceable as written, this Agreement shall be construed, to the greatest extent possible, or modified, to the extent allowable by law, in a manner which shall render it valid and enforceable. No invalidity or unenforceability of any provision contained herein shall affect any other portion of this Agreement.

8. Notices. Except as otherwise specifically provided herein, any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notices to the Executive shall be sent to the last known address in the Company's records or such other address as the Executive may specify in writing. Notices to the Company shall be sent to the Company's Chairman of the Board (or if the Chairman of the Board is also the CEO, to the Company’s Lead Director), or to such other Company representative as the Company may specify in writing.

9. Claims for Benefits. All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board and shall be in writing. Any denial by the Board of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon. The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim and shall further allow the Executive to appeal to the Board a decision of the Board within sixty (60) days after notification by the Board that the Executive's claim has been denied. In no event shall the Board’s claims or appeals determination be given any deference or weight in any subsequent legal proceeding.

Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration, paid for by the Company, in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect; provided, however, that the evidentiary standards set forth in this Agreement shall apply; and further provided that the parties agree that the binding arbitration protocol shall be structured such that a decision will issue not later than ninety (90) days following notice in the event of a dispute concerning Good Reason pursuant to Section 3(b). Judgment may be entered on the arbitrator’s award in any court having jurisdiction. Notwithstanding any provision of this Agreement to the contrary, the Executive shall be entitled to seek specific performance of the Executive’s right to

Executive Severance Agreement rev2017 (18)

be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

10. Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the Company and the Executive. The Company and the Executive agree that they will jointly execute an amendment to modify this Agreement to the extent necessary to comply with or be exempt from the requirements of Code Section 409A, or any successor statute, regulation and guidance thereto; provided that no such amendment shall increase the total financial obligation of the Company under this Agreement.

11. Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

12. Binding Effect; Assignment. The Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of the Executive upon the Executive’s death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of the Agreement for all purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of the Executive to receive any form of compensation payable pursuant to the Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of the Executive’s right to compensation or other benefits will be null and void.

13. Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the law of the Commonwealth of Massachusetts, without giving effect to the conflict of law principles thereof.

14. Attorneys’ Fees. The Company shall pay to the Executive all legal fees and expenses incurred by the Executive in disputing in good faith any issue hereunder relating to the termination of the Executive's employment, in seeking in good faith to obtain or enforce any benefit or right provided by this Agreement. Such payments shall be made within five (5) business days after delivery of the Executive's written requests for payment accompanied with such evidence of fees and expenses incurred as the Company reasonably may require.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

Executive Severance Agreement rev2017 (18)

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

17. Acknowledgment. The Executive acknowledges that he has had the opportunity to discuss this matter with and obtain advice from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of the Agreement, and is knowingly and voluntarily entering into the Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

19. Section 409A. The parties hereto intend that the payments and benefits provided by this Agreement shall be exempt to the maximum extent from the requirements of Code Section 409A and related regulations and Treasury pronouncements, and this Agreement shall be interpreted accordingly. To the extent subject to Code Section 409A, the Agreement shall be interpreted to comply with such requirements. Each separately identified payment or benefit hereunder shall be deemed to be a separately determinable payment for purposes of Code Section 409A, and each payment to be made in installments shall be deemed a series of separate payments. If any provision provided herein could result in the imposition of an additional tax under the provisions of Code Section 409A, the Executive and the Company agree that such provision will be reformed to avoid imposition of any such additional tax in the manner that the Executive and the Company mutually agree is appropriate to comply with or be exempt from Code Section 409A.

20. Reimbursements. To the extent there are any reimbursements of expenses under this Agreement including, without limitation, under Section 14 hereof, payments with respect to such reimbursements shall be made no later than on or before the last day of the calendar year following the calendar year in which the relevant expense is incurred. The amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year and any such reimbursements may not be exchanged or liquidated for any other benefit or payment.

[Signature Page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Title: President and Chief Executive Officer

EXECUTIVE:

/s/ Craig Barrows

Name: Craig Barrows

Executive Severance Agreement rev2017 (18)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), Craig Barrows (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

2.No Admissions. The Executive acknowledges and agrees that this General Release is not to be construed in any way as an admission of any liability whatsoever by any Company Released Party, any such liability being expressly denied.

3.Application to all Forms of Relief. This General Release applies to any relief no matter how called, including, without limitation, wages, back pay, front pay, compensatory damages, liquidated damages, punitive damages for pain or suffering, costs and attorney's fees and expenses.

Executive Severance Agreement rev2017 (18)

4.Specific Waiver. The Executive specifically acknowledges that his acceptance of the terms of this General Release is, among other things, a specific waiver of his rights, claims and causes of action under Title VII, ADEA, ADA, the Massachusetts Fair Employment Practices Act and any state or local law or regulation in respect of discrimination of any kind; provided, however, that nothing herein shall be deemed, nor does anything herein purport, to be a waiver of any right or claim or cause of action which by law the Executive is not permitted to waive.

The Executive expressly agrees and understands that the release of claims contained herein is a General Release and that any references to specific claims arising out of or in connection with the Executive’s employment or termination are not intended to limit the release of claims. The Executive expressly agrees and understands that this General Release means that the Executive is releasing, remising and discharging the Released Parties from and with respect to all claims, whether known or unknown, asserted or unasserted, and whether or not the claims arise out of or in connection with the Executive’s employment or termination, or otherwise, to the extent permitted by law.

5.No Complaints or Other Claims. The Executive acknowledges and agrees that he has not, with respect to any transaction or state of facts existing prior to the date hereof, filed any complaints, charges or lawsuits against any Company Released Party with any governmental agency, court or tribunal. This General Release does not: (i) prohibit or restrict Executive from communicating, providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental authority with responsibility for the administration of fair employment practices laws regarding a possible violation of such laws or responding to any inquiry from such authority, including an inquiry about the existence of this General Release or its underlying facts, or (ii) require Executive to notify the Company of such communications or inquiry.

6.Conditions of General Release.

(a) Terms and Conditions. From and after the date of termination of employment, the Executive shall abide by all the terms and conditions of this General Release and the terms and any conditions set forth in any employment or confidentiality agreements signed by the Executive, which is incorporated herein by reference.

(b) Confidentiality. The Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or any legal process, or as is necessary in connection with any adversarial proceeding against any member of the Company Affiliated Group (in which case the Executive shall cooperate with the Company in obtaining a protective order at the Company's expense against disclosure by a court of competent jurisdiction), communicate, to anyone other than the Company and those designated by the Company or on behalf of the Company in the furtherance of its business, any trade secrets, confidential information, knowledge or data relating to any member of the Company Affiliated Group, obtained by the Executive during the Executive's employment by the Company that is not generally available public knowledge (other than acts by the Executive in violation of this General Release). This confidentiality obligation is in addition to, and not in lieu of, any other

Executive Severance Agreement rev2017 (18)

contractual, statutory and common law confidentiality obligation of the Executive to the Company.

(c) Return of Company Material. The Executive represents that he has returned to the Company all Company Material (as defined below). For purposes of this Section 6(c), "Company Material" means any documents, files and other property and information of any kind belonging or relating to (i) any member of the Company Affiliated Group, (ii) the current and former suppliers, creditors, directors, officers, employees, agents and customers of any of them or (iii) the businesses, products, services and operations (including without limitation, business, financial and accounting practices) of any of them, in each case whether tangible or intangible (including, without limitation, credit cards, building and office access cards, keys, computer equipment, cellular telephones, pagers, electronic devices, hardware, manuals, files, documents, records, software, customer data, research, financial data and information, memoranda, surveys, correspondence, statistics and payroll and other employee data, and any copies, compilations, extracts, excerpts, summaries and other notes thereof or relating thereto), excluding only information (x) that is generally available public knowledge or (y) that relates to the Executive's compensation or Executive benefits.

(d) Cooperation. Following the date of termination of employment, the Executive shall reasonably cooperate with the Company upon reasonable request of the Board of Directors and be reasonably available to the Company with respect to matters arising out of the Executive's services to the Company Affiliated Group.

(e) Nondisparagement. The Executive acknowledges and agrees that, following execution of this General Release, he shall not make any statements that are professionally or personally disparaging about or adverse to the interests of any Company Released Party, including, but not limited to, any statements that disparage in any way whatsoever the Company’s products, services, businesses, finances, financial condition, capabilities or other characteristics.

(f) Ownership of Inventions, Non-Disclosure, Non-Competition and Non-Solicitation. The Executive expressly acknowledges and agrees that the Proprietary Information, Inventions, and Competition Agreement executed by him is incorporated herein by reference, and shall survive the execution of this General Release in full force and effect pursuant to its terms.

(g) No Representation. The Executive acknowledges that, other than as set forth in this General Release and the Agreement, (i) no promises have been made to him and (ii) in signing this General Release the Executive is not relying upon any statement or representation made by or on behalf of any Company Released Party and each or any of them concerning the merits of any claims or the nature, amount, extent or duration of any damages relating to any claims or the amount of any money, benefits, or compensation due the Executive or claimed by the Executive, or concerning the General Release or concerning any other thing or matter.

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive

Executive Severance Agreement rev2017 (18)

relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

7.Voluntariness. The Executive agrees that he is relying solely upon his own judgment; that the Executive is over eighteen years of age and is legally competent to sign this General Release; that the Executive is signing this General Release of his own free will; that the Executive has read and understood the General Release before signing it; and that the Executive is signing this General Release in exchange for consideration that he believes is satisfactory and adequate.

8.Legal Counsel. The Executive acknowledges that he has been informed of the right to consult with legal counsel and has been encouraged to do so.

9.Complete Agreement/Severability. Other than the agreements and/or obligations specifically referenced as surviving herein, this General Release constitutes the complete and final agreement between the parties and supersedes and replaces all prior or contemporaneous agreements, negotiations, or discussions relating to the subject matter of this General Release. All provisions and portions of this General Release are severable. If any provision or portion of this General Release or the application of any provision or portion of the General Release shall be determined to be invalid or unenforceable to any extent or for any reason, all other provisions and portions of this General Release shall remain in full force and shall continue to be enforceable to the fullest and greatest extent permitted by law.

10.Acceptance. The Executive acknowledges that he has been given a period of twenty-one (21) days within which to consider this General Release, unless applicable law requires a longer period, in which case the Executive shall be advised of such longer period and such longer period shall apply. The Executive may accept this General Release at any time within this period of time by signing the General Release and returning it to the Company.

11.Revocability. This General Release shall not become effective or enforceable until seven (7) calendar days after the Executive signs it. The Executive may revoke his acceptance of this General Release at any time within that seven (7) calendar day period by sending written notice to the Company. Such notice must be received by the Company within the seven (7) calendar day period in order to be effective and, if so received, would void this General Release for all purposes.

12.Governing Law. Except for issues or matters as to which federal law is applicable, this General Release shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts without giving effect to the conflicts of law principles thereof.

[Signature page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: Craig Barrows

Executive Severance Agreement rev2017 (18)

EX-10.3 3 imgn-20170331ex103494a5c.htm EX-10.3 imgn_Ex10_3

Exhibit 10.3

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Anna Berkenblit (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS, the Executive desires to enter into this Agreement to provide the Executive with certain financial protection in the event that her employment terminates under certain conditions following a change in control of the Company; and

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

Executive Severance Agreement rev2017 (18)

(d)Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence of one or more of the following without the Executive’s consent: (i) a change in the principal location at which the Executive performs her duties for the Company to a new location that is at least a forty (40) mile longer commute for the Executive from the prior work location; (ii) a material change in the Executive's authority, functions, duties or responsibilities as an executive of the Company, which would cause her position with the Company to become of less responsibility, importance or scope than her highest position with the Company at any time from the date of this Agreement to immediately prior to the Change in Control, provided, however, that such material change is not in connection with the termination of the Executive's employment by the Company for Cause or death or Disability and further provided that it shall not be considered a material change if the Company becomes a subsidiary of another entity and the Executive continues to hold a position in the subsidiary that is at least as high (in both title and scope of responsibilities) as the highest position she held with the Company at any time from

Executive Severance Agreement rev2017 (18)

3. Termination; Notice; Severance Compensation.

Executive Severance Agreement rev2017 (18)

4. No Duplication of Compensation. The Severance Compensation shall replace, and be provided in lieu of, any severance or similar compensation, excepting payment during the resolution of a dispute regarding Good Reason as provided in Section 3(b), that may be provided to the Executive under any other agreement or arrangement in relation to termination of employment; provided, however, that this prohibition against duplication shall not be construed to otherwise limit the Executive’s rights to payments or benefits provided under any pension plan (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended), deferred compensation, stock, stock option or similar plan sponsored by the Company. This Agreement supersedes any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof which may have been made by either party, including, without limitation, the Change in Control Severance Agreement dated as of March 30, 2015 between the Company and the Executive.

Executive Severance Agreement rev2017 (18)

be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

Executive Severance Agreement rev2017 (18)

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

17. Acknowledgment. The Executive acknowledges that she has had the opportunity to discuss this matter with and obtain advice from her private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of the Agreement, and is knowingly and voluntarily entering into the Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature Page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Title: President and Chief Executive Officer

EXECUTIVE:

/s/ Anna Berkenblit

Name: Anna Berkenblit

Executive Severance Agreement rev2017 (18)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), Anna Berkenblit (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

Executive Severance Agreement rev2017 (18)

4.Specific Waiver. The Executive specifically acknowledges that her acceptance of the terms of this General Release is, among other things, a specific waiver of her rights, claims and causes of action under Title VII, ADEA, ADA, the Massachusetts Fair Employment Practices Act and any state or local law or regulation in respect of discrimination of any kind; provided, however, that nothing herein shall be deemed, nor does anything herein purport, to be a waiver of any right or claim or cause of action which by law the Executive is not permitted to waive.

5.No Complaints or Other Claims. The Executive acknowledges and agrees that she has not, with respect to any transaction or state of facts existing prior to the date hereof, filed any complaints, charges or lawsuits against any Company Released Party with any governmental agency, court or tribunal. This General Release does not: (i) prohibit or restrict Executive from communicating, providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental authority with responsibility for the administration of fair employment practices laws regarding a possible violation of such laws or responding to any inquiry from such authority, including an inquiry about the existence of this General Release or its underlying facts, or (ii) require Executive to notify the Company of such communications or inquiry.

6.Conditions of General Release.

Executive Severance Agreement rev2017 (18)

contractual, statutory and common law confidentiality obligation of the Executive to the Company.

(c) Return of Company Material. The Executive represents that she has returned to the Company all Company Material (as defined below). For purposes of this Section 6(c), "Company Material" means any documents, files and other property and information of any kind belonging or relating to (i) any member of the Company Affiliated Group, (ii) the current and former suppliers, creditors, directors, officers, employees, agents and customers of any of them or (iii) the businesses, products, services and operations (including without limitation, business, financial and accounting practices) of any of them, in each case whether tangible or intangible (including, without limitation, credit cards, building and office access cards, keys, computer equipment, cellular telephones, pagers, electronic devices, hardware, manuals, files, documents, records, software, customer data, research, financial data and information, memoranda, surveys, correspondence, statistics and payroll and other employee data, and any copies, compilations, extracts, excerpts, summaries and other notes thereof or relating thereto), excluding only information (x) that is generally available public knowledge or (y) that relates to the Executive's compensation or Executive benefits.

(e) Nondisparagement. The Executive acknowledges and agrees that, following execution of this General Release, she shall not make any statements that are professionally or personally disparaging about or adverse to the interests of any Company Released Party, including, but not limited to, any statements that disparage in any way whatsoever the Company’s products, services, businesses, finances, financial condition, capabilities or other characteristics.

(f) Ownership of Inventions, Non-Disclosure, Non-Competition and Non-Solicitation. The Executive expressly acknowledges and agrees that the Proprietary Information, Inventions, and Competition Agreement executed by her is incorporated herein by reference, and shall survive the execution of this General Release in full force and effect pursuant to its terms.

(g) No Representation. The Executive acknowledges that, other than as set forth in this General Release and the Agreement, (i) no promises have been made to her and (ii) in signing this General Release the Executive is not relying upon any statement or representation made by or on behalf of any Company Released Party and each or any of them concerning the merits of any claims or the nature, amount, extent or duration of any damages relating to any claims or the amount of any money, benefits, or compensation due the Executive or claimed by the Executive, or concerning the General Release or concerning any other thing or matter.

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive

Executive Severance Agreement rev2017 (18)

relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

7.Voluntariness. The Executive agrees that she is relying solely upon her own judgment; that the Executive is over eighteen years of age and is legally competent to sign this General Release; that the Executive is signing this General Release of her own free will; that the Executive has read and understood the General Release before signing it; and that the Executive is signing this General Release in exchange for consideration that she believes is satisfactory and adequate.

8.Legal Counsel. The Executive acknowledges that she has been informed of the right to consult with legal counsel and has been encouraged to do so.

10.Acceptance. The Executive acknowledges that she has been given a period of twenty-one (21) days within which to consider this General Release, unless applicable law requires a longer period, in which case the Executive shall be advised of such longer period and such longer period shall apply. The Executive may accept this General Release at any time within this period of time by signing the General Release and returning it to the Company.

11.Revocability. This General Release shall not become effective or enforceable until seven (7) calendar days after the Executive signs it. The Executive may revoke her acceptance of this General Release at any time within that seven (7) calendar day period by sending written notice to the Company. Such notice must be received by the Company within the seven (7) calendar day period in order to be effective and, if so received, would void this General Release for all purposes.

[Signature page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: Anna Berkenblit

Executive Severance Agreement rev2017 (18)

EX-10.4 4 imgn-20170331ex104e6d1b2.htm EX-10.4 imgn_Ex10_4

Exhibit 10.4

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Mark J. Enyedy (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

Executive Severance Agreement rev2017 (24)

(d)Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence of one or more of the following without the Executive’s consent: (i) a change in the principal location at which the Executive performs his duties for the Company to a new location that is at least a forty (40) mile longer commute for the Executive from the prior work location; (ii) a material change in the Executive's authority, functions, duties or responsibilities as an executive of the Company, which would cause his position with the Company to become of less responsibility, importance or scope than his highest position with the Company at any time from the date of this Agreement to immediately prior to the Change in Control, provided, however, that such material change is not in connection with the termination of the Executive's employment by the Company for Cause or death or Disability; (iii) a material reduction in the Executive’s annual base salary; or (iv) a material reduction in the Executive’s target annual bonus as compared to the target annual bonus set for the previous fiscal year.

Executive Severance Agreement rev2017 (24)

3. Termination; Notice; Severance Compensation.

Executive Severance Agreement rev2017 (24)

Reason condition, or (ii) expiration of the thirty (30)-day cure period, either (A) the Company notifies the Executive in writing that it disputes whether the Executive has given the Executive’s Termination Notice in good faith and established Good Reason to quit, or (B) the Executive notifies the Company in writing that the Company has failed to cure the Good Reason condition, then the Executive’s termination date (the “Termination Date”) shall be extended until the sooner of (x) the resolution of the dispute by mutual agreement of the parties, or (y) final order, decree or judgment of an arbitrator (which the parties agree is not appealable), during which time (1) the Executive shall not be required to perform work for the Company, and (2) the Company shall continue to pay the Executive’s full salary in effect immediately prior to the Executive giving the Executive’s Termination Notice (or, if higher, immediately prior to the change in control), and continue the Executive as a participant in all compensation, benefit and insurance plans in which the Executive was participating when the Executive’s Termination Notice was given; provided that the amounts paid under this Section are in addition to all other amounts due under this Agreement and shall not be offset against or reduce any other amounts due under this Agreement.

(i) a lump sum payment from the Company in an amount equal to two (2) times the sum of the Executive's Annual Salary and the Executive’s target annual bonus for the fiscal year in which the termination occurs (without giving effect to any event or circumstance constituting Good Reason) at one hundred percent (100%) of such target annual bonus, which shall be paid on the sixtieth (60th) day following the Executive’s Termination Date, provided that the Release is executed and effective by then or the Executive shall forfeit the payment of such amount;

(iii) provided Executive elects continuation of medical insurance coverage for the Executive and/or the Executive’s family subject to and in accordance with the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), the Company will subsidize the Executive’s COBRA premiums at the same percentage as it subsidized health insurance premiums for the Executive immediately prior to the Executive’s Termination Date (or, if more favorable to the Executive, immediately prior to the consummation of the Change in Control) (the “COBRA Premium Subsidy”) during the applicable COBRA coverage period (“COBRA

Executive Severance Agreement rev2017 (24)

Period”); provided that following the expiration of the COBRA Period, the Company will pay to the Executive a taxable amount equal to the COBRA Premium Subsidy on a monthly basis (the “Post-COBRA Premium Support”) for period ending twenty-four (24) months from the Executive’s Termination Date; provided further that the Company shall have no obligation to provide the COBRA Premium Subsidy or the Post-COBRA Premium Support after the date the Executive becomes eligible for medical coverage with another employer or becomes entitled to receive Medicare, notice of which the Executive shall provide to the Company within five (5) business days of the eligibility event. If the Company determines that the COBRA Premium Subsidy is taxable income to the Executive, the income will be reported on Form W-2 as imputed income; and

(iv) the Company shall pay the cost of providing the Executive with outplacement services up to a maximum of $40,000, provided that (A) the Executive begins to use such services within six (6) months following the Executive ‘s Termination Date, and (B) such services are provided by an outplacement services provider approved by the Company (which approval shall not be unreasonably withheld, conditioned or delayed). Such payment shall be made by the Company directly to the service provider promptly following provision of such services and the presentation to the Company of documentation of the provision of such services. In no event will the Executive be entitled to receive the cash value of the outplacement services in lieu of the outplacement services.

(e) Notwithstanding any other provision with respect to the timing of payments, if, at the time of the Executive’s termination, the Executive is deemed to be a “specified employee”

Executive Severance Agreement rev2017 (24)

(within the meaning of Code Section 409A, and any successor statute, regulation and guidance thereto) of the Company, then solely to the extent necessary to comply with the requirements of Code Section 409A, any payments to which the Executive may become entitled under this Agreement which are subject to Code Section 409A (and not otherwise exempt from its application) will be withheld until the first (1st) business day of the seventh (7th) month following the termination of the Executive’s employment, at which time the Executive shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to the Executive under the terms of this Agreement.

4. No Duplication of Compensation. The Severance Compensation shall replace, and be provided in lieu of, any severance or similar compensation, excepting payment during the resolution of a dispute regarding Good Reason as provided in Section 3(b), that may be provided to the Executive under any other agreement or arrangement in relation to termination of employment; provided, however, that this prohibition against duplication shall not be construed to otherwise limit the Executive’s rights to payments or benefits provided under any pension plan (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended), deferred compensation, stock, stock option or similar plan sponsored by the Company. This Agreement supersedes any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof which may have been made by either party, including, without limitation, the Change in Control Severance Agreement dated as of May 16, 2016 between the Company and the Executive.

5. No Mitigation. If the Executive's employment with the Company terminates following a Change in Control, the Executive is not required to seek other employment or to attempt in any

Executive Severance Agreement rev2017 (24)

way to reduce any amounts payable to the Executive by the Company pursuant to Section 3 or Section 14. Except as set forth in Section 4, the amount of any payment or benefit provided for in this Agreement shall not be reduced by any compensation earned by the Executive as the result of employment by another employer (with the exception of the COBRA Premium Subsidy and the Post-COBRA Premium Support, which shall terminate when the Executive becomes eligible for medical insurance through another employer or the Executive becomes entitled to Medicare), by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company, or otherwise.

8. Notices. Except as otherwise specifically provided herein, any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notices to the Executive shall be sent to the last known address in the Company's records or such other address as the Executive may specify in writing. Notices to the Company shall be sent to the Company's Chairman of the Board (or if the Executive is also the Chairman of the Board, to the Company’s Lead Director), or to such other Company representative as the Company may specify in writing.

Executive Severance Agreement rev2017 (24)

however, that the evidentiary standards set forth in this Agreement shall apply; and further provided that the parties agree that the binding arbitration protocol shall be structured such that a decision will issue not later than ninety (90) days following notice in the event of a dispute concerning Good Reason pursuant to Section 3(b). Judgment may be entered on the arbitrator’s award in any court having jurisdiction. Notwithstanding any provision of this Agreement to the contrary, the Executive shall be entitled to seek specific performance of the Executive’s right to be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

Executive Severance Agreement rev2017 (24)

business days after delivery of the Executive's written requests for payment accompanied with such evidence of fees and expenses incurred as the Company reasonably may require.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature page follows]

Executive Severance Agreement rev2017 (24)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ David B. Johnston

Name: David B. Johnston

Title: Executive Vice President & CFO

EXECUTIVE:

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Executive Severance Agreement rev2017 (24)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), Mark J. Enyedy (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

Executive Severance Agreement rev2017 (24)

6.Conditions of General Release.

Executive Severance Agreement rev2017 (24)

General Release). This confidentiality obligation is in addition to, and not in lieu of, any other contractual, statutory and common law confidentiality obligation of the Executive to the Company.

Executive Severance Agreement rev2017 (24)

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

8.Legal Counsel. The Executive acknowledges that he has been informed of the right to consult with legal counsel and has been encouraged to do so.

[Signature page follows]

Executive Severance Agreement rev2017 (24)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: Mark J. Enyedy

Executive Severance Agreement rev2017 (24)

EX-10.5 5 imgn-20170331ex105352b3e.htm EX-10.5 imgn_Ex10_5

Exhibit 10.5

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Richard J. Gregory (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

Executive Severance Agreement rev2017 (18)

3. Termination; Notice; Severance Compensation.

Executive Severance Agreement rev2017 (18)

4. No Duplication of Compensation. The Severance Compensation shall replace, and be provided in lieu of, any severance or similar compensation, excepting payment during the resolution of a dispute regarding Good Reason as provided in Section 3(b), that may be provided to the Executive under any other agreement or arrangement in relation to termination of employment; provided, however, that this prohibition against duplication shall not be construed to otherwise limit the Executive’s rights to payments or benefits provided under any pension plan (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended), deferred compensation, stock, stock option or similar plan sponsored by the Company. This Agreement supersedes any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof which may have been made by either party, including, without limitation, the Change in Control Severance Agreement dated as of January 5, 2015 between the Company and the Executive.

Executive Severance Agreement rev2017 (18)

be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

Executive Severance Agreement rev2017 (18)

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature Page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Title: President and Chief Executive Officer

EXECUTIVE:

/s/ Richard J.Gregory

Name: Richard J. Gregory

Executive Severance Agreement rev2017 (18)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), Richard J. Gregory (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

Executive Severance Agreement rev2017 (18)

6.Conditions of General Release.

Executive Severance Agreement rev2017 (18)

contractual, statutory and common law confidentiality obligation of the Executive to the Company.

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive

Executive Severance Agreement rev2017 (18)

relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

8.Legal Counsel. The Executive acknowledges that he has been informed of the right to consult with legal counsel and has been encouraged to do so.

[Signature page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: Richard J. Gregory

Executive Severance Agreement rev2017 (18)

EX-10.6 6 imgn-20170331ex106ed231d.htm EX-10.6 imgn_Ex10_6

Exhibit 10.6

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and David B. Johnston (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

Executive Severance Agreement rev2017 (18)

3. Termination; Notice; Severance Compensation.

Executive Severance Agreement rev2017 (18)

4. No Duplication of Compensation. The Severance Compensation shall replace, and be provided in lieu of, any severance or similar compensation, excepting payment during the resolution of a dispute regarding Good Reason as provided in Section 3(b), that may be provided to the Executive under any other agreement or arrangement in relation to termination of employment; provided, however, that this prohibition against duplication shall not be construed to otherwise limit the Executive’s rights to payments or benefits provided under any pension plan (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended), deferred compensation, stock, stock option or similar plan sponsored by the Company. This Agreement supersedes any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof which may have been made by either party, including, without limitation, the Change in Control Severance Agreement dated as of December 30, 2013 between the Company and the Executive.

Executive Severance Agreement rev2017 (18)

be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

Executive Severance Agreement rev2017 (18)

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature Page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Title: President and Chief Executive Officer

EXECUTIVE:

/s/ David B. Johnston

Name: David B. Johnston

Executive Severance Agreement rev2017 (18)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), David B. Johnston (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

Executive Severance Agreement rev2017 (18)

6.Conditions of General Release.

Executive Severance Agreement rev2017 (18)

contractual, statutory and common law confidentiality obligation of the Executive to the Company.

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive

Executive Severance Agreement rev2017 (18)

relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

8.Legal Counsel. The Executive acknowledges that he has been informed of the right to consult with legal counsel and has been encouraged to do so.

[Signature page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: David B. Johnston

Executive Severance Agreement rev2017 (18)

EX-10.7 7 imgn-20170331ex1070bfcc3.htm EX-10.7 imgn_Ex10_7

Exhibit 10.7

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Thomas Ryll (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

Executive Severance Agreement rev2017 (18)

3. Termination; Notice; Severance Compensation.

Executive Severance Agreement rev2017 (18)

another employer or the Executive becomes entitled to Medicare), by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company, or otherwise.

Executive Severance Agreement rev2017 (18)

be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

Executive Severance Agreement rev2017 (18)

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature Page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Title: President and Chief Executive Officer

EXECUTIVE:

/s/ Thomas Ryll

Name: Thomas Ryll

Executive Severance Agreement rev2017 (18)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), Thomas Ryll (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

Executive Severance Agreement rev2017 (18)

6.Conditions of General Release.

Executive Severance Agreement rev2017 (18)

contractual, statutory and common law confidentiality obligation of the Executive to the Company.

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive

Executive Severance Agreement rev2017 (18)

relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

8.Legal Counsel. The Executive acknowledges that he has been informed of the right to consult with legal counsel and has been encouraged to do so.

[Signature page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: Thomas Ryll

Executive Severance Agreement rev2017 (18)

EX-10.8 8 imgn-20170331ex10851101e.htm EX-10.8 imgn_Ex10_8

Exhibit 10.8

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Peter Williams (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

Executive Severance Agreement rev2017 (18)

3. Termination; Notice; Severance Compensation.

Executive Severance Agreement rev2017 (18)

be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

Executive Severance Agreement rev2017 (18)

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature Page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Title: President and Chief Executive Officer

EXECUTIVE:

/s/ Peter Williams

Name: Peter Williams

Executive Severance Agreement rev2017 (18)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), Peter Williams (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

Executive Severance Agreement rev2017 (18)

6.Conditions of General Release.

Executive Severance Agreement rev2017 (18)

contractual, statutory and common law confidentiality obligation of the Executive to the Company.

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive

Executive Severance Agreement rev2017 (18)

relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

8.Legal Counsel. The Executive acknowledges that he has been informed of the right to consult with legal counsel and has been encouraged to do so.

[Signature page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: Peter Williams

Executive Severance Agreement rev2017 (18)

EX-10.9 9 imgn-20170331ex1099a4c54.htm EX-10.9 imgn_Ex10_9

Exhibit 10.9

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Agreement is entered into as of the 31st day of March, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Theresa G. Wingrove (the “Executive”).

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Definitions.

(b)Change in Control. For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

Executive Severance Agreement rev2017 (18)

(d)Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence of one or more of the following without the Executive’s consent: (i) a change in the principal location at which the Executive performs her duties for the Company to a new location that is at least a forty (40) mile longer commute for the Executive from the prior work location; (ii) a material change in the Executive's authority, functions, duties or responsibilities as an executive of the Company, which would cause her position with the Company to become of less responsibility, importance or scope than her highest position with the Company at any time from the date of this Agreement to immediately prior to the Change in Control, provided, however, that such material change is not in connection with the termination of the Executive's employment by the Company for Cause or death or Disability and further provided that it shall not be considered a material change if the Company becomes a subsidiary of another entity and the Executive continues to hold a position in the subsidiary that is at least as high (in both title and scope of responsibilities) as the highest position she held with the Company at any time from

Executive Severance Agreement rev2017 (18)

3. Termination; Notice; Severance Compensation.

Executive Severance Agreement rev2017 (18)

be paid until the Termination Date during the pendency of any dispute or controversy arising under of in connection with this Agreement.

15. Withholding. The Company is authorized to withhold, or to cause to be withheld, from any payment or benefit under the Agreement the full amount of any applicable withholding taxes.

Executive Severance Agreement rev2017 (18)

16. Tax Consequences. The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement.

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature Page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the parties have executed and delivered this Change in Control Severance Agreement as of the day and year first above written.

COMPANY:

IMMUNOGEN, INC.

/s/ Mark J. Enyedy

Name: Mark J. Enyedy

Title: President and Chief Executive Officer

EXECUTIVE:

/s/ Theresa Wingrove

Name: Theresa G. Wingrove

Executive Severance Agreement rev2017 (18)

Exhibit A

GENERAL RELEASE

1.General Release. In consideration of the payments and benefits to be made under that certain Change in Control Severance Agreement, dated March 31, 2017 (the “Agreement”), Theresa G. Wingrove (the “Executive”), with the intention of binding the Executive and the Executive's heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge ImmunoGen, Inc. (the “Company”) and each of its subsidiaries and affiliates (collectively, the “Company Affiliated Group”), their present and former officers, directors, executives, agents, insurers, attorneys, employees, and employee benefits plans (and the fiduciaries thereof), and the successors, predecessors, and assigns of each of the foregoing (collectively with the Company Affiliated Group, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses, attorneys' fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected which the Executive, individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, against any Company Released Party in any capacity, including, without limitation, any and all claims (i) arising out of or in any way connected with the Executive's service to any member of the Company Affiliated Group (or the predecessors thereof) in any capacity, or the termination of such service in any such capacity, (ii) for severance or vacation benefits, unpaid wages, rights in or for equity based awards, salary or incentive payments, (iii) for breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort and (iv) for any violation of applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices), any and all claims based on the Employee Retirement Income Security Act of 1974 (“ERISA”), any and all claims arising under the civil rights laws of any federal, state or local jurisdiction, including, without limitation, Title VII of the Civil Rights Act of 1964 (“Title VII”), the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act (“ADA”), Sections 503 and 504 of the Rehabilitation Act the Family and Medical Leave Act, the Massachusetts Fair Employment Practices Act, the Massachusetts Payment of Wages Law, An Act Relative to Domestic Violence, and any and all claims under any whistleblower laws or whistleblower provisions of other laws.

Executive Severance Agreement rev2017 (18)

6.Conditions of General Release.

Executive Severance Agreement rev2017 (18)

contractual, statutory and common law confidentiality obligation of the Executive to the Company.

(f) Ownership of Inventions, Non-Disclosure, Non-Competition and Non-Solicitation. The Executive expressly acknowledges and agrees that the Proprietary Information, Inventions, and Competition Agreement executed by her is incorporated herein by reference, and shall survive the execution of this General Release in full force and effect pursuant to its terms.

(h) Injunctive Relief. In the event of a breach or threatened breach by the Executive of this Section 6, the Executive agrees that the Company shall be entitled to injunctive

Executive Severance Agreement rev2017 (18)

relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, the Executive acknowledging that damages would be inadequate or insufficient.

8.Legal Counsel. The Executive acknowledges that she has been informed of the right to consult with legal counsel and has been encouraged to do so.

[Signature page follows]

Executive Severance Agreement rev2017 (18)

IN WITNESS WHEREOF, the Executive has executed this General Release as of the date last set forth below.

EXECUTIVE

_______________________________Date: __________________________

Name: Theresa G. Wingrove

Executive Severance Agreement rev2017 (18)

EX-31.1 10 imgn-20170331ex3114f478e.htm EX-31.1 imgn_Ex31_1

EXHIBIT 31.1

CERTIFICATIONS

I, Mark Enyedy, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ImmunoGen, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2017

/s/ Mark J. Enyedy
Mark J. Enyedy
President, Chief Executive Officer (Principal Executive Officer)

EX-31.2 11 imgn-20170331ex312a26405.htm EX-31.2 imgn_Ex31_2

EXHIBIT 31.2

CERTIFICATIONS

I, David B. Johnston, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ImmunoGen, Inc.;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2017

/s/ David B. Johnston
David B. Johnston
Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32 12 imgn-20170331xex32.htm EX-32 imgn_Ex32

EXHIBIT 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of ImmunoGen, Inc., a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the period ended March 31, 2017 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 5, 2017	/s/MARK J. ENYEDY
	Mark J. Enyedy
	President, Chief Executive Officer
	(Principal Executive Officer)

Dated: May 5, 2017	/s/ DAVID B. JOHNSTON
	David B. Johnston
	Executive Vice President, Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 13 imgn-20170331.xml EX-101.INS 0000855654 imgn:DeferredShareUnitsMember imgn:CompensationPolicyNonEmployeeDirectorMember 2017-01-01 2017-01-31 0000855654 imgn:DirectorPlan2001Member 2004-06-01 2004-06-30 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember 2017-03-31 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember 2016-12-31 0000855654 imgn:StockIncentivePlan2016Member 2016-12-09 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember 2017-01-01 2017-03-31 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember 2016-01-01 2016-03-31 0000855654 us-gaap:RestrictedStockMember 2017-03-31 0000855654 us-gaap:RestrictedStockMember 2016-12-31 0000855654 us-gaap:RestrictedStockMember 2017-02-01 2017-02-28 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember imgn:StockIncentivePlan2016Member us-gaap:MaximumMember 2017-01-01 2017-03-31 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember imgn:CompensationPolicyNonEmployeeDirectorMember 2016-12-01 2016-12-31 0000855654 us-gaap:EmployeeSeveranceMember 2016-09-01 2016-09-30 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember imgn:CompensationPolicyNonEmployeeDirectorMember 2015-11-01 2015-11-30 0000855654 imgn:CytomXTherapeuticsIncMember 2016-02-01 2016-02-29 0000855654 imgn:BayerHealthCareMember imgn:PhaseIIClinicalTrialMember 2016-01-01 2016-01-31 0000855654 imgn:CytomXTherapeuticsIncMember 2014-01-01 2014-01-31 0000855654 imgn:BayerHealthCareMember 2008-01-01 2016-12-31 0000855654 imgn:BayerHealthCareMember 2008-01-01 2008-12-31 0000855654 imgn:SanofiMember 2003-01-01 2016-12-31 0000855654 imgn:RocheMember imgn:KadcylaMember imgn:RegulatoryMilestonesMember 2000-01-01 2017-03-31 0000855654 imgn:RocheMember imgn:KadcylaMember imgn:DevelopmentMilestonesMember 2000-01-01 2017-03-31 0000855654 imgn:RocheMember imgn:KadcylaMember 2000-01-01 2000-12-31 0000855654 imgn:ManufacturingCommitmentsMember 2017-03-31 0000855654 imgn:RiverRidgeDrive100NorwoodMAMember 2017-01-01 2017-03-31 0000855654 imgn:ProvidenceHwy333NorwoodMMember 2017-01-01 2017-03-31 0000855654 imgn:RiverRidgeDrive100NorwoodMAMember 2013-04-01 2013-04-30 0000855654 imgn:WinterStreet930WalhamMaMember us-gaap:FacilityClosingMember 2016-09-26 0000855654 us-gaap:ConvertibleDebtMember 2017-01-01 2017-03-31 0000855654 imgn:StockIncentivePlan2016Member 2016-12-09 2016-12-09 0000855654 imgn:WinterStreet830WalthamMAMember 2015-12-31 0000855654 imgn:WinterStreet830WalthamMAMember 2014-04-30 0000855654 imgn:WinterStreet830WalthamMAMember 2013-12-31 0000855654 imgn:WinterStreet930WalhamMaMember us-gaap:FacilityClosingMember 2017-01-01 2017-03-31 0000855654 imgn:AccountingStandardsUpdate201609Member us-gaap:StateAndLocalJurisdictionMember us-gaap:RestatementAdjustmentMember 2017-01-01 0000855654 imgn:AccountingStandardsUpdate201609Member us-gaap:DomesticCountryMember us-gaap:RestatementAdjustmentMember 2017-01-01 0000855654 us-gaap:ConvertibleDebtMember 2017-03-31 0000855654 us-gaap:ConvertibleDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-03-31 0000855654 us-gaap:ConvertibleDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-03-31 0000855654 us-gaap:ConvertibleDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-12-31 0000855654 us-gaap:ConvertibleDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0000855654 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember imgn:SanofiMember 2017-01-01 2017-03-31 0000855654 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember imgn:RocheMember 2017-01-01 2017-03-31 0000855654 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember imgn:CytomXTherapeuticsIncMember 2017-01-01 2017-03-31 0000855654 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember imgn:RocheMember 2016-01-01 2016-03-31 0000855654 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember imgn:CytomXTherapeuticsIncMember 2016-01-01 2016-03-31 0000855654 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember imgn:BayerHealthCareMember 2016-01-01 2016-03-31 0000855654 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0000855654 us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0000855654 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000855654 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000855654 2016-03-31 0000855654 2015-12-31 0000855654 2016-01-01 2016-12-31 0000855654 imgn:WinterStreet830WalthamMAMember 2017-03-31 0000855654 imgn:WinterStreet930WalhamMaMember us-gaap:FacilityClosingMember 2016-02-29 0000855654 imgn:WinterStreet930WalhamMaMember 2016-02-29 0000855654 imgn:RiverRidgeDrive100NorwoodMAMember 2013-04-30 0000855654 imgn:DeferredShareUnitsMember imgn:CompensationPolicyNonEmployeeDirectorMember 2017-01-01 2017-03-31 0000855654 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0000855654 imgn:DirectorPlan2001Member 2017-01-01 2017-03-31 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember us-gaap:EmployeeSeveranceMember 2016-09-26 2016-09-26 0000855654 imgn:DeferredShareUnitsMember imgn:CompensationPolicyNonEmployeeDirectorMember 2016-01-01 2016-03-31 0000855654 us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-03-31 0000855654 imgn:DirectorPlan2001Member 2016-01-01 2016-03-31 0000855654 imgn:ImmunityRoyaltyHoldingsL.pMember imgn:KadcylaMember 2017-03-31 0000855654 imgn:ImmunityRoyaltyHoldingsL.pMember imgn:KadcylaMember 2016-12-31 0000855654 imgn:ManufacturingCommitmentsMember 2017-02-01 2017-02-28 0000855654 us-gaap:RestrictedStockMember 2016-08-01 2016-08-31 0000855654 imgn:StockIncentivePlan2016Member 2016-01-01 2016-12-31 0000855654 imgn:EmployeeDirectorsAndConsultantStockOptionsMember imgn:StockIncentivePlan2016Member 2017-01-01 2017-03-31 0000855654 imgn:DeferredShareUnitsMember imgn:CompensationPolicyNonEmployeeDirectorMember 2016-12-09 2016-12-09 0000855654 us-gaap:EmployeeSeveranceMember 2016-07-01 2016-12-31 0000855654 imgn:KadcylaMember 2015-04-01 2015-04-30 0000855654 imgn:ImmunityRoyaltyHoldingsL.pMember imgn:KadcylaMember 2015-04-01 2015-04-30 0000855654 imgn:BayerHealthCareMember us-gaap:MinimumMember 2008-01-01 2008-12-31 0000855654 imgn:BayerHealthCareMember us-gaap:MaximumMember 2008-01-01 2008-12-31 0000855654 us-gaap:EmployeeSeveranceMember 2016-09-26 2016-09-26 0000855654 imgn:WinterStreet930WalhamMaMember us-gaap:FacilityClosingMember 2016-09-26 2016-09-26 0000855654 2000-01-01 2000-12-31 0000855654 imgn:WinterStreet830WalthamMAMember 2017-01-01 2017-03-31 0000855654 imgn:RocheMember 2017-01-01 2017-03-31 0000855654 imgn:FusionPharmaceuticalsMember 2017-01-01 2017-03-31 0000855654 imgn:EliLillyAndCompanyMember 2017-01-01 2017-03-31 0000855654 imgn:CytomXTherapeuticsIncMember 2017-01-01 2017-03-31 0000855654 imgn:BiotestAGMember 2017-01-01 2017-03-31 0000855654 imgn:BayerHealthCareMember 2017-01-01 2017-03-31 0000855654 imgn:AmgenMember 2017-01-01 2017-03-31 0000855654 imgn:AmgenMember imgn:OxfordBiotherapeuticsLtdMember 2017-01-01 2017-03-31 0000855654 imgn:TakedaOncologyMember 2017-01-01 2017-03-31 0000855654 imgn:NovartisInstitutesForBioMedicalResearchIncMember 2017-01-01 2017-03-31 0000855654 imgn:SanofiMember 2017-01-01 2017-03-31 0000855654 us-gaap:AccountingStandardsUpdate201409Member us-gaap:MaximumMember 2017-01-01 2017-03-31 0000855654 imgn:RocheMember imgn:KadcylaMember 2017-01-01 2017-03-31 0000855654 imgn:RocheMember imgn:KadcylaMember 2016-01-01 2016-03-31 0000855654 imgn:ImmunityRoyaltyHoldingsL.pMember imgn:KadcylaMember 2017-01-01 2017-03-31 0000855654 imgn:ManufacturingCommitmentsMember 2017-02-28 0000855654 imgn:SanofiMember imgn:PhaseIIbClinicalTrialMember 2017-03-01 2017-03-31 0000855654 imgn:SanofiMember imgn:PhaseIIIClinicalTrialMember 2017-01-01 2017-01-31 0000855654 imgn:CytomXTherapeuticsIncMember 2017-01-01 2017-01-31 0000855654 imgn:ImmunityRoyaltyHoldingsL.pMember imgn:KadcylaMember 2015-04-01 2017-03-31 0000855654 2016-12-31 0000855654 us-gaap:ConvertibleDebtMember 2016-06-30 0000855654 us-gaap:ConvertibleDebtMember 2016-06-01 2016-06-30 0000855654 imgn:KadcylaMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0000855654 imgn:KadcylaMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0000855654 us-gaap:MinimumMember 2017-01-01 2017-03-31 0000855654 us-gaap:MaximumMember 2017-01-01 2017-03-31 0000855654 2016-01-01 2016-03-31 0000855654 imgn:RocheMember imgn:KadcylaMember imgn:RegulatoryMilestonesMember 2017-03-31 0000855654 imgn:SanofiMember imgn:RegulatoryMilestonesMember 2017-03-31 0000855654 imgn:SanofiMember imgn:PhaseIIIClinicalTrialMember 2017-03-31 0000855654 imgn:SanofiMember imgn:PhaseIIbClinicalTrialMember 2017-03-31 0000855654 imgn:SanofiMember imgn:PhaseIClinicalTrialMember 2017-03-31 0000855654 imgn:CytomXTherapeuticsIncMember imgn:DevelopmentMilestonesMember 2017-03-31 0000855654 imgn:BayerHealthCareMember imgn:RegulatoryMilestonesMember 2017-03-31 0000855654 imgn:BayerHealthCareMember imgn:DevelopmentMilestonesMember 2017-03-31 0000855654 imgn:CytomXTherapeuticsIncMember imgn:SalesMilestonesMember 2014-01-31 0000855654 imgn:CytomXTherapeuticsIncMember imgn:RegulatoryMilestonesMember 2014-01-31 0000855654 imgn:CytomXTherapeuticsIncMember imgn:DevelopmentMilestonesMember 2014-01-31 0000855654 imgn:CytomXTherapeuticsIncMember 2014-01-31 0000855654 imgn:BayerHealthCareMember imgn:SalesMilestonesMember 2008-12-31 0000855654 imgn:BayerHealthCareMember imgn:RegulatoryMilestonesMember 2008-12-31 0000855654 imgn:DevelopmentMilestonesMember 2008-12-31 0000855654 imgn:BayerHealthCareMember 2008-12-31 0000855654 imgn:SanofiMember imgn:RegulatoryMilestonesMember 2003-12-31 0000855654 imgn:SanofiMember imgn:DevelopmentMilestonesMember 2003-12-31 0000855654 imgn:SanofiMember 2003-12-31 0000855654 imgn:RocheMember imgn:KadcylaMember imgn:RegulatoryMilestonesMember 2000-12-31 0000855654 imgn:RocheMember imgn:KadcylaMember imgn:DevelopmentMilestonesMember 2000-12-31 0000855654 imgn:RocheMember imgn:KadcylaMember 2000-12-31 0000855654 2017-03-31 0000855654 2017-05-01 0000855654 2017-01-01 2017-03-31 iso4217:GBP iso4217:USD xbrli:shares utr:sqft imgn:employee iso4217:EUR xbrli:pure iso4217:USD imgn:item xbrli:shares false --12-31 Q1 2017 2017-03-31 10-Q 0000855654 89348389 Yes Accelerated Filer IMMUNOGEN INC 3 161800000 1200000 44000000 13500000 30500000 21500000 7500000 14000000 170500000 16000000 44500000 110000000 160000000 10000000 50000000 100000000 2000000 6000000 1000000 1000000 3000000 3000000 3000000 5000000 3000000 727000 P12Y P10Y P12Y P10Y P90D 1000 850000 832000 3144000 2943000 0.077 <div> <div> Financial Instruments and Concentration of Credit Risk   Cash and cash equivalents are primarily maintained with three financial institutions in the U.S. Deposits with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. The Company’s cash equivalents consist of money market funds with underlying investments primarily being U.S. Government issued securities and high quality, short term commercial paper. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. The Company held no marketable securities as of March 31, 2017 and December 31, 2016. The Company’s investment policy, approved by the Board of Directors, limits the amount it may invest in any one type of investment, thereby reducing credit risk concentrations. <div /></div> </div> -42000 -25000 0.005 2 0.005 0.005 P12M 0 0 403000 14470000 15664000 169858000 164460000 <div> <div> E.       Liability Related to Sale of Future Royalties   In April 2015, Immunity Royalty Holdings, L.P. (IRH) purchased the right to receive 100% of the royalty payments on commercial sales of Kadcyla subsequent to December 31, 2014, arising under the Company’s development and commercialization license with Genentech (a unit of Roche), until IRH has received aggregate royalties equal to $235 million or $260 million, depending on when the aggregate royalties received by IRH reach a specified milestone.  Once the applicable threshold is met, if ever, the Company will thereafter receive 85% and IRH will receive 15% of the Kadcyla royalties for the remaining royalty term.  At consummation of the transaction in April 2015, the Company received cash proceeds of $200 million.  As part of this sale, the Company incurred $5.9 million of transaction costs, which are presented net of the liability in the accompanying consolidated balance sheet and will be amortized to interest expense over the estimated life of the royalty purchase agreement.  Although the Company sold its rights to receive royalties from the sales of Kadcyla, as a result of its ongoing involvement in the cash flows related to these royalties, the Company will continue to account for these royalties as revenue and recorded the $200 million in proceeds from this transaction as a liability related to sale of future royalties (Royalty Obligation) that will be amortized using the interest method over the estimated life of the royalty purchase agreement.   The following table shows the activity within the liability account during the three-month period ended March 31, 2017 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Period from </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2016 to </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liability related to sale of future royalties, net — beginning balance </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184,328 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Non-cash Kadcyla royalty revenue </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (7,613) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Non-cash interest expense recognized </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,409 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Liability related to sale of future royalties, net  — ending balance </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 180,124 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   As royalties are remitted to IRH, the balance of the Royalty Obligation will be effectively repaid over the life of the agreement. In order to determine the amortization of the Royalty Obligation, the Company is required to estimate the total amount of future royalty payments to be received and remitted to IRH as noted above over the life of the agreement. The sum of these amounts less the $200 million proceeds the Company received will be recorded as interest expense over the life of the Royalty Obligation. Since inception, the Company’s  estimate of this total interest expense resulted in an effective annual interest rate of approximately 7.7%. The Company periodically assesses the estimated royalty payments to IRH and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the Royalty Obligation. There are a number of factors that could materially affect the amount and timing of royalty payments from Genentech, most of which are not within the Company’s control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, patent protection, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to IRH are made in U.S. dollars (USD) while significant portions of the underlying sales of Kadcyla are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from Kadcyla, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Obligation. Conversely, if sales of Kadcyla are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Obligation. In addition, the royalty purchase agreement grants IRH the right to receive certain reports and other information relating to the royalties and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. <div /></div> </div> 10077000 12700000 3000000 18730000 3000000 6300000 4972000 3575000 3409000 <div> <div> Non-cash Investing Activities   The Company had approximately $104,000 and $356,000 of accrued capital expenditures as of March 31, 2017 and December 31, 2016, respectively, which have been treated as a non-cash investing activity and, accordingly, are not reflected in the consolidated statement of cash flows.  <div /></div> </div> 7380000 7400000 7613000 7613000 7600000 10 1 1 2 1 1 2 1 1 1 3 1 5 5 1 2 2 3 2 P3M P9M 1 1 1059000 1478000 60 1 0.07 0.04 1 0.85 0.15 260000000 <div> <div> The following table shows the activity within the liability account during the three-month period ended March 31, 2017 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Period from </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2016 to </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liability related to sale of future royalties, net — beginning balance </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184,328 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Non-cash Kadcyla royalty revenue </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (7,613) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Non-cash interest expense recognized </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,409 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Liability related to sale of future royalties, net  — ending balance </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 180,124 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> 593000 0.50 11679000 13690000 1 1 3 P5Y 5900000 5000000

7895000

5100000

2026000

3893000

184328000

180124000

778847000

781492000

7200000

-32000

2800000

108000

837000

2600000

12000

38000

7507

10281

110000

198864000

163321000

176346000

142131000

<div> <div> Basis of Presentation   The accompanying unaudited consolidated financial statements at March 31, 2017 and December 31, 2016 and for the three months ended March 31, 2017 and 2016 include the accounts of ImmunoGen, Inc., or the Company, and its wholly owned subsidiaries, ImmunoGen Securities Corp., ImmunoGen Europe Limited and Hurricane, LLC. The consolidated financial statements include all of the adjustments, consisting only of normal recurring adjustments, which management considers necessary for a fair presentation of the Company’s financial position in accordance with accounting principles generally accepted in the U.S. for interim financial information. The December 31, 2016 condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. The preparation of interim financial statements requires the use of management’s estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenditures during the reported periods. The results of the interim periods are not necessarily indicative of the results for the entire year. Accordingly, the interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Transition Report on Form 10-K for the six months ended December 31, 2016. <div /></div> </div>

356000

104000

212283000

182913000

159964000

126568000

144176000

108296000

<div> <div> C.       Agreements Significant Collaborative Agreements Roche In 2000, the Company granted Genentech, now a unit of Roche, an exclusive license to use the Company’s maytansinoid ADC technology with antibodies, such as trastuzumab, or other proteins that target HER2. Under the terms of this agreement, Roche has exclusive worldwide rights to develop and commercialize maytansinoid ADC compounds targeting HER2. In 2013, the HER2‑targeting ADC compound, Kadcyla, was approved for marketing in the U.S., Japan and the European Union, or EU. Roche has also received marketing approval in various other countries around the world. Roche is responsible for the manufacturing, product development and marketing of any products resulting from the agreement. The Company received a $2 million non‑refundable upfront payment from Roche upon execution of the agreement. The Company is also entitled to receive up to a total of $44 million in milestone payments, plus royalties on the commercial sales of Kadcyla or any other resulting products. Total milestones are categorized as follows: development milestones—$13.5 million; and regulatory milestones—$30.5 million. Through March 31, 2017, the Company has received and recognized $13.5 million and $20.5 million in development and regulatory milestone payments, respectively, related to Kadcyla. The next potential milestone the Company will be entitled to receive will be a $5 million regulatory milestone for marketing approval of Kadcyla for a first extended indication as defined in the agreement. Based on an evaluation of the effort contributed towards the achievement of this future milestone, the Company determined this milestone is not substantive. The Company receives royalty reports and payments related to sales of Kadcyla from Roche one quarter in arrears. In accordance with the Company’s revenue recognition policy, $7.6 million of non-cash royalties on net sales of Kadcyla for the three‑month period ended December 31, 2016 were recorded and included in non-cash royalty revenue for the three-month period ended March 31, 2017 and $7.4 million of non-cash royalties on net sales of Kadcyla for the three‑month period ended December 31, 2015 is included in non-cash royalty revenue for the three-month period ended March 31, 2016. Kadcyla sales occurring after January 1, 2015 are covered by a royalty purchase agreement whereby the associated cash is remitted to Immunity Royalty Holdings, L.P, or IRH, as discussed further in Note E. Sanofi In 2003, the Company entered into a broad collaboration agreement with Sanofi (formerly Aventis) to discover, develop and commercialize antibody‑based products. The collaboration agreement provides Sanofi with worldwide development and commercialization rights to new antibody‑based products directed to targets that are included in the collaboration, including the exclusive right to use the Company’s maytansinoid ADC technology in the creation of products developed to these targets. The product candidates (targets) as of March 31, 2017 in the collaboration include isatuximab (CD38), SAR566658 (CA6), SAR408701 (CEACAM5) and one earlier‑stage program that has yet to be disclosed. The Company is entitled to receive milestone payments potentially totaling $21.5 million, per target, plus royalties on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$7.5 million; and regulatory milestones—$14 million. Through March 31, 2017, the Company has recognized an aggregate of $26.5 million in milestone payments for compounds covered under this agreement now or in the past. In January 2017, Sanofi enrolled its first patient in a Phase III clinical trial for isatuximab, and in March 2017, enrolled its first patient in a Phase IIb clinical trial (as defined in the agreement) for SAR566658, each of which triggered a $3 million milestone payment to the Company, which are included in license and milestone fee revenue for the three months ended March 31, 2017. The next potential milestone the Company will be entitled to receive for SAR566658 will be a development milestone for initiation of a Phase III clinical trial, which will result in a $3 million payment being due. The next potential milestone the Company will be entitled to receive with respect to isatuximab will be a regulatory milestone for submission of a new drug application to the U.S. Food and Drug Administration, which will result in a $3 million payment being due. The next potential milestone the Company will be entitled to receive for SAR408701 will be a development milestone for initiation of a Phase IIb clinical trial (as defined in the agreement), which will result in each case in a $3 million payment being due. The next potential milestone the Company will be entitled to receive for the unidentified target will be a development milestone for commencement of a Phase I clinical trial, which will result in a $1 million payment being due. At the time of execution of this agreement, there was significant uncertainty as to whether these milestones would be achieved. In consideration of this, as well as the Company’s past involvement in the research and manufacturing of these product candidates, these milestones were deemed substantive. Bayer In 2008, the Company granted Bayer an exclusive development and commercialization license to the Company’s maytansinoid ADC technology for use with antibodies or other proteins that target mesothelin. Bayer HealthCare is responsible for the research, development, manufacturing, and marketing of any products resulting from the license. The Company received a $4 million upfront payment upon execution of the agreement which was recognized as revenue ratably over the Company’s estimated period of substantial involvement which concluded in September 2012. For each compound developed and marketed by Bayer under this collaboration the Company is entitled to receive a total of $170.5 million in milestone payments, plus tiered royalties between 4 - 7% on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$16 million; regulatory milestones—$44.5 million; and sales milestones—$110 million. Through March 31, 2017, the Company has received and recognized an aggregate of $13 million in milestone payments under this agreement. In January 2016, Bayer initiated a Phase II clinical study designed to support registration of its ADC product candidate, anetumab ravtansine, triggering a $10 million development milestone payment to the Company which is included in license and milestone fee revenue for the three months ended March 31, 2016. The next potential milestone the Company will be entitled to receive will be either a development milestone for commencement of a pivotal clinical trial for a second indication for anetumab ravtansine which will result in a $2 million payment being due or a regulatory milestone for filing of regulatory approval for its first indication for anetumab ravtansine which will result in a $6 million payment being due. At the time of execution of this agreement, there was significant uncertainty as to whether these milestones would be achieved. In consideration of this, as well as the Company’s past involvement in the research and supply of cytotoxic agent for this product candidate, these milestones was deemed substantive. CytomX In January 2014, we entered into a reciprocal right‑to‑test agreement with CytomX. The agreement provides CytomX with the right to test our payload agents and linkers with CytomX antibodies that utilize their proprietary antibody-masking technology, termed ProbodiesTM for a specified number of targets and to subsequently take an exclusive, worldwide license to use our technology to develop and commercialize Probody-drug conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. We received no upfront cash payment in connection with the execution of the right‑to‑test agreement. Instead, we received reciprocal rights to test our payload agents and linkers with ImmunoGen antibodies masked using CytomX technology to create Probody-drug conjugates directed to a specified number of targets and to subsequently take exclusive, worldwide licenses to develop and commercialize such conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. The terms of the right‑to‑test agreement require us and CytomX to each take its respective development and commercialization licenses by the end of the term of the research license. In addition, both we and CytomX are required to perform specific research activities under the right‑to‑test agreement on behalf of the other party for no monetary consideration. In February 2016, CytomX took its development and commercialization license for a specified target.  An amendment of the agreement executed simultaneously with that license granted CytomX the right, for a specified period of time, to substitute the specified target with another as yet unspecified target.  Accordingly, the revenue associated with this license was deferred until the expiration of that substitution right in January 2017, whereupon we recognized $12.7 million of the $13 million of arrangement consideration allocated to the development and commercialization license, which is included in license and milestone fee revenue for the three months ended March 31, 2017.  With respect to the development and commercialization license taken by CytomX, the Company is entitled to receive up to a total of $160 million in milestone payments plus royalties on the commercial sales of any resulting product. The total milestones are categorized as follows: development milestones—$10 million; regulatory milestones—$50 million; and sales milestones—$100 million. In addition, CytomX may be liable to pay annual maintenance fees if the licensed product candidate covered under the development and commercialization license has not progressed to a specified stage of development within a specified time frame.  Assuming no annual maintenance fee is payable, the next payment the Company could receive would be a $1 million development milestone payment with commencement of a Phase I clinical trial. At the time of execution of the right-to-test agreement, there was significant uncertainty as to whether the milestone related to the Phase I clinical trial would be achieved. In consideration of this, as well as the Company's expected involvement in the research and manufacturing of any product candidate, this milestone was deemed substantive. CytomX is responsible for the manufacturing, product development and marketing of any product resulting from the development and commercialization license taken by CytomX under this collaboration.  For additional information related to these agreements, as well as the Company’s other significant collaborative agreements, please read Note C, Agreements, to the consolidated financial statements included within the Company’s 2016 Transition Report on Form 10-K   <div /></div> </div>

<div> <div> H.       Commitments and Contingencies   Leases   The Company currently has a lease agreement with CRP/King 830 Winter L.L.C. for the rental of approximately 110,000 square feet of laboratory and office space at 830 Winter Street, Waltham, MA through March 2026. The Company uses this space for its corporate headquarters and other operations. The Company may extend the lease for two additional terms of five years. Pursuant to lease amendments executed in December 2013, April 2014, and December 2015, the Company received construction allowances of approximately $746,000, $1.1 million, and $186,000, respectively, to build out office and lab space to the Company’s specifications. The Company is required to pay certain operating expenses for the leased premises subject to escalation charges for certain expense increases over a base amount.   In February 2016, the Company entered into a lease agreement with PDM 930 Unit, LLC for the rental of 10,281 square feet of additional office space at 930 Winter Street, Waltham, MA through August 31, 2021. The Company received approximately $617,000 as a construction allowance to build out the office space to the Company’s specifications. The Company is required to pay certain operating expenses for the leased premises based on its pro-rata share of such expenses for the entire rentable space of the building. The Company is actively seeking to sub-lease this space.   The Company also leases manufacturing and office space at 333 Providence Highway, Norwood, MA under an agreement through 2018 with an option to extend the lease for an additional term of five years. The Company is required to pay certain operating expenses for the leased premises subject to escalation charges for certain expense increases over a base amount.   Effective April 2013, the Company entered into a lease agreement with River Ridge Limited Partnership for the rental of 7,507 square feet of additional office space at 100 River Ridge Drive, Norwood, MA. The initial term of the lease is for five years and two months commencing in July 2013 with an option for the Company to extend the lease for an additional term of five years. The Company is required to pay certain operating expenses for the leased premises subject to escalation charges for certain expense increases over a base amount. The Company entered into a sublease in December 2014 for this space, effective from January 2015 through July 2018. That sublease is in process of being terminated due to payment delinquency.  Due to the short span of time remaining on the lease and the estimated amount of time it would take to find another sub-tenant, the remainder of this lease was accrued as a charge in the quarter in the amount of $169,000.   The minimum rental commitments for the Company’s facilities, including real estate taxes and other expenses, for the next five fiscal years and thereafter under the non-cancelable operating lease agreements discussed above are as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 (nine months remaining) </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,959 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,736 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,235 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,283 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,107 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 30,794 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 66,114 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   There are no obligations under capital leases as of March 31, 2017, as all of the capital leases were single payment obligations which have all been made.   Collaborations   The Company is contractually obligated to make potential future success-based development, regulatory or sales milestone payments in conjunction with certain collaborative agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. As of March 31, 2017, the maximum amount that may be payable in the future under the Company’s current collaborative agreements is $161.8 million, $1.2 million of which is reimbursable by a third party under a separate agreement.   The Company is party to a license agreement covering the manufacture of the antibodies used in certain of product candidates which, under certain circumstances, requires periodic payments once the product reaches a specified stage of clinical development, and royalties on commercial sales of the product. The Company believes that the license agreement, by its terms, does not obligate it to make any further payments thereunder and accordingly, has not accrued a potential payment of £300,000 for one of its product candidates that has reached this stage. Manufacturing Commitments As of March 31, 2017, the Company has noncancelable obligations under several agreements related to in-process and future manufacturing of antibody and cytotoxic agents required for clinical supply of the Company’s product candidates totaling $8.6 million, of which $6.8 million will be paid in 2017 and $1.8 million will be paid in 2018. In February 2017, the Company executed a letter agreement with one of its antibody manufacturers to reserve capacity through calendar 2021. The total commitment over the five-year term of the agreement is €46.2 million, however only €6.3 million euros is noncancelable as of March 31, 2017. <div /></div> </div>

0.01

150000000

87301000

89348000

87301000

89348000

873000

893000

-31928000

-17345000

0.51

0.03

0.3700

0.48

0.2700

0.21

100000000

79000000

100000000

111000000

96965000

97131000

<div> <div> D.       Convertible 4.5% Senior Notes In June 2016, the Company issued Convertible 4.5% Senior Notes with an aggregate principal amount of $100 million. The Company received net proceeds of approximately $96.6 million from the sale of the Convertible Notes, after deducting fees and expenses of approximately $3.4 million. The Convertible Notes are governed by the terms of an indenture between the Company, as issuer, and Wilmington Trust, National Association, as the trustee. The Convertible Notes are senior unsecured obligations and bear interest at a rate of 4.5% per year, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2017. The Company recorded approximately $1.1 million of interest expense in the three months ended March 31, 2017. The Convertible Notes will mature on July 1, 2021, unless earlier repurchased or converted. Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the stated maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted notes a number of shares equally to the conversion rate, which will initially be 238.7775 shares of common stock, equivalent to an initial conversion price of approximately $4.19. The conversion rate will be subject to adjustment in some circumstances, but will not be adjusted for any accrued and unpaid interest. In addition, if a “make-whole fundamental change” (as defined in the offering memorandum) occurs prior to the stated maturity date, the Company will increase the conversion rate for a holder who elects to convert its notes in connection with such make-whole fundamental change in certain circumstances. If the Company undergoes a fundamental change, subject to certain conditions, holders may require the Company to repurchase for cash all or part of their notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date. In addition, upon an event of default, the holders may require the Company to repurchase for cash all of their notes at a purchase price equal to 100% of the principal amount, plus accrued and unpaid interest. Upon bankruptcy, this becomes an automatic repurchase obligation. Also, if the Company fails to comply with certain reporting requirements as described in the indenture it will constitute an event of default, however the Company may elect to pay additional interest at an annual rate equal to 0.5% of the principal amount for the 90 days following such event as a remedy for the default. Subsequent to the 90 days, if still in default, the principal amount of the notes and accrued interest may become immediately due and payable. If a “restricted event” occurs as described in the indenture that causes the notes not to become freely tradable by holders other than our affiliates after the first anniversary of the original issuance date of the notes, the Company would also become obligated to pay additional interest at an annual rate equal to 0.5% of the principal amount. The combined additional interest rate under these two circumstances, however, cannot exceed 0.5%. The Company analyzed the terms of the Convertible Notes and determined that under current accounting guidance the notes would be entirely accounted for as debt and none of the terms of the notes require separate accounting. As part of the issuance of the Convertible Notes, the Company incurred $3.4 million of transaction costs, which are netted against the Convertible Notes in the accompanying consolidated balance sheet as and are being amortized to interest expense ratably over the term of the Convertible Notes. <div /></div> </div>

4.19

238.7775

23878

100000000

0.045

3035000

2869000

14531000

1814000

19086000

18992000

9200000

1200000

9200000

1200000

1435000

1506000

-0.37

-0.20

<div> <div> Computation of Net Loss per Common Share   Basic and diluted net loss per share is calculated based upon the weighted average number of common shares outstanding during the period. During periods of income, participating securities are allocated a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities (the “two-class method”). Shares of the Company’s restricted stock participate in any dividends declared by the Company and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to participating securities since they have no contractual obligation to share in the losses of the Company. Diluted (loss) income per share is computed after giving consideration to the dilutive effect of stock options and restricted stock that are outstanding during the period, except where such non-participating securities would be anti-dilutive.  The Company’s common stock equivalents, as calculated in accordance with the treasury‑stock method for the options and the if-converted method for the convertible notes, are shown in the following table (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options outstanding to purchase common stock and unvested restricted stock </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,690 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,679 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock equivalents under treasury stock method for options </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 110 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 361 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Shares issuable upon conversion of convertible notes </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,878 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock equivalents under if-converted method for convertible notes </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,878 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> The Company’s common stock equivalents have not been included in the net loss per share calculation because their effect is anti‑dilutive due to the Company’s net loss position. <div /></div> </div>

6946000

4927000

20200000

P2Y

<div> <div> As of March 31, 2017, the Company held certain assets that are required to be measured at fair value on a recurring basis.  The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2017 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="12" valign="bottom" style="width:50.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements at March 31, 2017 Using </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Unobservable </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,296 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,296 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis. The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2016 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:51.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements at December 31, 2016 Using </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 144,176 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 144,176 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Fair Value of Financial Instruments   Fair value is defined under ASC Topic 820, “Fair Value Measurements and Disclosures,” as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.  The standard describes a fair value hierarchy to measure fair value which is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 1 - Quoted prices in active markets for identical assets or liabilities.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr></table></div>   As of March 31, 2017, the Company held certain assets that are required to be measured at fair value on a recurring basis.  The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2017 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="12" valign="bottom" style="width:50.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements at March 31, 2017 Using </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Unobservable </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,296 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,296 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis. The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2016 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:51.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements at December 31, 2016 Using </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 144,176 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 144,176 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The fair value of the Company’s cash equivalents is based on quoted prices from active markets.   The carrying amounts reflected in the consolidated balance sheets for accounts receivable, unbilled revenue, prepaid and other current assets, accounts payable, accrued compensation, and other accrued liabilities approximate fair value due to their short‑term nature. The gross carrying amount and estimated fair value of the convertible 4.5% senior notes was $100.0 million and $111.0 million, respectively, as of March 31, 2017 compared to $100.0 million and $79.0 million, respectively, as of December 31, 2016. The increase in estimated fair value as of March 31, 2017 compared to December 31, 2016 is due primarily to an increase in the Company’s stock price. The fair value of the Convertible Notes is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in a market which is a Level 2 input for fair value purposes. <div /></div> </div>

3000

-180000

11235000

8119000

970000

386000

746000

1100000

186000

617000

5914000

5718000

-2378000

-2543000

-699000

1867000

-1232000

-12811000

1134000

-2019000

-629000

1033000

1490000

775000

-17000

173000

717000

1008000

142000

-4727000

23878000

361000

14250000

110000

1125000

1100000

2192000

3225000

<div> <div> Inventory   Inventory costs relate to clinical trial materials being manufactured for sale to the Company’s collaborators. Inventory is stated at the lower of cost or net realizable value as determined on a first-in, first-out (FIFO) basis.   Inventory at March 31, 2017  and December 31, 2016 is summarized below (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 125 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 357 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,100 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,835 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,225 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,192 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div> Raw materials inventory consists entirely of proprietary cell‑killing agents the Company developed as part of its ADC technology. All raw materials inventory is currently procured from two suppliers. The Company considers more than a twelve month supply of raw materials that is not supported by firm, fixed orders and/or projections from its collaborators to be excess and establishes a reserve to reduce to zero the value of any such excess raw material inventory with a corresponding charge to research and development expense. In accordance with this policy, the Company recorded $403,000 of expense related to excess inventory in the three months ended March 31, 2017 as a result of inventory purchased in the current period in order to manufacture drug product to supply the Company’s mirvetuximab soravtansine studies. There were no expenses recorded for excess inventory during the three-month period ended March 31, 2016. Work in process inventory consists of conjugate manufactured for sale to the Company’s collaborators to be used in preclinical and clinical studies.  All conjugate is made to order at the request of the collaborators and subject to the terms and conditions of respective supply agreements.  Based on historical reprocessing or reimbursement required for conjugate that did not meet specification and status of current conjugate on hand or conjugate shipped to collaborators but not yet released per the terms of the respective supply agreements, no reserve for work in process inventory was determined to be required at March 31, 2017. As discussed above, the Company’s costs to manufacture conjugate on behalf of its partners are greater than the supply prices charged to partners, and therefore costs are capitalized into inventory at the supply prices which represents net realizable value. <div /></div> </div>

357000

125000

1835000

3100000

108000

115000

193000

784000

P5Y

P5Y2M

351714000

330851000

198864000

163321000

55776000

40367000

<div> <div> IMMUNOGEN, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<a name="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_1"></a> March 31, 2017   A.Nature of Business and Plan of Operations   ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development of antibody-drug conjugates, or ADCs, for the treatment of cancer.    In August 2014, the FASB issued ASU 2014‑15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. (ASU 2015-14). Under the new standard, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates  substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.    Generally, to be considered probable of being effectively implemented, the plans must have been approved before the date that the financial statements are issued. This standard was adopted by the Company at December 31, 2016.     The Company has incurred operating losses and negative cash flows from operations since inception, incurred a net loss of approximately $17.3 million during the three months ended March 31, 2017, and has an accumulated deficit of approximately $949.9  million as of March 31, 2017. The Company has primarily funded these losses through payments received from its collaborations and equity and convertible debt financings. To date, the Company has no product revenue and management expects operating losses to continue for the foreseeable future. At March 31, 2017, the Company had $126.6 million of cash and cash equivalents on hand. The Company anticipates that its current capital resources and expected future collaborator payments will enable it to meet its operational expenses and capital expenditures (operating plan) into the second quarter of calendar year 2018. Without such collaborator payments, the Company’s existing capital resources at March 31, 2017 would not be sufficient to support the current operating plan through May 5, 2018, which is twelve months after the date that the March 2017 financial statements were issued. Management expects to seek additional funds from collaboration partners through a combination of upfront license payments, milestone payments, royalty payments, research funding, and clinical material reimbursement or from equity or debt financings. Because those plans have not been finalized, receipt of additional funding is not considered probable under the new standard. If the Company does not obtain sufficient funds when needed, the Company expects it would scale back its operating plan by deferring or limiting some or all of its research, development or clinical projects, or initiate further reductions to its workforce. Because such contingency plans have not been finalized (because the specifics would depend on the situation at the time), such actions also are not considered probable for purposes of the new standard. Because, under the new standard, neither receipt of future collaboration payments, nor management’s contingency plans to mitigate the risk and extend cash resources through May 5, 2018, are considered probable, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern.   The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, collaboration arrangements, third‑party reimbursements and compliance with governmental regulations.     <div /></div> </div>

-29370000

-33396000

188000

-3479000

-437000

-26079000

-32959000

-31928000

-17345000

<div> <div> Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014‑9, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company anticipates using the modified retrospective approach to implement this standard.  The Company has begun to analyze its existing revenue agreements to evaluate the impact of adoption. The Company has less than ten contracts that have remaining performance obligations that will need to be evaluated under the provisions of the new standard as of January 1, 2018. In performing this assessment, the Company noted that we will be required to recognize royalty income in the same period as the related sales occur on Kadcyla rather than one quarter in arrears, which is the point in which the amount is fixed and determinable. This will require the Company to make an estimate of the royalties as the information is not provided to the Company until 90 days after the end of the quarter. Additionally, some partner milestones, depending on the probability of occurring, may be recognized sooner and at different values than they currently would be under the current accounting standards. The Company is in the process of estimating the impact of adopting the new standard on its consolidated financial statements, however, the Company expects to record a material adjustment upon adoption, which will be recorded as a cumulative effect of initially applying the standard to opening accumulated deficit as of January 1, 2018. The Company will continue to provide disclosures under the legacy accounting for the year ended December 31, 2018. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330). To simplify the principles for subsequent measurement of inventory, this new standard requires inventory measured using any method other than LIFO or the retail method shall be measured at the lower of cost and net realizable value, rather than lower of cost or market. This guidance is effective for annual reporting beginning after December 15, 2016, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.   In January 2016, the FASB issued ASU 2016-1, Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825). The amendments in this Update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. The amendments allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment. The amendments also require enhanced disclosures about those investments. The amendments improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. This guidance is effective for annual reporting beginning after December 15, 2017, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, the standard is effective for the Company on January 1, 2018. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.   In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842) that primarily requires lessees to recognize most leases on their balance sheets but record expenses on their income statements in a manner similar to current accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and calls for retrospective application, with early adoption permitted. Accordingly, the standard is effective for the Company on January 1, 2019. The Company is currently evaluating the impact of this guidance on our financial statements and the timing of adoption.   In March 2016, the FASB issued ASU 2016-9, Improvements to Employee Share-Based Payment Accounting (Topic 718) that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. As a result of the adoption of this guidance, the net operating losses deferred tax assets for federal and state purposes increased by $9.2 million and $1.2 million, respectively, and will be offset by corresponding increases in the valuation allowance. The adoption of the guidance has no impact on the Company’s consolidated financial statements. The Company elected not to adopt the provision that would allow actual forfeitures to be recognized in lieu of maintaining a forfeitures reserve. As such, the Company will continue to estimate forfeitures. <div /></div> </div>

47329000

41393000

-27615000

-12894000

66114000

7107000

7283000

7235000

7736000

30794000

5959000

169000

<div> <div> B.Summary of Significant Accounting Policies   Basis of Presentation   The accompanying unaudited consolidated financial statements at March 31, 2017 and December 31, 2016 and for the three months ended March 31, 2017 and 2016 include the accounts of ImmunoGen, Inc., or the Company, and its wholly owned subsidiaries, ImmunoGen Securities Corp., ImmunoGen Europe Limited and Hurricane, LLC. The consolidated financial statements include all of the adjustments, consisting only of normal recurring adjustments, which management considers necessary for a fair presentation of the Company’s financial position in accordance with accounting principles generally accepted in the U.S. for interim financial information. The December 31, 2016 condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. The preparation of interim financial statements requires the use of management’s estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenditures during the reported periods. The results of the interim periods are not necessarily indicative of the results for the entire year. Accordingly, the interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Transition Report on Form 10-K for the six months ended December 31, 2016.   Subsequent Events   The Company has evaluated all events or transactions that occurred after March 31, 2017  up through the date the Company issued these financial statements. The Company did not have any material recognizable or unrecognizable subsequent events during this period.   Revenue Recognition   The Company enters into licensing and development agreements with collaborative partners for the development of ADC therapeutics. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company’s antibody‑drug conjugate, or ADC, technology, (ii) rights to future technological improvements, (iii) research activities to be performed on behalf of the collaborative partner, (iv) delivery of cytotoxic agents and (v) the manufacture of preclinical or clinical materials for the collaborative partner. Payments to the Company under these agreements may include upfront fees, option fees, exercise fees, payments for research activities, payments for the manufacture of preclinical or clinical materials, payments based upon the achievement of certain milestones and royalties on product sales. The Company follows the provisions of the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605‑25, “Revenue Recognition—Multiple‑Element Arrangements,” and ASC Topic 605‑28, “Revenue Recognition—Milestone Method,” in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has stand‑alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. At March 31, 2017, the Company had the following two material types of agreements with the parties identified below: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Development and commercialization licenses, which provide the party with the right to use the Company’s ADC technology and/or certain other intellectual property to develop compounds to a specified antigen target:</td></tr></table></div> Amgen (two exclusive single-target licenses(1))   Bayer (one exclusive single-target license) Biotest (one exclusive single-target license) CytomX (one exclusive single-target license) Fusion Pharmaceuticals (one exclusive single-target license) Lilly (three exclusive single-target licenses) Novartis (five exclusive single-target licenses and one license to two related targets: one target on an exclusive basis and the second target on a non-exclusive basis) Roche, through its Genentech unit (five exclusive single-target licenses) Sanofi (one exclusive single-target license and one exclusive license to multiple individual targets) Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (one exclusive single-target license) <div><hr style="border-width:0;width:25%;height:.75pt;color:black;background-color:black;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Amgen has sublicensed one of its exclusive single-target licenses to Oxford BioTherapeutics Ltd.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Research license/option agreement for a defined period of time to secure development and commercialization licenses to use the Company’s ADC technology to develop anticancer compounds to specified targets on established terms (referred to herein as right-to-test agreements):</td></tr></table></div> CytomX Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.  There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company. Development and Commercialization Licenses The deliverables under a development and commercialization license agreement generally include the license to the Company’s ADC technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research activities to be performed on behalf of the collaborative partner and the manufacture of preclinical or clinical materials for the collaborative partner. Generally, development and commercialization licenses contain non‑refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator’s request, provide research services at negotiated prices which are generally consistent with what other third parties would charge, (ii) at the collaborator’s request, manufacture and provide to it preclinical and clinical materials or deliver cytotoxic agents at negotiated prices which are generally consistent with what other third parties would charge, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments, generally until the later of the last applicable patent expiration or 10 to 12 years after product launch. In the case of Kadcyla®, however, the minimum royalty term is 10 years and the maximum royalty term is 12 years on a country‑by‑country basis, regardless of patent protection. Royalty rates may vary over the royalty term depending on the Company’s intellectual property rights and/or the presence of comparable competing products. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. The Company does not directly control when or whether any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments. As a result, the Company cannot predict when or if it will recognize revenues in connection with any of the foregoing. In determining the units of accounting, management evaluates whether the license has stand‑alone value from the undelivered elements to the collaborative partner based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of ADC technology research expertise in the general marketplace. If the Company concludes that the license has stand‑alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity‑specific factors such as the terms of the Company’s previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s ADC technology, the Company’s pricing practices and pricing objectives, the likelihood that technological improvements will be made, and, if made, will be used by the Company’s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Upfront payments on development and commercialization licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand‑alone value from the undelivered elements, which generally include rights to future technological improvements, research services, delivery of cytotoxic agents and the manufacture of preclinical and clinical materials. The Company recognizes revenue related to research services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license. The Company may also provide cytotoxic agents to its collaborators or produce preclinical and clinical materials at negotiated prices which are generally consistent with what other third parties would charge. The Company recognizes revenue on cytotoxic agents and on preclinical and clinical materials when the materials have passed all quality testing required for collaborator acceptance and title and risk of loss have transferred to the collaborator. Arrangement consideration allocated to the manufacture of preclinical and clinical materials in a multiple‑deliverable arrangement is below the Company’s full cost, and the Company’s full cost is not expected to ever be below its contract selling prices for its existing collaborations. During the three months ended March 31, 2017 and 2016, the difference between the Company’s full cost to manufacture preclinical and clinical materials on behalf of its collaborators as compared to total amounts received from collaborators for the manufacture of preclinical and clinical materials was $727,000 and $3.0 million, respectively. The majority of the Company’s costs to produce these preclinical and clinical materials are fixed and then allocated to each batch based on the number of batches produced during the period. Therefore, the Company’s costs to produce these materials are significantly affected by the number of batches produced during the period. The volume of preclinical and clinical materials the Company produces is directly related to the scale and scope of preclinical activities and the number of clinical trials the Company and its collaborators are preparing for or currently have underway, the speed of enrollment in those trials, the dosage schedule of each clinical trial and the time period such trials last. Accordingly, the volume of preclinical and clinical materials produced, and therefore the Company’s per‑batch costs to manufacture these preclinical and clinical materials, may vary significantly from period to period. The Company may also produce research material for potential collaborators under material transfer agreements. Additionally, the Company performs research activities, including developing antibody specific conjugation processes, on behalf of its collaborators and potential collaborators during the early evaluation and preclinical testing stages of drug development. The Company records amounts received for research materials produced or services performed as a component of research and development support revenue. The Company also develops conjugation processes for materials for later stage testing and commercialization for certain collaborators. The Company is compensated at negotiated rates and may receive milestone payments for developing these processes which are recorded as a component of research and development support revenue. The Company’s development and commercialization license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration, or FDA, or other countries’ regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non‑refundable development and regulatory milestones that are expected to be achieved as a result of the Company’s efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we do not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. Under the Company’s development and commercialization license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. Generally, under these agreements the Company is to receive royalty reports and payments from its licensees approximately one quarter in arrears, that is, generally in the second or third month of the quarter after the licensee has sold the royalty bearing product or products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. As such, the Company generally recognizes royalty revenues in the quarter reported to the Company by its licensees, or one quarter following the quarter in which sales by the Company’s licensees occurred. Right‑to‑Test Agreements The Company’s right‑to‑test agreements provide collaborators the right to (a) test the Company’s ADC technology for a defined period of time through a research, or right‑to‑test, license, (b) take options, for a defined period of time, to specified targets and (c) upon exercise of those options, secure or “take” licenses to develop and commercialize products for the specified targets on established terms. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as “upfront” fees or payments), (ii) upon taking an option with respect to a specific target (referred to as option fees or payments earned, if any, when the option is “taken”), (iii) upon the exercise of a previously taken option to acquire a development and commercialization license(s) (referred to as exercise fees or payments earned, if any, when the development and commercialization license is “taken”), or (iv) some combination of all of these fees. The accounting for right to test agreements is dependent on the nature of the options granted to the collaborative partner. Options are considered substantive if, at the inception of a right to test agreement, the Company is at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments or economic penalties imposed on the collaborator as a result of exercising the options. None of the Company’s right to test agreements entered into subsequent to the adoption of Accounting Standards Update, or ASU, No. 2009 13, “Revenue Arrangements with Multiple Deliverables” on July 1, 2010 has been determined to contain substantive options. For right to test agreements where the options to secure development and commercialization licenses to the Company’s ADC technology are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple element revenue recognition criteria to determine the appropriate revenue recognition. Subsequent to the adoption of ASU No. 2009-13, the Company determined that its research licenses lack stand-alone value and are considered for aggregation with the other elements of the arrangement and accounted for as one unit of accounting. The Company does not control when or if any collaborator will exercise its options for development and commercialization licenses. As a result, the Company cannot predict when or if it will recognize revenues in connection with any of the foregoing.   Financial Instruments and Concentration of Credit Risk   Cash and cash equivalents are primarily maintained with three financial institutions in the U.S. Deposits with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. The Company’s cash equivalents consist of money market funds with underlying investments primarily being U.S. Government issued securities and high quality, short term commercial paper. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. The Company held no marketable securities as of March 31, 2017 and December 31, 2016. The Company’s investment policy, approved by the Board of Directors, limits the amount it may invest in any one type of investment, thereby reducing credit risk concentrations.   Cash and Cash Equivalents   All highly liquid financial instruments with maturities of three months or less when purchased are considered cash equivalents. As of March 31, 2017 and December 31, 2016, the Company held $126.6 million and $160.0 million, respectively, in cash and money market funds consisting principally of U.S. Government-issued securities and high quality, short-term commercial paper which were classified as cash and cash equivalents.   Non-cash Investing Activities   The Company had approximately $104,000 and $356,000 of accrued capital expenditures as of March 31, 2017 and December 31, 2016, respectively, which have been treated as a non-cash investing activity and, accordingly, are not reflected in the consolidated statement of cash flows.    Fair Value of Financial Instruments   Fair value is defined under ASC Topic 820, “Fair Value Measurements and Disclosures,” as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.  The standard describes a fair value hierarchy to measure fair value which is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 1 - Quoted prices in active markets for identical assets or liabilities.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr></table></div>   As of March 31, 2017, the Company held certain assets that are required to be measured at fair value on a recurring basis.  The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2017 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="12" valign="bottom" style="width:50.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements at March 31, 2017 Using </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;"> Unobservable </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.85pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="3" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td colspan="2" valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,296 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,296 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis. The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2016 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:51.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements at December 31, 2016 Using </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:46.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 144,176 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 144,176 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The fair value of the Company’s cash equivalents is based on quoted prices from active markets.   The carrying amounts reflected in the consolidated balance sheets for accounts receivable, unbilled revenue, prepaid and other current assets, accounts payable, accrued compensation, and other accrued liabilities approximate fair value due to their short‑term nature. The gross carrying amount and estimated fair value of the convertible 4.5% senior notes was $100.0 million and $111.0 million, respectively, as of March 31, 2017 compared to $100.0 million and $79.0 million, respectively, as of December 31, 2016. The increase in estimated fair value as of March 31, 2017 compared to December 31, 2016 is due primarily to an increase in the Company’s stock price. The fair value of the Convertible Notes is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in a market which is a Level 2 input for fair value purposes. Unbilled Revenue   The majority of the Company’s unbilled revenue at March 31, 2017 represents research funding earned prior to that date based on actual resources utilized under the Company’s agreements with various collaborators.  In addition to  that type of unbilled revenue, also included in unbilled revenue at December 31, 2016 was a $5 million partner milestone achieved in December 2016 which was subsequently invoiced in January 2017 and received in March 2017.   Inventory   Inventory costs relate to clinical trial materials being manufactured for sale to the Company’s collaborators. Inventory is stated at the lower of cost or net realizable value as determined on a first-in, first-out (FIFO) basis.   Inventory at March 31, 2017  and December 31, 2016 is summarized below (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 125 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 357 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,100 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,835 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,225 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,192 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div> Raw materials inventory consists entirely of proprietary cell‑killing agents the Company developed as part of its ADC technology. All raw materials inventory is currently procured from two suppliers. The Company considers more than a twelve month supply of raw materials that is not supported by firm, fixed orders and/or projections from its collaborators to be excess and establishes a reserve to reduce to zero the value of any such excess raw material inventory with a corresponding charge to research and development expense. In accordance with this policy, the Company recorded $403,000 of expense related to excess inventory in the three months ended March 31, 2017 as a result of inventory purchased in the current period in order to manufacture drug product to supply the Company’s mirvetuximab soravtansine studies. There were no expenses recorded for excess inventory during the three-month period ended March 31, 2016. Work in process inventory consists of conjugate manufactured for sale to the Company’s collaborators to be used in preclinical and clinical studies.  All conjugate is made to order at the request of the collaborators and subject to the terms and conditions of respective supply agreements.  Based on historical reprocessing or reimbursement required for conjugate that did not meet specification and status of current conjugate on hand or conjugate shipped to collaborators but not yet released per the terms of the respective supply agreements, no reserve for work in process inventory was determined to be required at March 31, 2017. As discussed above, the Company’s costs to manufacture conjugate on behalf of its partners are greater than the supply prices charged to partners, and therefore costs are capitalized into inventory at the supply prices which represents net realizable value.   Computation of Net Loss per Common Share   Basic and diluted net loss per share is calculated based upon the weighted average number of common shares outstanding during the period. During periods of income, participating securities are allocated a proportional share of income determined by dividing total weighted average participating securities by the sum of the total weighted average common shares and participating securities (the “two-class method”). Shares of the Company’s restricted stock participate in any dividends declared by the Company and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to participating securities since they have no contractual obligation to share in the losses of the Company. Diluted (loss) income per share is computed after giving consideration to the dilutive effect of stock options and restricted stock that are outstanding during the period, except where such non-participating securities would be anti-dilutive.  The Company’s common stock equivalents, as calculated in accordance with the treasury‑stock method for the options and the if-converted method for the convertible notes, are shown in the following table (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options outstanding to purchase common stock and unvested restricted stock </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,690 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,679 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock equivalents under treasury stock method for options </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 110 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 361 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Shares issuable upon conversion of convertible notes </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,878 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock equivalents under if-converted method for convertible notes </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,878 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> The Company’s common stock equivalents have not been included in the net loss per share calculation because their effect is anti‑dilutive due to the Company’s net loss position. Stock-Based Compensation   As of December 31, 2016, the Company is authorized to grant future awards under one employee share‑based compensation plan, which is the ImmunoGen, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan, or the 2016 Plan. At the annual meeting of shareholders on December 9, 2016, the 2016 Plan was approved and provides for the issuance of Stock Grants, the grant of Options and the grant of Stock‑Based Awards for up to 5,500,000 shares of the Company’s common stock, as well as up to 14,250,000 shares of common stock which represent awards granted under the previous stock option plan, the ImmunoGen, Inc. 2006 Employee, Director and Consultant Equity Incentive Plan, or the 2006 Plan, that forfeit, expire, or cancel without delivery of shares of common stock or which resulted in the forfeiture of shares of common stock back to the Company subsequent to December 9, 2016. Option awards are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Options vest at various periods of up to four years and may be exercised within ten years of the date of grant.   The stock-based awards are accounted for under ASC Topic 718, “Compensation—Stock Compensation.” Pursuant to Topic 718, the estimated grant date fair value of awards is charged to the statement of operations and comprehensive loss over the requisite service period, which is the vesting period. Such amounts have been reduced by an estimate of forfeitures of all unvested awards. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model with the assumptions noted in the following table. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. Expected volatility is based exclusively on historical volatility data of the Company’s stock. The expected term of stock options granted is based exclusively on historical data and represents the period of time that stock options granted are expected to be outstanding. The expected term is calculated for and applied to one group of stock options as the Company does not expect substantially different exercise or post-vesting termination behavior among its option recipients. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended March 31, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> None </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> None </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Volatility </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 66.89 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 63.90 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.03 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.61 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected life (years) </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.0 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.3 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Using the Black-Scholes option-pricing model, the weighted average grant date fair values of options granted during the three months ended March 31, 2017 and 2016 were $1.52 and $5.55 per share, respectively.   A summary of option activity under the 2006 and 2016 Plans as of March 31, 2017, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,679 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10.70 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,187 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.48 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited/Canceled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,176) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.27 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at March 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,690 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.94 </td> </tr> </table></div>   In August 2016 and February 2017, the Company granted 117,800 shares and 529,830 shares of restricted common stock with grant date fair values of $3.15 and $2.47, respectively, to certain officers of the Company. These restrictions will lapse in three equal installments upon the achievement of specified performance goals within the next five years. The Company determined it is not currently probable that these performance goals will be achieved, and therefore, no expense has been recorded to date.   A summary of restricted stock activity under the 2006 and 2016 Plans (inclusive of the performance awards noted above) as of March 31, 2017 and changes during the three month period ended March 31, 2017 is presented below (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Restricted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at December 31, 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>199 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.41 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Awarded </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.47 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (6) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.53 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.15 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at March 31, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,187 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.63 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Stock compensation expense related to stock options and restricted stock awards granted under the 2016 and 2006 Plans was $2.6 million and $7.2 million during the three months ended March 31, 2017 and 2016, respectively. During the three months ended March 31, 2016, the Company recorded $2.8 million of stock compensation cost related to the modification of certain outstanding common stock options with the former Chief Executive Officer’s succession plan. The decrease in expense is also attributable to lower fair values associated with awards vesting in the current period, level of forfeitures experienced since the prior year due to the restructuring disclosed in Note G and greater forfeitures recorded in the current period substantially resulting from the departure of certain senior-level employees. As of March 31, 2017, the estimated fair value of unvested employee awards was $20.2 million, net of estimated forfeitures. The weighted-average remaining vesting period for these awards is approximately two years. Also included in stock compensation expense for the three months ended March 31, 2017 and 2016 are $38,000 and $108,000, respectively, of expense recorded for directors’ deferred share units, the details of which are discussed in Note F.   Segment Information   During the three months ended March 31, 2017, the Company continued to operate in one operating segment which is the business of discovery of monoclonal antibody-based anticancer therapeutics.   The percentages of revenues recognized from significant customers of the Company in the three months ended March 31, 2017 and 2016 are included in the following table:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Collaborative Partner: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Bayer </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 51 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> CytomX </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 48 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Roche </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 37 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Sanofi </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   There were no other customers of the Company with significant revenues in the three months ended March 31, 2017 and 2016.   Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014‑9, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company anticipates using the modified retrospective approach to implement this standard.  The Company has begun to analyze its existing revenue agreements to evaluate the impact of adoption. The Company has less than ten contracts that have remaining performance obligations that will need to be evaluated under the provisions of the new standard as of January 1, 2018. In performing this assessment, the Company noted that we will be required to recognize royalty income in the same period as the related sales occur on Kadcyla rather than one quarter in arrears, which is the point in which the amount is fixed and determinable. This will require the Company to make an estimate of the royalties as the information is not provided to the Company until 90 days after the end of the quarter. Additionally, some partner milestones, depending on the probability of occurring, may be recognized sooner and at different values than they currently would be under the current accounting standards. The Company is in the process of estimating the impact of adopting the new standard on its consolidated financial statements, however, the Company expects to record a material adjustment upon adoption, which will be recorded as a cumulative effect of initially applying the standard to opening accumulated deficit as of January 1, 2018. The Company will continue to provide disclosures under the legacy accounting for the year ended December 31, 2018. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330). To simplify the principles for subsequent measurement of inventory, this new standard requires inventory measured using any method other than LIFO or the retail method shall be measured at the lower of cost and net realizable value, rather than lower of cost or market. This guidance is effective for annual reporting beginning after December 15, 2016, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.   In January 2016, the FASB issued ASU 2016-1, Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825). The amendments in this Update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. The amendments allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment. The amendments also require enhanced disclosures about those investments. The amendments improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. This guidance is effective for annual reporting beginning after December 15, 2017, including interim periods within the year of adoption, and calls for prospective application, with early application permitted. Accordingly, the standard is effective for the Company on January 1, 2018. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.   In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842) that primarily requires lessees to recognize most leases on their balance sheets but record expenses on their income statements in a manner similar to current accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and calls for retrospective application, with early adoption permitted. Accordingly, the standard is effective for the Company on January 1, 2019. The Company is currently evaluating the impact of this guidance on our financial statements and the timing of adoption.   In March 2016, the FASB issued ASU 2016-9, Improvements to Employee Share-Based Payment Accounting (Topic 718) that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. As a result of the adoption of this guidance, the net operating losses deferred tax assets for federal and state purposes increased by $9.2 million and $1.2 million, respectively, and will be offset by corresponding increases in the valuation allowance. The adoption of the guidance has no impact on the Company’s consolidated financial statements. The Company elected not to adopt the provision that would allow actual forfeitures to be recognized in lieu of maintaining a forfeitures reserve. As such, the Company will continue to estimate forfeitures.  <div /></div> </div>

11150000

12078000

3020000

3193000

8600000

6800000

1800000

4115000

4183000

551000

134000

1287000

3400000

3479000

437000

0.01

5000

5386000

6394000

2000000

13500000

20500000

26500000

4000000

13000000

10000000

13000000

26500000

96600000

200000000

188000

19498000

17997000

46200000

300000

1198000

678000

36094000

32888000

<div> <div> G.       Restructuring Charge On September 26, 2016, the Board of Directors approved a plan to reengineer the business, resulting in a reduction of the workforce by approximately 17%, or 65 positions, which included the separation of 60 current employees. Communication of the plan to the impacted employees was substantially completed on September 29, 2016. All of the workforce reduction was completed as of December 31, 2016. As a result of the workforce reduction, in the six months ended December 31, 2016, the Company recorded a restructuring charge totaling $4.4 million related to termination benefits and other related charges, of which $2.8 million was recorded as a one-time termination benefit, and $593,000 recorded as a benefit under an ongoing benefit plan. The related cash payments initiated in October 2016 and will be substantially paid out by June 30, 2017. Additionally, approximately 762,000 stock options forfeited in connection with the workforce reduction, and as a result, the Company recorded an approximate $837,000 credit to stock compensation expense in September 2016, which was included in research and development expense and general and administrative expense in that period. In addition to the termination benefits and other related charges, the Company is seeking to sub-lease 10,281 square feet of unoccupied office space in Waltham that was leased in February 2016. As of September 30, 2016, based on an estimate of the potential time it would take to find a tenant of approximately nine months, the anticipated sub-lease terms, and consideration of the tenant allowance that was given to the Company to build out the space, the Company determined it did not need to record a loss on the sub-lease. The Company also evaluated the balance of the leasehold improvements for potential impairment as of September 30, 2016. In performing the recoverability test, the Company concluded that a substantial portion of the leasehold improvements were not recoverable. The Company recorded an impairment charge of $970,000 related to these assets after comparing the fair value (using probability weighted scenarios with discounted cash flows) to the leasehold improvements’ carrying value, leaving a $193,000 remaining cost basis.  As of March 31, 2017, based on further evaluation of the prospects for sub-leasing the space, the Company determined that additional time would be required to find a tenant.  Accordingly, the calculation for the potential sub-lease loss was updated and it was determined that the remaining balance of the leasehold improvements were impaired.  Also, due to the additional time that is expected to secure a tenant, a lease loss was recorded based on the change in estimate of the sub-lease assumption.  The total of these charges was $386,000. A summary of activity against the restructuring charge related to the employee terminations during the three-month period ended March 31, 2017 is as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Period from </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2016 to </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  2017 </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance December 31, 2016 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,751 </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Payments for the period </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,287) </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance March 31, 2017 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 464 </td> </tr> </table></div>   In September 2016, the Compensation Committee of the Board of Directors approved cash and stock option retention incentive awards for certain remaining eligible employees who continue employment with the Company in order to execute the Company’s strategic priorities. The cash awards will be payable to these employees in either October 2017 or March 2018 based on continued employment and services performed during these periods. Stock option awards covering 847,000 shares were granted and will vest annually in equal installments over three years from the date of grant, and the related compensation expense for the three months ended March 31, 2017 is included in the amounts discussed in the “Stock-Based Compensation” section of footnote B above.   <div /></div> </div>

0.17

4400000

386000

1751000

464000

-932570000

-949915000

<div> <div> Revenue Recognition   The Company enters into licensing and development agreements with collaborative partners for the development of ADC therapeutics. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company’s antibody‑drug conjugate, or ADC, technology, (ii) rights to future technological improvements, (iii) research activities to be performed on behalf of the collaborative partner, (iv) delivery of cytotoxic agents and (v) the manufacture of preclinical or clinical materials for the collaborative partner. Payments to the Company under these agreements may include upfront fees, option fees, exercise fees, payments for research activities, payments for the manufacture of preclinical or clinical materials, payments based upon the achievement of certain milestones and royalties on product sales. The Company follows the provisions of the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605‑25, “Revenue Recognition—Multiple‑Element Arrangements,” and ASC Topic 605‑28, “Revenue Recognition—Milestone Method,” in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has stand‑alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. At March 31, 2017, the Company had the following two material types of agreements with the parties identified below: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Development and commercialization licenses, which provide the party with the right to use the Company’s ADC technology and/or certain other intellectual property to develop compounds to a specified antigen target:</td></tr></table></div> Amgen (two exclusive single-target licenses(1))   Bayer (one exclusive single-target license) Biotest (one exclusive single-target license) CytomX (one exclusive single-target license) Fusion Pharmaceuticals (one exclusive single-target license) Lilly (three exclusive single-target licenses) Novartis (five exclusive single-target licenses and one license to two related targets: one target on an exclusive basis and the second target on a non-exclusive basis) Roche, through its Genentech unit (five exclusive single-target licenses) Sanofi (one exclusive single-target license and one exclusive license to multiple individual targets) Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (one exclusive single-target license) <div><hr style="border-width:0;width:25%;height:.75pt;color:black;background-color:black;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Amgen has sublicensed one of its exclusive single-target licenses to Oxford BioTherapeutics Ltd.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Research license/option agreement for a defined period of time to secure development and commercialization licenses to use the Company’s ADC technology to develop anticancer compounds to specified targets on established terms (referred to herein as right-to-test agreements):</td></tr></table></div> CytomX Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.  There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company. Development and Commercialization Licenses The deliverables under a development and commercialization license agreement generally include the license to the Company’s ADC technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research activities to be performed on behalf of the collaborative partner and the manufacture of preclinical or clinical materials for the collaborative partner. Generally, development and commercialization licenses contain non‑refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator’s request, provide research services at negotiated prices which are generally consistent with what other third parties would charge, (ii) at the collaborator’s request, manufacture and provide to it preclinical and clinical materials or deliver cytotoxic agents at negotiated prices which are generally consistent with what other third parties would charge, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments, generally until the later of the last applicable patent expiration or 10 to 12 years after product launch. In the case of Kadcyla®, however, the minimum royalty term is 10 years and the maximum royalty term is 12 years on a country‑by‑country basis, regardless of patent protection. Royalty rates may vary over the royalty term depending on the Company’s intellectual property rights and/or the presence of comparable competing products. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. The Company does not directly control when or whether any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments. As a result, the Company cannot predict when or if it will recognize revenues in connection with any of the foregoing. In determining the units of accounting, management evaluates whether the license has stand‑alone value from the undelivered elements to the collaborative partner based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of ADC technology research expertise in the general marketplace. If the Company concludes that the license has stand‑alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity‑specific factors such as the terms of the Company’s previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s ADC technology, the Company’s pricing practices and pricing objectives, the likelihood that technological improvements will be made, and, if made, will be used by the Company’s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Upfront payments on development and commercialization licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand‑alone value from the undelivered elements, which generally include rights to future technological improvements, research services, delivery of cytotoxic agents and the manufacture of preclinical and clinical materials. The Company recognizes revenue related to research services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license. The Company may also provide cytotoxic agents to its collaborators or produce preclinical and clinical materials at negotiated prices which are generally consistent with what other third parties would charge. The Company recognizes revenue on cytotoxic agents and on preclinical and clinical materials when the materials have passed all quality testing required for collaborator acceptance and title and risk of loss have transferred to the collaborator. Arrangement consideration allocated to the manufacture of preclinical and clinical materials in a multiple‑deliverable arrangement is below the Company’s full cost, and the Company’s full cost is not expected to ever be below its contract selling prices for its existing collaborations. During the three months ended March 31, 2017 and 2016, the difference between the Company’s full cost to manufacture preclinical and clinical materials on behalf of its collaborators as compared to total amounts received from collaborators for the manufacture of preclinical and clinical materials was $727,000 and $3.0 million, respectively. The majority of the Company’s costs to produce these preclinical and clinical materials are fixed and then allocated to each batch based on the number of batches produced during the period. Therefore, the Company’s costs to produce these materials are significantly affected by the number of batches produced during the period. The volume of preclinical and clinical materials the Company produces is directly related to the scale and scope of preclinical activities and the number of clinical trials the Company and its collaborators are preparing for or currently have underway, the speed of enrollment in those trials, the dosage schedule of each clinical trial and the time period such trials last. Accordingly, the volume of preclinical and clinical materials produced, and therefore the Company’s per‑batch costs to manufacture these preclinical and clinical materials, may vary significantly from period to period. The Company may also produce research material for potential collaborators under material transfer agreements. Additionally, the Company performs research activities, including developing antibody specific conjugation processes, on behalf of its collaborators and potential collaborators during the early evaluation and preclinical testing stages of drug development. The Company records amounts received for research materials produced or services performed as a component of research and development support revenue. The Company also develops conjugation processes for materials for later stage testing and commercialization for certain collaborators. The Company is compensated at negotiated rates and may receive milestone payments for developing these processes which are recorded as a component of research and development support revenue. The Company’s development and commercialization license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration, or FDA, or other countries’ regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non‑refundable development and regulatory milestones that are expected to be achieved as a result of the Company’s efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we do not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. Under the Company’s development and commercialization license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. Generally, under these agreements the Company is to receive royalty reports and payments from its licensees approximately one quarter in arrears, that is, generally in the second or third month of the quarter after the licensee has sold the royalty bearing product or products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. As such, the Company generally recognizes royalty revenues in the quarter reported to the Company by its licensees, or one quarter following the quarter in which sales by the Company’s licensees occurred. Right‑to‑Test Agreements The Company’s right‑to‑test agreements provide collaborators the right to (a) test the Company’s ADC technology for a defined period of time through a research, or right‑to‑test, license, (b) take options, for a defined period of time, to specified targets and (c) upon exercise of those options, secure or “take” licenses to develop and commercialize products for the specified targets on established terms. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as “upfront” fees or payments), (ii) upon taking an option with respect to a specific target (referred to as option fees or payments earned, if any, when the option is “taken”), (iii) upon the exercise of a previously taken option to acquire a development and commercialization license(s) (referred to as exercise fees or payments earned, if any, when the development and commercialization license is “taken”), or (iv) some combination of all of these fees. The accounting for right to test agreements is dependent on the nature of the options granted to the collaborative partner. Options are considered substantive if, at the inception of a right to test agreement, the Company is at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments or economic penalties imposed on the collaborator as a result of exercising the options. None of the Company’s right to test agreements entered into subsequent to the adoption of Accounting Standards Update, or ASU, No. 2009 13, “Revenue Arrangements with Multiple Deliverables” on July 1, 2010 has been determined to contain substantive options. For right to test agreements where the options to secure development and commercialization licenses to the Company’s ADC technology are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple element revenue recognition criteria to determine the appropriate revenue recognition. Subsequent to the adoption of ASU No. 2009-13, the Company determined that its research licenses lack stand-alone value and are considered for aggregation with the other elements of the arrangement and accounted for as one unit of accounting. The Company does not control when or if any collaborator will exercise its options for development and commercialization licenses. As a result, the Company cannot predict when or if it will recognize revenues in connection with any of the foregoing. <div /></div> </div>

19714000

28499000

235000000

<div> <div>   The Company’s common stock equivalents, as calculated in accordance with the treasury‑stock method for the options and the if-converted method for the convertible notes, are shown in the following table (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options outstanding to purchase common stock and unvested restricted stock </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,690 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,679 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock equivalents under treasury stock method for options </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 110 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 361 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Shares issuable upon conversion of convertible notes </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,878 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock equivalents under if-converted method for convertible notes </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,878 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The minimum rental commitments for the Company’s facilities, including real estate taxes and other expenses, for the next five fiscal years and thereafter under the non-cancelable operating lease agreements discussed above are as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 (nine months remaining) </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,959 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,736 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,235 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,283 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,107 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 30,794 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 66,114 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Inventory at March 31, 2017  and December 31, 2016 is summarized below (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 125 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 357 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,100 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,835 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,225 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,192 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> A summary of activity against the restructuring charge related to the employee terminations during the three-month period ended March 31, 2017 is as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Period from </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2016 to </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:18.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  2017 </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance December 31, 2016 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,751 </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Payments for the period </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,287) </td> </tr> <tr> <td valign="bottom" style="width:79.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance March 31, 2017 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 464 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:23.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Collaborative Partner: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Bayer </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 51 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> CytomX </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 48 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Roche </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 37 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Sanofi </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21 </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> A summary of restricted stock activity under the 2006 and 2016 Plans (inclusive of the performance awards noted above) as of March 31, 2017 and changes during the three month period ended March 31, 2017 is presented below (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Restricted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at December 31, 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>199 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.41 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Awarded </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.47 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (6) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.53 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.15 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at March 31, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,187 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.63 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> A summary of option activity under the 2006 and 2016 Plans as of March 31, 2017, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,679 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10.70 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,187 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.48 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited/Canceled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,176) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.27 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at March 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,690 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.94 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended March 31, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> None </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> None </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Volatility </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 66.89 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 63.90 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.03 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.61 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected life (years) </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.0 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.3 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

2800000

7283000

2665000

P1Y

P3Y

P1Y

P4Y

20000

3.15

117800

2014000

529830

3.15

2.47

199000

2187000

4.41

2.63

6000

6.53

P5Y

P10Y

0.0000

P6Y3M18D

P6Y

0.6390

0.6689

0.0161

0.0203

5500000

762000

1176

11.27

80000

847000

40000

1187

5.55

1.52

13679

13690

10.70

9.94

53248

2.48

<div> <div> Stock-Based Compensation   As of December 31, 2016, the Company is authorized to grant future awards under one employee share‑based compensation plan, which is the ImmunoGen, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan, or the 2016 Plan. At the annual meeting of shareholders on December 9, 2016, the 2016 Plan was approved and provides for the issuance of Stock Grants, the grant of Options and the grant of Stock‑Based Awards for up to 5,500,000 shares of the Company’s common stock, as well as up to 14,250,000 shares of common stock which represent awards granted under the previous stock option plan, the ImmunoGen, Inc. 2006 Employee, Director and Consultant Equity Incentive Plan, or the 2006 Plan, that forfeit, expire, or cancel without delivery of shares of common stock or which resulted in the forfeiture of shares of common stock back to the Company subsequent to December 9, 2016. Option awards are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Options vest at various periods of up to four years and may be exercised within ten years of the date of grant.   The stock-based awards are accounted for under ASC Topic 718, “Compensation—Stock Compensation.” Pursuant to Topic 718, the estimated grant date fair value of awards is charged to the statement of operations and comprehensive loss over the requisite service period, which is the vesting period. Such amounts have been reduced by an estimate of forfeitures of all unvested awards. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model with the assumptions noted in the following table. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. Expected volatility is based exclusively on historical volatility data of the Company’s stock. The expected term of stock options granted is based exclusively on historical data and represents the period of time that stock options granted are expected to be outstanding. The expected term is calculated for and applied to one group of stock options as the Company does not expect substantially different exercise or post-vesting termination behavior among its option recipients. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended March 31, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> None </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> None </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Volatility </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 66.89 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 63.90 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.03 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.61 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:76.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected life (years) </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.0 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.3 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Using the Black-Scholes option-pricing model, the weighted average grant date fair values of options granted during the three months ended March 31, 2017 and 2016 were $1.52 and $5.55 per share, respectively.   A summary of option activity under the 2006 and 2016 Plans as of March 31, 2017, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,679 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10.70 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,187 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.48 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited/Canceled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,176) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.27 </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at March 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,690 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.94 </td> </tr> </table></div>   In August 2016 and February 2017, the Company granted 117,800 shares and 529,830 shares of restricted common stock with grant date fair values of $3.15 and $2.47, respectively, to certain officers of the Company. These restrictions will lapse in three equal installments upon the achievement of specified performance goals within the next five years. The Company determined it is not currently probable that these performance goals will be achieved, and therefore, no expense has been recorded to date.   A summary of restricted stock activity under the 2006 and 2016 Plans (inclusive of the performance awards noted above) as of March 31, 2017 and changes during the three month period ended March 31, 2017 is presented below (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Restricted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at December 31, 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>199 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.41 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Awarded </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.47 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (6) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.53 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.15 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at March 31, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,187 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.63 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Stock compensation expense related to stock options and restricted stock awards granted under the 2016 and 2006 Plans was $2.6 million and $7.2 million during the three months ended March 31, 2017 and 2016, respectively. During the three months ended March 31, 2016, the Company recorded $2.8 million of stock compensation cost related to the modification of certain outstanding common stock options with the former Chief Executive Officer’s succession plan. The decrease in expense is also attributable to lower fair values associated with awards vesting in the current period, level of forfeitures experienced since the prior year due to the restructuring disclosed in Note G and greater forfeitures recorded in the current period substantially resulting from the departure of certain senior-level employees. As of March 31, 2017, the estimated fair value of unvested employee awards was $20.2 million, net of estimated forfeitures. The weighted-average remaining vesting period for these awards is approximately two years. Also included in stock compensation expense for the three months ended March 31, 2017 and 2016 are $38,000 and $108,000, respectively, of expense recorded for directors’ deferred share units, the details of which are discussed in Note F. <div /></div> </div>

<div> <div> F.       Capital Stock   2001 Non-Employee Director Stock Plan   During the three months ended March 31, 2017, the Company recorded approximately $12,000 in expense related to stock units outstanding under the Company’s 2001 Non-Employee Director Stock Plan, or the 2001 Plan, compared to ($32,000) in expense reduction recorded during the three months ended March 31, 2016. The value of the stock units are classified as a liability and adjusted to market value at each reporting period as the redemption amount of stock units for this plan will be paid in cash.  No stock units have been issued under the 2001 Plan subsequent to June 30, 2004.   Compensation Policy for Non-Employee Directors   On December 9, 2016 the Board amended the Compensation Policy for Non-Employee Directors to create a transition period due to the change in the year-end.  Effectively, one-half of the annual compensation awards described below were awarded to the directors on December 9, 2016 and a full-year’s compensation will be awarded  at the date of the next annual meeting.   Pursuant to the Compensation Policy for Non-Employee Directors, the redemption amount of deferred share units issued will be paid in shares of common stock of the Company on the date a director ceases to be a member of the Board. Annual retainers vest quarterly over approximately one year from the date of grant, contingent upon the individual remaining a director of ImmunoGen as of each vesting date.  The number of deferred share units awarded is fixed per the plan on the date of the award. All unvested deferred stock awards will automatically vest immediately prior to the occurrence of a change of control.   During the three months ended March 31, 2017, the Company recorded approximately $38,000 in compensation expense, respectively, related to deferred share units issued and outstanding under the Company’s Compensation Policy for Non-Employee Directors, compared to $108,000 in compensation expense recorded during the three months ended March 31, 2016. Pursuant to the Compensation Policy for Non-Employee Directors, in January 2017, the Company issued a retiring director 53,248 shares of common stock of the Company to settle outstanding deferred share units.   In addition to the deferred share units, the Non-Employee Directors are also entitled to receive a fixed number of stock options determined using the Black-Scholes option pricing model measured on the date of grant, which would be the date of the annual meeting of shareholders.  These options vest quarterly over approximately one year from the date of grant.  Any new directors will receive a pro-rated award, depending on their date of election to the Board.  The directors received a total of 80,000 stock options in November of 2015 and a total of 40,000 options in December 2016, and the related compensation expense for the three months ended March 31, 2017 and 2016 is included in the amounts discussed in the “Stock-Based Compensation” section of footnote B above. <div /></div> </div>

-152850000

-167530000

<div> <div> Unbilled Revenue   The majority of the Company’s unbilled revenue at March 31, 2017 represents research funding earned prior to that date based on actual resources utilized under the Company’s agreements with various collaborators.  In addition to  that type of unbilled revenue, also included in unbilled revenue at December 31, 2016 was a $5 million partner milestone achieved in December 2016 which was subsequently invoiced in January 2017 and received in March 2017. <div /></div> </div>

6778000

2051000

87035000

87160000

EX-101.SCH 14 imgn-20170331.xsd EX-101.SCH 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Plan of Operations link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Agreements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Convertible 4.5% Senior Notes link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Liability Related to Sale of Future Royalties link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Restructuring Charge link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Liability Related to Sale of Future Royalties (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Restructuring Charge (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business and Plan of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - FinInst (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies - Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of Significant Accounting Policies - EPS and SBC (Details) link:presentationLink link:calculationLink link:definitionLink 40206 - Disclosure - Summary of Significant Accounting Policies - Segments (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Agreements - Roche (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Agreements - Sanofi (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Agreements - Bayer (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Agreements - CytomX (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Convertible 4.5% Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Liability Related to Sale of Future Royalties (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Capital Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Restructuring Charge (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 imgn-20170331_cal.xml EX-101.CAL EX-101.DEF 16 imgn-20170331_def.xml EX-101.DEF EX-101.LAB 17 imgn-20170331_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, ending balance Cash and cash equivalents, beginning balance Cash and cash equivalents Accounts Receivable, Gross, Current Accounts receivable Unbilled Receivables, Current Unbilled revenue Inventory, Net Inventory Total Prepaid Expense and Other Assets, Current Prepaid and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net of accumulated depreciation Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' DEFICIT Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Accrued compensation Other Accrued Liabilities, Current Other accrued liabilities Lease Incentive, Payable, Current Current portion of deferred lease incentive The carrying amount of consideration received or receivable from sale of future royalties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer Liability related to sale of future royalties, current Current portion of liability related to the sale of future royalties, net of deferred financing costs of $xxx and $850, respectively Deferred Revenue, Current Current portion of deferred revenue Liabilities, Current Total current liabilities Incentive from Lessor Construction allowance Deferred lease incentive, net of current portion Deferred Revenue, Noncurrent Deferred revenue, net of current portion Convertible Debt, Noncurrent Convertible 4.5% senior notes, net of deferred financing costs of $2,869 and $3,035, respectively The noncurrent portion of deferred revenue related to sale of future royalties as of balance sheet date Liability Related To Sale Of Future Royalties Noncurrent Liability related to the sale of future royalties, net of current portion and deferred financing costs of $2,943 and $3,144, respectively Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note H) Stockholders' Equity Attributable to Parent [Abstract] Shareholders' deficit: Preferred Stock, Value, Issued Preferred stock, $0.01 par value; authorized 5,000 shares; no shares issued and outstanding Common Stock, Value, Issued Common stock, $0.01 par value; authorized 150,000 shares; issued and outstanding 89,348 and 87,301 shares as of March 31, 2017 and December 31, 2016, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total shareholders’ deficit Liabilities and Equity Total liabilities and shareholders’ deficit Amount, after accumulated amortization, of debt issuance costs classified as current for the liability related to the sale of future royalties. Deferred Financing Costs, Liability Sale Of Future Royalties, Current Current portion of deferred financing costs for the liability related to the sale of future royalties Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Deferred Finance Costs, Noncurrent, Net Non-current deferred financing costs Amount, after accumulated amortization, of debt issuance costs classified as long-term for the liability related to the sale of future royalties. Deferred Financing Costs, Liability Sale Of Future Royalties, Noncurrent Noncurrent portion of deferred financing costs for the liability related to the sale of future royalties Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, authorized shares Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, authorized shares Common Stock, Shares, Issued Common stock, issued shares Common Stock, Shares, Outstanding Common stock, outstanding shares CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Revenues: Revenues: Revenue from multiple-deliverable arrangements that include milestone and licensing fees revenue. Milestone revenue is consideration received upon achieving contractual goals. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. License and Milestone Fees License and milestone fees Amount of arrangement consideration included in license and milestone fees Revenue earned from sale of future royalties during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property Non cash royalty revenue related to sale of future royalties Non-cash royalty revenue related to sale of future royalties Non-cash Kadcyla royalty revenue Non-cash royalty revenue related to the sale of future royalties Non-cash royalty revenue related to sale of future royalties This element represents the revenue pertaining to research and development support, which includes research funding earned based on actual resources utilized under agreements with collaborators, may also include development fees charged for reimbursement of direct and overhead costs. Research and Development Revenue Research and development support Reimbursement Revenue Clinical materials revenue Revenues Total revenues Operating Expenses: Operating Expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Restructuring Charges Restructuring charges Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Investment Income, Net Investment income, net Amount of the cost of borrowed funds accounted for as interest expense on liability related to the sale of future royalties and other debt. Non cash interest expense from sale of future royalties Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes Non-cash interest expense on liability related to sale of future royalties and convertible senior notes Interest Expense, Debt Interest expense on convertible senior notes Interest expense Other Nonoperating Income (Expense) Other income, net Net Income (Loss) Available to Common Stockholders, Basic Net loss Net loss Earnings Per Share, Basic and Diluted Basic and diluted net loss per common share (in dollar per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted weighted average common shares outstanding (in shares) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used for operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Gain (Loss) on Disposition of Property Plant Equipment Loss (gain) on sale/disposal of fixed assets and impairment charges Share-based Compensation Stock and deferred share unit compensation The net change during the reporting period in the amount paid that is the result of the cumulative difference between actual rent payment and rent expense recognized on a straight-line basis. Increase (Decrease) in Deferred Rent Deferred rent Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Unbilled Receivables Unbilled revenue Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Employee Related Liabilities Accrued compensation Increase (Decrease) in Other Accrued Liabilities Other accrued liabilities Increase (Decrease) in Deferred Revenue Deferred revenue, net of non-cash upfront license payment Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used for operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used for investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Stock Options Exercised Proceeds from stock options exercised Cash received for exercise of stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Continuing Operations Net change in cash and cash equivalents Nature of Business and Plan of Operations Nature of Operations [Text Block] Nature of Business and Plan of Operations Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies No definition available. Agreements Collaborative Arrangement Disclosure [Text Block] Agreements Convertible 4.5% Senior Notes Debt Disclosure [Text Block] Convertible 4.5% Senior Notes Liability Related to Sale of Future Royalties Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement [Line Items] Liability Related to Sale of Future Royalties The entire disclosure of liabilities related to the sale of future royalties. Liability Related To Sale of Future Royalties [ Text Block ] Liability Related to Sale of Future Royalties Capital Stock Shareholders' Equity and Share-based Payments [Text Block] Capital Stock Restructuring Charge Restructuring and Related Activities Disclosure [Text Block] Restructuring Charge Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Subsequent Events, Policy [Policy Text Block] Subsequent Events Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Inventory, Policy [Policy Text Block] Inventory Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block] Unbilled Revenue Disclosure of accounting policy for financial instruments and concentration of credit risk. Financial Instruments and Concentration of Credit Risk [Policy Text Block] Financial Instruments and Concentration of Credit Risk Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Disclosure information about significant noncash (or part noncash) investing activities required to be supplementally disclosed. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period. Non-cash Investing Activities Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Earnings Per Share, Policy [Policy Text Block] Computation of Net Loss per Common Share Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Segment Reporting, Policy [Policy Text Block] Segment Information New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of assets that are required to be measured at fair value on a recurring basis Schedule of Inventory, Current [Table Text Block] Schedule of inventory Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of common stock equivalents, as calculated in accordance with the treasury-stock method Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Summary of restricted stock activity Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Schedule of percentage of total revenues recognized from each significant customer Tabular disclosure of the royalty transaction that were outstanding at the beginning and end of the year, and the amount of proceeds, revenue and expense from future royalty income. Schedule of royalty transaction, activity [Table Text Block] Schedule of Liability account during the period from the inception of the royalty transaction Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule activity against the restructuring charge Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of minimum rental commitments Sales Revenue, Goods, Net Product revenue Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Represents Amgen, a collaborative partner of the entity. Amgen [Member] Amgen Represents Bayer HealthCare, a collaborative partner of the entity. Bayer Health Care [Member] Bayer Represents Biotest AG, a collaborative partner of the entity. Biotest A G [Member] Biotest Represents Eli Lilly & Co., a collaborative partner of the entity. Eli Lilly And Company [Member] Lilly Represents Novartis Institutes for Bio Medical Research, Inc., a collaborative partner of the entity. Novartis Institutes For Bio Medical Research Inc [Member] Novartis Represents Roche, a collaborative partner of the entity, through its Genentech unit. Roche [Member] Roche Represents Sanofi, a collaborative partner of the entity. Sanofi [Member] Sanofi Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] Represents the Kadcyla product which is an advanced compound with ADC technology. Kadcyla [Member] Kadcyla Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Agreements disclosures Summary of Significant Accounting Policies Represents the number of types of licensing and development agreements with collaborative partners. Number of Types of Licensing and Development Agreements with Collaborative Partners Number of types of licensing and development agreements with collaborative partners Represents the number of single-target licenses the company has right to use. Number of Single Target Licenses Number of single-target licenses Represents the number of licenses to two related targets. Number of Licenses to Two Related Targets Number of licenses to two related targets Represents the number of related targets. Number of Related Targets Number of undisclosed targets with exclusive licenses Number of related targets Represents the number of licenses to multiple individual targets. Number of Licenses to Multiple Individual Targets Number of licenses to multiple individual targets Represents the period after product launch in which the company will earn royalty payments under the collaborative agreement. Collaborative Arrangements, Period after Product Launch to Earn Royalty Payments Period to earn royalty payments Represents the difference between the entity's full cost to manufacture preclinical and clinical materials on behalf of its collaborators as compared to total amounts received from collaborators. Collaborative Arrangements, Difference Between Cost of Manufacture and Amount Received from Collaborators Difference between the full cost to manufacture and amounts received from collaborators for preclinical and clinical materials Represents the types of milestone payments under collaborative arrangements. Number of Types of Milestone Payments under Collaborative Arrangements Number of types of milestone payments under collaborative arrangements Represents the number of quarters in arrear for revenue recognition. Revenue Recognition Number of Quarters Arrears Number of quarters in arrear for revenue recognition Financial Instruments, Owned, at Fair Value [Abstract] Financial Instruments and Concentration of Credit Risk Represents the number of financial institutions in which cash and cash equivalents are primarily maintained. Cash and Cash Equivalents, Number of Financial Institutions Number of financial institutions in the U.S. in which cash and cash equivalents are primarily maintained Marketable Securities. Marketable securities held by entity Cash and Cash Equivalents, at Carrying Value [Abstract] Cash and Cash Equivalents Noncash Investing and Financing Items [Abstract] Noncash Investing Activities Capital Expenditures Incurred but Not yet Paid Accrued capital expenditures Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring basis Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value hierarchy for the Company's financial assets measured at fair value Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Convertible Debt, Fair Value Disclosures Convertible debt fair value Represents the amount of partner milestone achieved which forms the part of unbilled revenue. Unbilled Revenue, Partner Milestone Achieved Unbilled partner milestone Inventory, Net [Abstract] Inventory Inventory, Raw Materials, Net of Reserves Raw materials EX-101.PRE 18 imgn-20170331_pre.xml EX-101.PRE XML 19 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 01, 2017
Document and Entity Information
Entity Registrant Name	IMMUNOGEN INC
Entity Central Index Key	0000855654
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		89,348,389
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

XML 20 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 126,568	$ 159,964
Accounts receivable	3,893	2,026
Unbilled revenue	2,051	6,778
Inventory	3,225	2,192
Prepaid and other current assets	6,394	5,386
Total current assets	142,131	176,346
Property and equipment, net of accumulated depreciation	17,997	19,498
Other assets	3,193	3,020
Total assets	163,321	198,864
LIABILITIES AND SHAREHOLDERS' DEFICIT
Accounts payable	5,100	7,895
Accrued compensation	4,927	6,946
Other accrued liabilities	12,078	11,150
Current portion of deferred lease incentive	784	784
Current portion of liability related to the sale of future royalties, net of deferred financing costs of $xxx and $850, respectively	15,664	14,470
Current portion of deferred revenue	1,814	14,531
Total current liabilities	40,367	55,776
Deferred lease incentive, net of current portion	5,718	5,914
Deferred revenue, net of current portion	18,992	19,086
Convertible 4.5% senior notes, net of deferred financing costs of $2,869 and $3,035, respectively	97,131	96,965
Liability related to the sale of future royalties, net of current portion and deferred financing costs of $2,943 and $3,144, respectively	164,460	169,858
Other long-term liabilities	4,183	4,115
Total liabilities	330,851	351,714
Commitments and contingencies (Note H)
Shareholders' deficit:
Preferred stock, $0.01 par value; authorized 5,000 shares; no shares issued and outstanding
Common stock, $0.01 par value; authorized 150,000 shares; issued and outstanding 89,348 and 87,301 shares as of March 31, 2017 and December 31, 2016, respectively	893	873
Additional paid-in capital	781,492	778,847
Accumulated deficit	(949,915)	(932,570)
Total shareholders’ deficit	(167,530)	(152,850)
Total liabilities and shareholders’ deficit	$ 163,321	$ 198,864

XML 21 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CONSOLIDATED BALANCE SHEETS
Current portion of deferred financing costs for the liability related to the sale of future royalties	$ 832	$ 850
Interest rate (as a percent)	4.50%
Non-current deferred financing costs	$ 2,869	3,035
Noncurrent portion of deferred financing costs for the liability related to the sale of future royalties	$ 2,943	$ 3,144
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares	150,000,000	150,000,000
Common stock, issued shares	89,348,000	87,301,000
Common stock, outstanding shares	89,348,000	87,301,000

XML 22 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
License and milestone fees	$ 18,730	$ 10,077
Non-cash royalty revenue related to the sale of future royalties	7,613	7,380
Research and development support	1,478	1,059
Clinical materials revenue	678	1,198
Total revenues	28,499	19,714
Operating Expenses:
Research and development	32,888	36,094
General and administrative	8,119	11,235
Restructuring charges	386
Total operating expenses	41,393	47,329
Loss from operations	(12,894)	(27,615)
Investment income, net	115	108
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(3,575)	(4,972)
Interest expense on convertible senior notes	(1,125)
Other income, net	134	551
Net loss	$ (17,345)	$ (31,928)
Basic and diluted net loss per common share (in dollar per share)	$ (0.20)	$ (0.37)
Basic and diluted weighted average common shares outstanding (in shares)	87,160	87,035
Total comprehensive loss	$ (17,345)	$ (31,928)

XML 23 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (17,345)	$ (31,928)
Adjustments to reconcile net loss to net cash used for operating activities:
Non-cash royalty revenue related to sale of future royalties	(7,613)	(7,380)
Non-cash interest expense on liability related to sale of future royalties and convertible senior notes	3,575	4,972
Depreciation and amortization	1,506	1,435
Loss (gain) on sale/disposal of fixed assets and impairment charges	180	(3)
Stock and deferred share unit compensation	2,665	7,283
Deferred rent	25	42
Change in operating assets and liabilities:
Accounts receivable	(1,867)	699
Unbilled revenue	4,727	(142)
Inventory	(1,033)	629
Prepaid and other current assets	(1,008)	(717)
Other assets	(173)	17
Accounts payable	(2,543)	(2,378)
Accrued compensation	(2,019)	1,134
Other accrued liabilities	775	1,490
Deferred revenue, net of non-cash upfront license payment	(12,811)	(1,232)
Net cash used for operating activities	(32,959)	(26,079)
Cash flows from investing activities:
Purchases of property and equipment	(437)	(3,479)
Net cash used for investing activities	(437)	(3,479)
Cash flows from financing activities:
Proceeds from stock options exercised		188
Net cash provided by financing activities		188
Net change in cash and cash equivalents	(33,396)	(29,370)
Cash and cash equivalents, beginning balance	159,964	212,283
Cash and cash equivalents, ending balance	$ 126,568	$ 182,913

XML 24 R6.htm IDEA: XBRL DOCUMENT

Nature of Business and Plan of Operations	3 Months Ended
Nature of Business and Plan of Operations	Mar. 31, 2017
Nature of Business and Plan of Operations
Nature of Business and Plan of Operations	IMMUNOGEN, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS March 31, 2017 A.Nature of Business and Plan of Operations ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development of antibody-drug conjugates, or ADCs, for the treatment of cancer. In August 2014, the FASB issued ASU 2014‑15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. (ASU 2015-14). Under the new standard, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved before the date that the financial statements are issued. This standard was adopted by the Company at December 31, 2016. The Company has incurred operating losses and negative cash flows from operations since inception, incurred a net loss of approximately $17.3 million during the three months ended March 31, 2017, and has an accumulated deficit of approximately $949.9 million as of March 31, 2017. The Company has primarily funded these losses through payments received from its collaborations and equity and convertible debt financings. To date, the Company has no product revenue and management expects operating losses to continue for the foreseeable future. At March 31, 2017, the Company had $126.6 million of cash and cash equivalents on hand. The Company anticipates that its current capital resources and expected future collaborator payments will enable it to meet its operational expenses and capital expenditures (operating plan) into the second quarter of calendar year 2018. Without such collaborator payments, the Company’s existing capital resources at March 31, 2017 would not be sufficient to support the current operating plan through May 5, 2018, which is twelve months after the date that the March 2017 financial statements were issued. Management expects to seek additional funds from collaboration partners through a combination of upfront license payments, milestone payments, royalty payments, research funding, and clinical material reimbursement or from equity or debt financings. Because those plans have not been finalized, receipt of additional funding is not considered probable under the new standard. If the Company does not obtain sufficient funds when needed, the Company expects it would scale back its operating plan by deferring or limiting some or all of its research, development or clinical projects, or initiate further reductions to its workforce. Because such contingency plans have not been finalized (because the specifics would depend on the situation at the time), such actions also are not considered probable for purposes of the new standard. Because, under the new standard, neither receipt of future collaboration payments, nor management’s contingency plans to mitigate the risk and extend cash resources through May 5, 2018, are considered probable, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, collaboration arrangements, third‑party reimbursements and compliance with governmental regulations.

XML 25 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

B.Summary of Significant Accounting Policies

Basis of Presentation

Subsequent Events

Revenue Recognition

At March 31, 2017, the Company had the following two material types of agreements with the parties identified below:

Amgen (two exclusive single-target licenses(1))

Bayer (one exclusive single-target license)

Biotest (one exclusive single-target license)

CytomX (one exclusive single-target license)

Fusion Pharmaceuticals (one exclusive single-target license)

Lilly (three exclusive single-target licenses)

Novartis (five exclusive single-target licenses and one license to two related targets: one target on an exclusive basis and the second target on a non-exclusive basis)

Roche, through its Genentech unit (five exclusive single-target licenses)

Sanofi (one exclusive single-target license and one exclusive license to multiple individual targets)

Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (one exclusive single-target license)

⁽¹⁾

Amgen has sublicensed one of its exclusive single-target licenses to Oxford BioTherapeutics Ltd.

CytomX

Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.

There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.

Development and Commercialization Licenses

In determining the units of accounting, management evaluates whether the license has stand‑alone value from the undelivered elements to the collaborative partner based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the partner and the availability of ADC technology research expertise in the general marketplace. If the Company concludes that the license has stand‑alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity‑specific factors such as the terms of the Company’s previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s ADC technology, the Company’s pricing practices and pricing objectives, the likelihood that technological improvements will be made, and, if made, will be used by the Company’s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services.

Right‑to‑Test Agreements

Financial Instruments and Concentration of Credit Risk

Cash and Cash Equivalents

Non-cash Investing Activities

Fair Value of Financial Instruments

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value Measurements at March 31, 2017 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

108,296

—

Fair Value Measurements at December 31, 2016 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

144,176

—

The fair value of the Company’s cash equivalents is based on quoted prices from active markets.

Unbilled Revenue

Inventory

Inventory at March 31, 2017 and December 31, 2016 is summarized below (in thousands):


	March 31,		December 31,
	2017		2016
Raw materials	$	125	$	357
Work in process		3,100		1,835
Total	$	3,225	$	2,192

Raw materials inventory consists entirely of proprietary cell‑killing agents the Company developed as part of its ADC technology. All raw materials inventory is currently procured from two suppliers. The Company considers more than a twelve month supply of raw materials that is not supported by firm, fixed orders and/or projections from its collaborators to be excess and establishes a reserve to reduce to zero the value of any such excess raw material inventory with a corresponding charge to research and development expense. In accordance with this policy, the Company recorded $403,000 of expense related to excess inventory in the three months ended March 31, 2017 as a result of inventory purchased in the current period in order to manufacture drug product to supply the Company’s mirvetuximab soravtansine studies. There were no expenses recorded for excess inventory during the three-month period ended March 31, 2016.

Computation of Net Loss per Common Share


	Three Months Ended
	March 31,
	2017	2016
Options outstanding to purchase common stock and unvested restricted stock	13,690	11,679
Common stock equivalents under treasury stock method for options	110	361
Shares issuable upon conversion of convertible notes	23,878	—
Common stock equivalents under if-converted method for convertible notes	23,878	—

The Company’s common stock equivalents have not been included in the net loss per share calculation because their effect is anti‑dilutive due to the Company’s net loss position.

Stock-Based Compensation



	Three Months Ended March 31,
	2017		2016
Dividend	None		None
Volatility	66.89	%	63.90	%
Risk-free interest rate	2.03	%	1.61	%
Expected life (years)	6.0		6.3

A summary of option activity under the 2006 and 2016 Plans as of March 31, 2017, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):


		Weighted-
	Number	Average
	of Stock	Exercise
	Options	Price
Outstanding at December 31, 2016	13,679	$	10.70
Granted	1,187	$	2.48
Exercised	—
Forfeited/Canceled	(1,176)	$	11.27
Outstanding at March 31, 2017	13,690	$	9.94


		Weighted-
	Number of	Average
	Restricted	Exercise
	Stock Shares	Price
Unvested at December 31, 2016	199	$	4.41
Awarded	2,014	$	2.47
Vested	(6)	$	6.53
Forfeited	(20)	$	3.15
Unvested at March 31, 2017	2,187	$	2.63

Segment Information

During the three months ended March 31, 2017, the Company continued to operate in one operating segment which is the business of discovery of monoclonal antibody-based anticancer therapeutics.

The percentages of revenues recognized from significant customers of the Company in the three months ended March 31, 2017 and 2016 are included in the following table:


	Three Months Ended
	March 31,
Collaborative Partner:	2017		2016
Bayer	—	%	51	%
CytomX	48	%	3	%
Roche	27	%	37	%
Sanofi	21	%	—	%

There were no other customers of the Company with significant revenues in the three months ended March 31, 2017 and 2016.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014‑9, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company anticipates using the modified retrospective approach to implement this standard. The Company has begun to analyze its existing revenue agreements to evaluate the impact of adoption. The Company has less than ten contracts that have remaining performance obligations that will need to be evaluated under the provisions of the new standard as of January 1, 2018. In performing this assessment, the Company noted that we will be required to recognize royalty income in the same period as the related sales occur on Kadcyla rather than one quarter in arrears, which is the point in which the amount is fixed and determinable. This will require the Company to make an estimate of the royalties as the information is not provided to the Company until 90 days after the end of the quarter. Additionally, some partner milestones, depending on the probability of occurring, may be recognized sooner and at different values than they currently would be under the current accounting standards. The Company is in the process of estimating the impact of adopting the new standard on its consolidated financial statements, however, the Company expects to record a material adjustment upon adoption, which will be recorded as a cumulative effect of initially applying the standard to opening accumulated deficit as of January 1, 2018. The Company will continue to provide disclosures under the legacy accounting for the year ended December 31, 2018.

In March 2016, the FASB issued ASU 2016-9, Improvements to Employee Share-Based Payment Accounting (Topic 718) that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. As a result of the adoption of this guidance, the net operating losses deferred tax assets for federal and state purposes increased by $9.2 million and $1.2 million, respectively, and will be offset by corresponding increases in the valuation allowance. The adoption of the guidance has no impact on the Company’s consolidated financial statements. The Company elected not to adopt the provision that would allow actual forfeitures to be recognized in lieu of maintaining a forfeitures reserve. As such, the Company will continue to estimate forfeitures.

XML 26 R8.htm IDEA: XBRL DOCUMENT

Agreements	3 Months Ended
Agreements	Mar. 31, 2017
Agreements
Agreements	C. Agreements Significant Collaborative Agreements Roche In 2000, the Company granted Genentech, now a unit of Roche, an exclusive license to use the Company’s maytansinoid ADC technology with antibodies, such as trastuzumab, or other proteins that target HER2. Under the terms of this agreement, Roche has exclusive worldwide rights to develop and commercialize maytansinoid ADC compounds targeting HER2. In 2013, the HER2‑targeting ADC compound, Kadcyla, was approved for marketing in the U.S., Japan and the European Union, or EU. Roche has also received marketing approval in various other countries around the world. Roche is responsible for the manufacturing, product development and marketing of any products resulting from the agreement. The Company received a $2 million non‑refundable upfront payment from Roche upon execution of the agreement. The Company is also entitled to receive up to a total of $44 million in milestone payments, plus royalties on the commercial sales of Kadcyla or any other resulting products. Total milestones are categorized as follows: development milestones—$13.5 million; and regulatory milestones—$30.5 million. Through March 31, 2017, the Company has received and recognized $13.5 million and $20.5 million in development and regulatory milestone payments, respectively, related to Kadcyla. The next potential milestone the Company will be entitled to receive will be a $5 million regulatory milestone for marketing approval of Kadcyla for a first extended indication as defined in the agreement. Based on an evaluation of the effort contributed towards the achievement of this future milestone, the Company determined this milestone is not substantive. The Company receives royalty reports and payments related to sales of Kadcyla from Roche one quarter in arrears. In accordance with the Company’s revenue recognition policy, $7.6 million of non-cash royalties on net sales of Kadcyla for the three‑month period ended December 31, 2016 were recorded and included in non-cash royalty revenue for the three-month period ended March 31, 2017 and $7.4 million of non-cash royalties on net sales of Kadcyla for the three‑month period ended December 31, 2015 is included in non-cash royalty revenue for the three-month period ended March 31, 2016. Kadcyla sales occurring after January 1, 2015 are covered by a royalty purchase agreement whereby the associated cash is remitted to Immunity Royalty Holdings, L.P, or IRH, as discussed further in Note E. Sanofi In 2003, the Company entered into a broad collaboration agreement with Sanofi (formerly Aventis) to discover, develop and commercialize antibody‑based products. The collaboration agreement provides Sanofi with worldwide development and commercialization rights to new antibody‑based products directed to targets that are included in the collaboration, including the exclusive right to use the Company’s maytansinoid ADC technology in the creation of products developed to these targets. The product candidates (targets) as of March 31, 2017 in the collaboration include isatuximab (CD38), SAR566658 (CA6), SAR408701 (CEACAM5) and one earlier‑stage program that has yet to be disclosed. The Company is entitled to receive milestone payments potentially totaling $21.5 million, per target, plus royalties on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$7.5 million; and regulatory milestones—$14 million. Through March 31, 2017, the Company has recognized an aggregate of $26.5 million in milestone payments for compounds covered under this agreement now or in the past. In January 2017, Sanofi enrolled its first patient in a Phase III clinical trial for isatuximab, and in March 2017, enrolled its first patient in a Phase IIb clinical trial (as defined in the agreement) for SAR566658, each of which triggered a $3 million milestone payment to the Company, which are included in license and milestone fee revenue for the three months ended March 31, 2017. The next potential milestone the Company will be entitled to receive for SAR566658 will be a development milestone for initiation of a Phase III clinical trial, which will result in a $3 million payment being due. The next potential milestone the Company will be entitled to receive with respect to isatuximab will be a regulatory milestone for submission of a new drug application to the U.S. Food and Drug Administration, which will result in a $3 million payment being due. The next potential milestone the Company will be entitled to receive for SAR408701 will be a development milestone for initiation of a Phase IIb clinical trial (as defined in the agreement), which will result in each case in a $3 million payment being due. The next potential milestone the Company will be entitled to receive for the unidentified target will be a development milestone for commencement of a Phase I clinical trial, which will result in a $1 million payment being due. At the time of execution of this agreement, there was significant uncertainty as to whether these milestones would be achieved. In consideration of this, as well as the Company’s past involvement in the research and manufacturing of these product candidates, these milestones were deemed substantive. Bayer In 2008, the Company granted Bayer an exclusive development and commercialization license to the Company’s maytansinoid ADC technology for use with antibodies or other proteins that target mesothelin. Bayer HealthCare is responsible for the research, development, manufacturing, and marketing of any products resulting from the license. The Company received a $4 million upfront payment upon execution of the agreement which was recognized as revenue ratably over the Company’s estimated period of substantial involvement which concluded in September 2012. For each compound developed and marketed by Bayer under this collaboration the Company is entitled to receive a total of $170.5 million in milestone payments, plus tiered royalties between 4 - 7% on the commercial sales of any resulting products. The total milestones are categorized as follows: development milestones—$16 million; regulatory milestones—$44.5 million; and sales milestones—$110 million. Through March 31, 2017, the Company has received and recognized an aggregate of $13 million in milestone payments under this agreement. In January 2016, Bayer initiated a Phase II clinical study designed to support registration of its ADC product candidate, anetumab ravtansine, triggering a $10 million development milestone payment to the Company which is included in license and milestone fee revenue for the three months ended March 31, 2016. The next potential milestone the Company will be entitled to receive will be either a development milestone for commencement of a pivotal clinical trial for a second indication for anetumab ravtansine which will result in a $2 million payment being due or a regulatory milestone for filing of regulatory approval for its first indication for anetumab ravtansine which will result in a $6 million payment being due. At the time of execution of this agreement, there was significant uncertainty as to whether these milestones would be achieved. In consideration of this, as well as the Company’s past involvement in the research and supply of cytotoxic agent for this product candidate, these milestones was deemed substantive. CytomX In January 2014, we entered into a reciprocal right‑to‑test agreement with CytomX. The agreement provides CytomX with the right to test our payload agents and linkers with CytomX antibodies that utilize their proprietary antibody-masking technology, termed ProbodiesTM for a specified number of targets and to subsequently take an exclusive, worldwide license to use our technology to develop and commercialize Probody-drug conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. We received no upfront cash payment in connection with the execution of the right‑to‑test agreement. Instead, we received reciprocal rights to test our payload agents and linkers with ImmunoGen antibodies masked using CytomX technology to create Probody-drug conjugates directed to a specified number of targets and to subsequently take exclusive, worldwide licenses to develop and commercialize such conjugates directed to the specified targets on terms agreed upon at the inception of the right‑to‑test agreement. The terms of the right‑to‑test agreement require us and CytomX to each take its respective development and commercialization licenses by the end of the term of the research license. In addition, both we and CytomX are required to perform specific research activities under the right‑to‑test agreement on behalf of the other party for no monetary consideration. In February 2016, CytomX took its development and commercialization license for a specified target. An amendment of the agreement executed simultaneously with that license granted CytomX the right, for a specified period of time, to substitute the specified target with another as yet unspecified target. Accordingly, the revenue associated with this license was deferred until the expiration of that substitution right in January 2017, whereupon we recognized $12.7 million of the $13 million of arrangement consideration allocated to the development and commercialization license, which is included in license and milestone fee revenue for the three months ended March 31, 2017. With respect to the development and commercialization license taken by CytomX, the Company is entitled to receive up to a total of $160 million in milestone payments plus royalties on the commercial sales of any resulting product. The total milestones are categorized as follows: development milestones—$10 million; regulatory milestones—$50 million; and sales milestones—$100 million. In addition, CytomX may be liable to pay annual maintenance fees if the licensed product candidate covered under the development and commercialization license has not progressed to a specified stage of development within a specified time frame. Assuming no annual maintenance fee is payable, the next payment the Company could receive would be a $1 million development milestone payment with commencement of a Phase I clinical trial. At the time of execution of the right-to-test agreement, there was significant uncertainty as to whether the milestone related to the Phase I clinical trial would be achieved. In consideration of this, as well as the Company's expected involvement in the research and manufacturing of any product candidate, this milestone was deemed substantive. CytomX is responsible for the manufacturing, product development and marketing of any product resulting from the development and commercialization license taken by CytomX under this collaboration. For additional information related to these agreements, as well as the Company’s other significant collaborative agreements, please read Note C, Agreements, to the consolidated financial statements included within the Company’s 2016 Transition Report on Form 10-K

XML 27 R9.htm IDEA: XBRL DOCUMENT

Convertible 4.5% Senior Notes	3 Months Ended
Convertible 4.5% Senior Notes	Mar. 31, 2017
Convertible 4.5% Senior Notes
Convertible 4.5% Senior Notes	D. Convertible 4.5% Senior Notes In June 2016, the Company issued Convertible 4.5% Senior Notes with an aggregate principal amount of $100 million. The Company received net proceeds of approximately $96.6 million from the sale of the Convertible Notes, after deducting fees and expenses of approximately $3.4 million. The Convertible Notes are governed by the terms of an indenture between the Company, as issuer, and Wilmington Trust, National Association, as the trustee. The Convertible Notes are senior unsecured obligations and bear interest at a rate of 4.5% per year, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2017. The Company recorded approximately $1.1 million of interest expense in the three months ended March 31, 2017. The Convertible Notes will mature on July 1, 2021, unless earlier repurchased or converted. Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the stated maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted notes a number of shares equally to the conversion rate, which will initially be 238.7775 shares of common stock, equivalent to an initial conversion price of approximately $4.19. The conversion rate will be subject to adjustment in some circumstances, but will not be adjusted for any accrued and unpaid interest. In addition, if a “make-whole fundamental change” (as defined in the offering memorandum) occurs prior to the stated maturity date, the Company will increase the conversion rate for a holder who elects to convert its notes in connection with such make-whole fundamental change in certain circumstances. If the Company undergoes a fundamental change, subject to certain conditions, holders may require the Company to repurchase for cash all or part of their notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date. In addition, upon an event of default, the holders may require the Company to repurchase for cash all of their notes at a purchase price equal to 100% of the principal amount, plus accrued and unpaid interest. Upon bankruptcy, this becomes an automatic repurchase obligation. Also, if the Company fails to comply with certain reporting requirements as described in the indenture it will constitute an event of default, however the Company may elect to pay additional interest at an annual rate equal to 0.5% of the principal amount for the 90 days following such event as a remedy for the default. Subsequent to the 90 days, if still in default, the principal amount of the notes and accrued interest may become immediately due and payable. If a “restricted event” occurs as described in the indenture that causes the notes not to become freely tradable by holders other than our affiliates after the first anniversary of the original issuance date of the notes, the Company would also become obligated to pay additional interest at an annual rate equal to 0.5% of the principal amount. The combined additional interest rate under these two circumstances, however, cannot exceed 0.5%. The Company analyzed the terms of the Convertible Notes and determined that under current accounting guidance the notes would be entirely accounted for as debt and none of the terms of the notes require separate accounting. As part of the issuance of the Convertible Notes, the Company incurred $3.4 million of transaction costs, which are netted against the Convertible Notes in the accompanying consolidated balance sheet as and are being amortized to interest expense ratably over the term of the Convertible Notes.

XML 28 R10.htm IDEA: XBRL DOCUMENT

Liability Related to Sale of Future Royalties

3 Months Ended

Mar. 31, 2017

E. Liability Related to Sale of Future Royalties

The following table shows the activity within the liability account during the three-month period ended March 31, 2017 (in thousands):


	Period from
	December 31, 2016 to
	March 31, 2017
Liability related to sale of future royalties, net — beginning balance	$	184,328
Non-cash Kadcyla royalty revenue		(7,613)
Non-cash interest expense recognized		3,409
Liability related to sale of future royalties, net — ending balance	$	180,124

XML 29 R11.htm IDEA: XBRL DOCUMENT

Capital Stock	3 Months Ended
Capital Stock	Mar. 31, 2017
Capital Stock
Capital Stock	F. Capital Stock 2001 Non-Employee Director Stock Plan During the three months ended March 31, 2017, the Company recorded approximately $12,000 in expense related to stock units outstanding under the Company’s 2001 Non-Employee Director Stock Plan, or the 2001 Plan, compared to ($32,000) in expense reduction recorded during the three months ended March 31, 2016. The value of the stock units are classified as a liability and adjusted to market value at each reporting period as the redemption amount of stock units for this plan will be paid in cash. No stock units have been issued under the 2001 Plan subsequent to June 30, 2004. Compensation Policy for Non-Employee Directors On December 9, 2016 the Board amended the Compensation Policy for Non-Employee Directors to create a transition period due to the change in the year-end. Effectively, one-half of the annual compensation awards described below were awarded to the directors on December 9, 2016 and a full-year’s compensation will be awarded at the date of the next annual meeting. Pursuant to the Compensation Policy for Non-Employee Directors, the redemption amount of deferred share units issued will be paid in shares of common stock of the Company on the date a director ceases to be a member of the Board. Annual retainers vest quarterly over approximately one year from the date of grant, contingent upon the individual remaining a director of ImmunoGen as of each vesting date. The number of deferred share units awarded is fixed per the plan on the date of the award. All unvested deferred stock awards will automatically vest immediately prior to the occurrence of a change of control. During the three months ended March 31, 2017, the Company recorded approximately $38,000 in compensation expense, respectively, related to deferred share units issued and outstanding under the Company’s Compensation Policy for Non-Employee Directors, compared to $108,000 in compensation expense recorded during the three months ended March 31, 2016. Pursuant to the Compensation Policy for Non-Employee Directors, in January 2017, the Company issued a retiring director 53,248 shares of common stock of the Company to settle outstanding deferred share units. In addition to the deferred share units, the Non-Employee Directors are also entitled to receive a fixed number of stock options determined using the Black-Scholes option pricing model measured on the date of grant, which would be the date of the annual meeting of shareholders. These options vest quarterly over approximately one year from the date of grant. Any new directors will receive a pro-rated award, depending on their date of election to the Board. The directors received a total of 80,000 stock options in November of 2015 and a total of 40,000 options in December 2016, and the related compensation expense for the three months ended March 31, 2017 and 2016 is included in the amounts discussed in the “Stock-Based Compensation” section of footnote B above.

XML 30 R12.htm IDEA: XBRL DOCUMENT

Restructuring Charge

3 Months Ended

Mar. 31, 2017

Restructuring Charge

Restructuring Charge

G. Restructuring Charge

A summary of activity against the restructuring charge related to the employee terminations during the three-month period ended March 31, 2017 is as follows (in thousands):



	Period from
	December 31, 2016 to
	March 31, 2017
Balance December 31, 2016	$	1,751
Payments for the period		(1,287)
Balance March 31, 2017	$	464

XML 31 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies

Commitments and Contingencies

H. Commitments and Contingencies

Leases


2017 (nine months remaining)	$	5,959
2018		7,736
2019		7,235
2020		7,283
2021		7,107
Thereafter		30,794
Total minimum lease payments	$	66,114

There are no obligations under capital leases as of March 31, 2017, as all of the capital leases were single payment obligations which have all been made.

Collaborations

Manufacturing Commitments

XML 32 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies

Basis of Presentation

Subsequent Events

Revenue Recognition

At March 31, 2017, the Company had the following two material types of agreements with the parties identified below:

Amgen (two exclusive single-target licenses(1))

Bayer (one exclusive single-target license)

Biotest (one exclusive single-target license)

CytomX (one exclusive single-target license)

Fusion Pharmaceuticals (one exclusive single-target license)

Lilly (three exclusive single-target licenses)

Novartis (five exclusive single-target licenses and one license to two related targets: one target on an exclusive basis and the second target on a non-exclusive basis)

Roche, through its Genentech unit (five exclusive single-target licenses)

Sanofi (one exclusive single-target license and one exclusive license to multiple individual targets)

Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (one exclusive single-target license)

⁽¹⁾

Amgen has sublicensed one of its exclusive single-target licenses to Oxford BioTherapeutics Ltd.

CytomX

Takeda, through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.

There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.

Development and Commercialization Licenses

Right‑to‑Test Agreements

Inventory

Inventory at March 31, 2017 and December 31, 2016 is summarized below (in thousands):


	March 31,		December 31,
	2017		2016
Raw materials	$	125	$	357
Work in process		3,100		1,835
Total	$	3,225	$	2,192

Unbilled Revenue

Financial Instruments and Concentration of Credit Risk

Cash and Cash Equivalents

Non-cash Investing Activities

Fair Value of Financial Instruments

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value Measurements at March 31, 2017 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

108,296

—

Fair Value Measurements at December 31, 2016 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

144,176

—

The fair value of the Company’s cash equivalents is based on quoted prices from active markets.

Computation of Net Loss per Common Share


	Three Months Ended
	March 31,
	2017	2016
Options outstanding to purchase common stock and unvested restricted stock	13,690	11,679
Common stock equivalents under treasury stock method for options	110	361
Shares issuable upon conversion of convertible notes	23,878	—
Common stock equivalents under if-converted method for convertible notes	23,878	—

The Company’s common stock equivalents have not been included in the net loss per share calculation because their effect is anti‑dilutive due to the Company’s net loss position.

Stock-Based Compensation



	Three Months Ended March 31,
	2017		2016
Dividend	None		None
Volatility	66.89	%	63.90	%
Risk-free interest rate	2.03	%	1.61	%
Expected life (years)	6.0		6.3

A summary of option activity under the 2006 and 2016 Plans as of March 31, 2017, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):


		Weighted-
	Number	Average
	of Stock	Exercise
	Options	Price
Outstanding at December 31, 2016	13,679	$	10.70
Granted	1,187	$	2.48
Exercised	—
Forfeited/Canceled	(1,176)	$	11.27
Outstanding at March 31, 2017	13,690	$	9.94


		Weighted-
	Number of	Average
	Restricted	Exercise
	Stock Shares	Price
Unvested at December 31, 2016	199	$	4.41
Awarded	2,014	$	2.47
Vested	(6)	$	6.53
Forfeited	(20)	$	3.15
Unvested at March 31, 2017	2,187	$	2.63

Segment Information

During the three months ended March 31, 2017, the Company continued to operate in one operating segment which is the business of discovery of monoclonal antibody-based anticancer therapeutics.

The percentages of revenues recognized from significant customers of the Company in the three months ended March 31, 2017 and 2016 are included in the following table:


	Three Months Ended
	March 31,
Collaborative Partner:	2017		2016
Bayer	—	%	51	%
CytomX	48	%	3	%
Roche	27	%	37	%
Sanofi	21	%	—	%

There were no other customers of the Company with significant revenues in the three months ended March 31, 2017 and 2016.

Recent Accounting Pronouncements

In March 2016, the FASB issued ASU 2016-9, Improvements to Employee Share-Based Payment Accounting (Topic 718) that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. Accordingly, the standard was adopted by the Company on January 1, 2017. As a result of the adoption of this guidance, the net operating losses deferred tax assets for federal and state purposes increased by $9.2 million and $1.2 million, respectively, and will be offset by corresponding increases in the valuation allowance. The adoption of the guidance has no impact on the Company’s consolidated financial statements. The Company elected not to adopt the provision that would allow actual forfeitures to be recognized in lieu of maintaining a forfeitures reserve. As such, the Company will continue to estimate forfeitures.

XML 33 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies

Schedule of assets that are required to be measured at fair value on a recurring basis

Fair Value Measurements at March 31, 2017 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

108,296

—

Fair Value Measurements at December 31, 2016 Using

Quoted Prices in

Significant

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Total

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

144,176

—

Schedule of inventory

Inventory at March 31, 2017 and December 31, 2016 is summarized below (in thousands):


	March 31,		December 31,
	2017		2016
Raw materials	$	125	$	357
Work in process		3,100		1,835
Total	$	3,225	$	2,192

Schedule of common stock equivalents, as calculated in accordance with the treasury-stock method


	Three Months Ended
	March 31,
	2017	2016
Options outstanding to purchase common stock and unvested restricted stock	13,690	11,679
Common stock equivalents under treasury stock method for options	110	361
Shares issuable upon conversion of convertible notes	23,878	—
Common stock equivalents under if-converted method for convertible notes	23,878	—

Schedule of assumptions



	Three Months Ended March 31,
	2017		2016
Dividend	None		None
Volatility	66.89	%	63.90	%
Risk-free interest rate	2.03	%	1.61	%
Expected life (years)	6.0		6.3

Summary of stock option activity

A summary of option activity under the 2006 and 2016 Plans as of March 31, 2017, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):


		Weighted-
	Number	Average
	of Stock	Exercise
	Options	Price
Outstanding at December 31, 2016	13,679	$	10.70
Granted	1,187	$	2.48
Exercised	—
Forfeited/Canceled	(1,176)	$	11.27
Outstanding at March 31, 2017	13,690	$	9.94

Summary of restricted stock activity


		Weighted-
	Number of	Average
	Restricted	Exercise
	Stock Shares	Price
Unvested at December 31, 2016	199	$	4.41
Awarded	2,014	$	2.47
Vested	(6)	$	6.53
Forfeited	(20)	$	3.15
Unvested at March 31, 2017	2,187	$	2.63

Schedule of percentage of total revenues recognized from each significant customer


	Three Months Ended
	March 31,
Collaborative Partner:	2017		2016
Bayer	—	%	51	%
CytomX	48	%	3	%
Roche	27	%	37	%
Sanofi	21	%	—	%

XML 34 R16.htm IDEA: XBRL DOCUMENT

Liability Related to Sale of Future Royalties (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Liability account during the period from the inception of the royalty transaction

The following table shows the activity within the liability account during the three-month period ended March 31, 2017 (in thousands):


	Period from
	December 31, 2016 to
	March 31, 2017
Liability related to sale of future royalties, net — beginning balance	$	184,328
Non-cash Kadcyla royalty revenue		(7,613)
Non-cash interest expense recognized		3,409
Liability related to sale of future royalties, net — ending balance	$	180,124

XML 35 R17.htm IDEA: XBRL DOCUMENT

Restructuring Charge (Tables)

3 Months Ended

Mar. 31, 2017

Restructuring Charge

Schedule activity against the restructuring charge

A summary of activity against the restructuring charge related to the employee terminations during the three-month period ended March 31, 2017 is as follows (in thousands):



	Period from
	December 31, 2016 to
	March 31, 2017
Balance December 31, 2016	$	1,751
Payments for the period		(1,287)
Balance March 31, 2017	$	464

XML 36 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies

Schedule of minimum rental commitments


2017 (nine months remaining)	$	5,959
2018		7,736
2019		7,235
2020		7,283
2021		7,107
Thereafter		30,794
Total minimum lease payments	$	66,114

XML 37 R19.htm IDEA: XBRL DOCUMENT

Nature of Business and Plan of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Nature of Business and Plan of Operations
Net loss	$ (17,345)	$ (31,928)
Accumulated deficit	(949,915)		$ (932,570)
Product revenue	0
Cash and cash equivalents	$ 126,568	$ 182,913	$ 159,964	$ 212,283

XML 38 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Revenue (Details)	3 Months Ended
	Mar. 31, 2017 USD ($) item	Mar. 31, 2016 USD ($)
Summary of Significant Accounting Policies
Number of types of licensing and development agreements with collaborative partners	2
Difference between the full cost to manufacture and amounts received from collaborators for preclinical and clinical materials \| $	$ 727,000	$ 3,000,000
Number of types of milestone payments under collaborative arrangements	3
Number of quarters in arrear for revenue recognition	1
Minimum
Summary of Significant Accounting Policies
Period to earn royalty payments	10 years
Maximum
Summary of Significant Accounting Policies
Period to earn royalty payments	12 years
Kadcyla \| Minimum
Summary of Significant Accounting Policies
Period to earn royalty payments	10 years
Kadcyla \| Maximum
Summary of Significant Accounting Policies
Period to earn royalty payments	12 years
Amgen
Summary of Significant Accounting Policies
Number of single-target licenses	2
Amgen \| Oxford BioTherapeutics Ltd Member
Summary of Significant Accounting Policies
Number of related targets	1
Bayer
Summary of Significant Accounting Policies
Number of single-target licenses	1
Biotest
Summary of Significant Accounting Policies
Number of single-target licenses	1
CytomX
Summary of Significant Accounting Policies
Number of single-target licenses	1
Fusion Pharmaceuticals
Summary of Significant Accounting Policies
Number of single-target licenses	1
Lilly
Summary of Significant Accounting Policies
Number of single-target licenses	3
Novartis
Summary of Significant Accounting Policies
Number of single-target licenses	5
Number of licenses to two related targets	1
Number of related targets	2
Roche
Summary of Significant Accounting Policies
Number of single-target licenses	5
Sanofi
Summary of Significant Accounting Policies
Number of single-target licenses	1
Number of licenses to multiple individual targets	1
Takeda
Summary of Significant Accounting Policies
Number of related targets	1

XML 39 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - FinInst (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2017 USD ($) item	Dec. 31, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Financial Instruments and Concentration of Credit Risk
Number of financial institutions in the U.S. in which cash and cash equivalents are primarily maintained \| item	3
Marketable securities held by entity	$ 0		$ 0
Cash and Cash Equivalents
Cash and cash equivalents	126,568,000	$ 159,964,000	$ 182,913,000	$ 212,283,000
Noncash Investing Activities
Accrued capital expenditures	$ 104,000	$ 356,000

XML 40 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016
Fair value hierarchy for the Company's financial assets measured at fair value
Interest rate (as a percent)	4.50%
Recurring basis
Fair value hierarchy for the Company's financial assets measured at fair value
Cash equivalents	$ 108,296	$ 144,176
Recurring basis \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair value hierarchy for the Company's financial assets measured at fair value
Cash equivalents	$ 108,296	144,176
Convertible Notes
Fair value hierarchy for the Company's financial assets measured at fair value
Interest rate (as a percent)	4.50%		4.50%
Convertible Notes \| Significant Other Observable Inputs (Level 2) \| Face Value
Fair value hierarchy for the Company's financial assets measured at fair value
Convertible debt fair value	$ 100,000	100,000
Convertible Notes \| Significant Other Observable Inputs (Level 2) \| Estimated fair value
Fair value hierarchy for the Company's financial assets measured at fair value
Convertible debt fair value	$ 111,000	$ 79,000

XML 41 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Inventory (Details)	3 Months Ended
	Mar. 31, 2017 USD ($) item	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Summary of Significant Accounting Policies
Unbilled partner milestone			$ 5,000,000
Inventory
Raw materials	$ 125,000		357,000
Work in process	3,100,000		1,835,000
Total	$ 3,225,000		$ 2,192,000
Number of suppliers \| item	2
Minimum supply period of raw materials that is not supported by firm, fixed orders and/or projections from collaborators considered to expense inventory	12 months
Charges to research and development expense related to raw material inventory identified as excess	$ 403,000	$ 0
Reserve for work in process	$ 0

XML 42 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - EPS and SBC (Details)			1 Months Ended					3 Months Ended		12 Months Ended
	Dec. 09, 2016 shares	Sep. 26, 2016 USD ($) shares	Feb. 28, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares	Sep. 30, 2016 shares	Aug. 31, 2016 item $ / shares shares	Nov. 30, 2015 shares	Mar. 31, 2017 USD ($) item $ / shares shares	Mar. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2016 employee $ / shares shares
Computation of Net Loss per Common Share
Options outstanding to purchase common stock and unvested restricted stock								13,690,000	11,679,000
Common stock equivalents under treasury stock method for options (in shares)								110,000	361,000
Shares issuable upon conversion of convertible notes (in shares) \| item								23,878
Common stock equivalents under if-converted method for convertible notes (in shares)								23,878,000
Additional disclosure for options
Stock compensation expense (reduction) \| $								$ 2,600,000	$ 7,200,000
Estimated fair value of unvested employee awards, net of estimated forfeitures \| $								$ 20,200,000
Weighted average vesting period of unvested employee awards								2 years
Cash received for exercise of stock options \| $									188,000
Chief Executive Officer
Additional disclosure for options
Stock compensation expense (reduction) \| $									$ 2,800,000
Stock options
Weighted-average assumptions used to estimate the fair value of each stock option
Dividend (as a percent)								0.00%	0.00%
Volatility (as a percent)								66.89%	63.90%
Risk-free interest rate (as a percent)								2.03%	1.61%
Expected life								6 years	6 years 3 months 18 days
Weighted-average grant date fair values of options granted (in dollars per share) \| $ / shares								$ 1.52	$ 5.55
Number of Stock Options
Outstanding at the beginning of the period (in shares)								13,679
Granted (in shares)								1,187
Forfeited/Canceled (in shares)								(1,176)
Outstanding at the end of the period (in shares)				13,679				13,690		13,679
Weighted-Average Exercise Price
Outstanding at the beginning of the period (in dollars per share) \| $ / shares								$ 10.70
Granted (in dollars per share) \| $ / shares								2.48
Forfeited/Canceled (in dollars per share) \| $ / shares								11.27
Outstanding at the end of the period (in dollars per share) \| $ / shares				$ 10.70				$ 9.94		$ 10.70
Restricted stock
Stock-Based Compensation
Exercise period						5 years
Number of equal installments restrictions lapse \| item						3
Number of Restricted Stock
Unvested at the beginning of the period (in shares)								199,000
Awarded (in shares)			529,830			117,800		2,014,000
Vested (in shares)								(6,000)
Forfeited (in shares)								(20,000)
Unvested at the end of the period (in shares)				199,000				2,187,000		199,000
Weighted-Average Exercise Price
Unvested at the beginning of the period (in dollars per share) \| $ / shares								$ 4.41
Awarded (in dollars per share) \| $ / shares			$ 2.47			$ 3.15		2.47
Vested (in dollars per share) \| $ / shares								6.53
Forfeited (in dollars per share) \| $ / shares								3.15
Unvested at the end of the period (in dollars per share) \| $ / shares				$ 4.41				$ 2.63		$ 4.41
Additional disclosure for options
Stock compensation expense (reduction) \| $								$ 0
Compensation Policy for Non-Employee Directors \| Stock options
Stock-Based Compensation
Vesting period				1 year			1 year
Number of Stock Options
Granted (in shares)				40,000			80,000
Compensation Policy for Non-Employee Directors \| Deferred share units
Stock-Based Compensation
Vesting period	1 year
Additional disclosure for options
Stock compensation expense (reduction) \| $								$ 38,000	$ 108,000
2016 Plan
Computation of Net Loss per Common Share
Common stock equivalents under treasury stock method for options (in shares)	14,250,000
Stock-Based Compensation
Number of employee share-based compensation plans \| employee										1
Common stock authorized for issuance (in shares)	5,500,000
2016 Plan \| Stock options
Weighted-average assumptions used to estimate the fair value of each stock option
Number of group of awards for which expected term is calculated for and applied \| item								1
2016 Plan \| Stock options \| Maximum
Stock-Based Compensation
Vesting period								4 years
Exercise period								10 years
Workforce reduction
Stock-Based Compensation
Vesting period					3 years
Number of Stock Options
Granted (in shares)					847,000
Workforce reduction \| Stock options
Number of Stock Options
Forfeited/Canceled (in shares)		(762,000)
Additional disclosure for options
Stock compensation expense (reduction) \| $		$ 837,000

XML 43 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Segments (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) item	Mar. 31, 2016	Jan. 01, 2017 USD ($)	Dec. 31, 2016 USD ($)
Segment Information
Number of operating segments \| item	1
Recent Accounting Pronouncements
Prepaid and other current assets	$ 6,394			$ 5,386
Other assets	$ 3,193			$ 3,020
Bayer \| Revenues percentage \| Customer concentration
Segment Information
Percentages of revenue recognized		51.00%
CytomX \| Revenues percentage \| Customer concentration
Segment Information
Percentages of revenue recognized	48.00%	3.00%
Roche \| Revenues percentage \| Customer concentration
Segment Information
Percentages of revenue recognized	27.00%	37.00%
Sanofi \| Revenues percentage \| Customer concentration
Segment Information
Percentages of revenue recognized	21.00%
Maximum \| Accounting Standards Update 2014-09
Recent Accounting Pronouncements
Number of contracts requiring evaluation \| item	10
Federal \| New accounting pronouncement \| Accounting Standards Update 2016-09
Recent Accounting Pronouncements
Net deferred tax assets			$ 9,200
Valuation allowance			9,200
State \| New accounting pronouncement \| Accounting Standards Update 2016-09
Recent Accounting Pronouncements
Net deferred tax assets			1,200
Valuation allowance			$ 1,200

XML 44 R26.htm IDEA: XBRL DOCUMENT

Agreements - Roche (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended	207 Months Ended
Agreements - Roche (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2000	Mar. 31, 2017	Dec. 31, 2008
Collaborative Agreements disclosures
Period in arrears to receive royalty reports and payments related to sales of Kadcyla			3 months
Non-cash royalty revenue related to sale of future royalties	$ 7,613	$ 7,380
Development milestones
Collaborative Agreements disclosures
Potential milestone payments					$ 16,000
Roche \| Kadcyla
Collaborative Agreements disclosures
Payments received under collaboration agreement			$ 2,000
Potential milestone payments			44,000
Non-cash royalty revenue related to sale of future royalties	7,600	$ 7,400
Roche \| Kadcyla \| Development milestones
Collaborative Agreements disclosures
Payments received under collaboration agreement				$ 13,500
Potential milestone payments			13,500
Roche \| Kadcyla \| Regulatory milestones
Collaborative Agreements disclosures
Payments received under collaboration agreement				20,500
Potential milestone payments	$ 5,000		$ 30,500	$ 5,000

XML 45 R27.htm IDEA: XBRL DOCUMENT

Agreements - Sanofi (Details) $ in Thousands	1 Months Ended		3 Months Ended		168 Months Ended
Agreements - Sanofi (Details) $ in Thousands	Mar. 31, 2017 USD ($)	Jan. 31, 2017 USD ($)	Mar. 31, 2017 USD ($) item	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2008 USD ($)	Dec. 31, 2003 USD ($)
Collaborative Agreements disclosures
License and milestone fees			$ 18,730	$ 10,077
Development milestones
Collaborative Agreements disclosures
Potential milestone payments						$ 16,000
Sanofi
Collaborative Agreements disclosures
Potential milestone payments							$ 21,500
Payments received under collaboration agreement			$ 26,500		$ 26,500
Number of single-target licenses \| item			1
Sanofi \| Development milestones
Collaborative Agreements disclosures
Potential milestone payments							7,500
Sanofi \| Phase I clinical trial
Collaborative Agreements disclosures
Potential milestone payments	$ 1,000		$ 1,000
Sanofi \| Phase IIb Clinical Trial
Collaborative Agreements disclosures
Potential milestone payments	3,000		3,000
License and milestone fees	3,000
Sanofi \| Phase III Clinical Trial
Collaborative Agreements disclosures
Potential milestone payments	3,000		3,000
License and milestone fees		$ 3,000
Sanofi \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments	$ 3,000		$ 3,000				$ 14,000

XML 46 R28.htm IDEA: XBRL DOCUMENT

Agreements - Bayer (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended	108 Months Ended
Agreements - Bayer (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2008	Dec. 31, 2016
Collaborative Agreements disclosures
Amount of arrangement consideration included in license and milestone fees		$ 18,730	$ 10,077
Development milestones
Collaborative Agreements disclosures
Potential milestone payments				$ 16,000
Bayer
Collaborative Agreements disclosures
Payments received under collaboration agreement		13,000		4,000	$ 13,000
Potential milestone payments				$ 170,500
Bayer \| Minimum
Collaborative Agreements disclosures
Percentage of royalty payments				4.00%
Bayer \| Maximum
Collaborative Agreements disclosures
Percentage of royalty payments				7.00%
Bayer \| Development milestones
Collaborative Agreements disclosures
Potential milestone payments		2,000
Bayer \| Phase II clinical trial
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 10,000
Bayer \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments		$ 6,000		$ 44,500
Bayer \| Sales milestones
Collaborative Agreements disclosures
Potential milestone payments				$ 110,000

XML 47 R29.htm IDEA: XBRL DOCUMENT

Agreements - CytomX (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended
Agreements - CytomX (Details) - USD ($) $ in Thousands	Jan. 31, 2017	Feb. 29, 2016	Jan. 31, 2014	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2008
Collaborative Agreements disclosures
License and milestone fees				$ 18,730	$ 10,077
Development milestones
Collaborative Agreements disclosures
Potential milestone payments						$ 16,000
CytomX
Collaborative Agreements disclosures
Payments received under collaboration agreement		$ 13,000	$ 0
License and milestone fees	$ 12,700
Potential milestone payments			160,000
CytomX \| Development milestones
Collaborative Agreements disclosures
Potential milestone payments			10,000	$ 1,000
CytomX \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments			50,000
CytomX \| Sales milestones
Collaborative Agreements disclosures
Potential milestone payments			$ 100,000

XML 48 R30.htm IDEA: XBRL DOCUMENT

Convertible 4.5% Senior Notes (Details)	1 Months Ended	3 Months Ended
Convertible 4.5% Senior Notes (Details)	Jun. 30, 2016 USD ($) item $ / shares	Mar. 31, 2017 USD ($)
Convertible debt
Interest rate (as a percent)		4.50%
Interest expense		$ 1,125,000
Convertible Notes
Convertible debt
Interest rate (as a percent)	4.50%	4.50%
Principal amount of debt	$ 100,000,000
Proceeds from issuance of debt	96,600,000
Issuance of debt transaction costs	3,400,000
Interest expense		$ 1,100,000
Principal amount of debt for conversion calculations	$ 1,000
Ratio issued upon conversion	238.7775
Initial conversion price (in dollars per share) \| $ / shares	$ 4.19
Principal amount of notes to be repurchased under certain conditions (as a percent)	100.00%
Principal amount of notes to be repurchased upon default (as a percent)	100.00%
Additional interest for reporting requirement failure (as a percent)	0.50%
Default cure period	90 days
Additional interest for restricted event (as a percent)	0.50%
Number of additional interest rate percentage penalty circumstances \| item	2
Maximum additional interest rate (as a percent)	0.50%

XML 49 R31.htm IDEA: XBRL DOCUMENT

Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		24 Months Ended
	Apr. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017
Roll forward
Non-cash Kadcyla royalty revenue		$ (7,613)	$ (7,380)
Non-cash interest expense on liability related to sale of future royalties and convertible senior notes		3,575	$ 4,972
Kadcyla
Liability Related to Sale of Future Royalties
Percentage of royalty payments if applicable threshold is met	85.00%
Kadcyla \| IRH
Liability Related to Sale of Future Royalties
Percentage of royalty payments	100.00%
Royalty revenue	$ 235,000
Royalties on net sales of Kadcyla when royalties to the purchaser reach a specified milestone	$ 260,000
Percentage of royalty payments if applicable threshold is met	15.00%
Proceeds from sale of future royalties - net	$ 200,000
Transaction costs for royalty agreements	$ 5,900
Roll forward
Liability related to sale of future royalties, net — beginning balance		184,328
Non-cash Kadcyla royalty revenue		(7,613)
Non-cash interest expense on liability related to sale of future royalties and convertible senior notes		3,409
Liability related to sale of future royalties, net — ending balance		$ 180,124		$ 180,124
Effective annual interest rate				7.70%

XML 50 R32.htm IDEA: XBRL DOCUMENT

Capital Stock (Details) - USD ($)		1 Months Ended				3 Months Ended
Capital Stock (Details) - USD ($)	Dec. 09, 2016	Jan. 31, 2017	Dec. 31, 2016	Nov. 30, 2015	Jun. 30, 2004	Mar. 31, 2017	Mar. 31, 2016
Stock-based compensation disclosure
Stock compensation expense (reduction)						$ 2,600,000	$ 7,200,000
Stock options
Stock-based compensation disclosure
Stock options granted to directors (in shares)						1,187
2001 Director Plan
Stock-based compensation disclosure
Stock compensation expense (reduction)						$ 12,000	(32,000)
Stock units issued (in shares)					0
Compensation Policy for Non-Employee Directors \| Stock options
Stock-based compensation disclosure
Vesting period			1 year	1 year
Stock options granted to directors (in shares)			40,000	80,000
Compensation Policy for Non-Employee Directors \| Deferred share units
Stock-based compensation disclosure
Stock compensation expense (reduction)						$ 38,000	$ 108,000
Stock units issued (in shares)		53,248
Shares issued on annual basis (as a percent)	50.00%
Vesting period	1 year

XML 51 R33.htm IDEA: XBRL DOCUMENT

Restructuring Charge (Details)		1 Months Ended	3 Months Ended		6 Months Ended
Restructuring Charge (Details)	Sep. 26, 2016 USD ($) item shares	Sep. 30, 2016 shares	Mar. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Feb. 29, 2016 USD ($) ft²
Restructuring
Restructuring charges			$ 386,000
Stock compensation expense (reduction)			2,600,000	$ 7,200,000
Construction allowance			5,718,000		$ 5,914,000
Restructuring Reserve
Initial charge related to employee benefits, Beginning Balance			1,751,000
Payments for the period			(1,287,000)
Balance at the End of the year			464,000		1,751,000
Workforce reduction
Restructuring
Approximate positions to be eliminated (as a percent)	17.00%
Approximate positions to be eliminated \| item	65
Approximate current positions to be eliminated \| item	60
Restructuring charges					4,400,000
One-time termination benefit					2,800,000
Benefit plan severance cost					$ 593,000
Granted (in shares) \| shares		847,000
Vesting period		3 years
930 Winter Street, Walham, MA
Restructuring
Area of space leased \| ft²						10,281
Construction allowance						$ 617,000
930 Winter Street, Walham, MA \| Lease
Restructuring
Area of space leased \| ft²						10,281
Estimated period to sub-lease	9 months
Leasehold impairment charge	$ 970,000		$ 386,000
Leasehold improvement cost	$ 193,000
Stock options
Restructuring
Forfeited (in shares) \| shares			1,176
Granted (in shares) \| shares			1,187
Stock options \| Workforce reduction
Restructuring
Forfeited (in shares) \| shares	762,000
Stock compensation expense (reduction)	$ 837,000

XML 52 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) € in Millions	1 Months Ended		3 Months Ended
Commitments and Contingencies (Details) € in Millions	Feb. 28, 2017 EUR (€)	Apr. 30, 2013 ft²	Mar. 31, 2017 USD ($) item	Mar. 31, 2017 GBP (£) ft²	Mar. 31, 2017 USD ($) ft²	Dec. 31, 2016 USD ($)	Feb. 29, 2016 USD ($) ft²	Dec. 31, 2015 USD ($)	Apr. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)
Operating leases
Construction allowance					$ 5,718,000	$ 5,914,000
Minimum rental commitments under the non-cancelable operating lease agreements
2017 (nine months remaining)					5,959,000
2018					7,736,000
2019					7,235,000
2020					7,283,000
2021					7,107,000
Thereafter					30,794,000
Total minimum lease payments					66,114,000
Obligations under capital leases					0
Collaborations and Licenses
Potential milestone payable					161,800,000
Amount reimbursable by a third party					1,200,000
Obligation to make payment to vendor for certain contractual services \| £				£ 300,000
Manufacturing Commitments
Collaborations and Licenses
Obligation to make payment to vendor for certain contractual services \| €	€ 46.2
Other commitment					8,600,000
Due 2017					6,800,000
Due 2018					$ 1,800,000
Term of agreement	5 years
Noncancelable commitment \| €	€ 6.3
830 Winter Street, Waltham, MA
Operating leases
Area of space leased \| ft²				110,000	110,000
Number of additional terms for which lease agreement can be extended \| item			2
Lease term extension period			5 years
Construction allowance								$ 186,000	$ 1,100,000	$ 746,000
930 Winter Street, Walham, MA
Operating leases
Area of space leased \| ft²							10,281
Construction allowance							$ 617,000
333 Providence Hwy, Norwood MA
Operating leases
Lease term extension period			5 years
100 River Ridge Drive, Norwood, MA
Operating leases
Area of space leased \| ft²		7,507
Lease term extension period		5 years
Lease term period		5 years 2 months
Facilities rent expense, net of sublease income			$ 169,000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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